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“Variability is the law of life,  
and as no two faces are the same, so no two bodies are alike, 
and no two individuals react alike and behave alike under the abnormal conditions 
which we know as disease.” 
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Headache disorders are ubiquitous, with almost half of the world’s adult population 
having recently experienced one or more headache types [1]. Migraine, tension-
type headache and medication overuse headache (MOH) are currently the most 
common headache disorders worldwide, leading to significantly reduced patients’ 
quality of life and higher costs for society [2]. The Global Burden of Disease Study 
2013 (GBD2013) reported migraine as the sixth highest cause of disability in the 
world and, for the first time, highlighted the relevance of MOH as the 18th most 
disabling disease [3]. Despite the substantial contribute to public-ill-health of such 
headache types, their burden is still paradoxically ignored.  
 
Migraine as well as medication overuse headache still remain under-recognized, 
under-diagnosed and under-treated, with more than 50% of patients worldwide 
estimated to be primarily self-treated and not consulting a specialist [1].  
In the light of the aforementioned remarks, healthcare for headache disorders has 
the need to be still more improved at multiple levels, with the final aim of 
successfully diagnose and effectively treat these neurological conditions, primarily 




Migraine is a common primary headache disorder that affects around 10% of the 
worldwide adult population [4] [5], with a male to female ratio of 1:3 [6].  
This neurobiological condition is characterized by altered brain sensitivity and its 
clinical presentation, in terms of pain intensity, attack frequency and associated 
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symptoms, broadly varies among migraineurs [7]. Individual variability in migraine 
phenotype has emerged as presumably resulting from the interaction between 
multiple genetic and non-genetic (endogenous or exogenous) risk factors [8]. 
Supporting this, genetic epidemiologic studies reported migraine as a strongly 
heritable disorder with a substantial risk of familiar occurrence. Twin studies have 
revealed that almost 50% of migraine susceptibility risk could be attributable to 
additive genes while the remainder may be due to shared or unshared 
environmental factors among twins [9]. Exposure to stress, odours, bright lights 
and sounds, hypoglycemia, consumption of certain foods (for example chocolate, 
salami, milk, alcohol and excessive caffeine intake) smoking, and sleep 
disturbances are now listed among potential exogenous triggers of migraine attacks 
in predisposed subjects [10]. 
 
Gender differences in migraine occurrence were also hypothesized on the basis of 
epidemiological evidences reporting a major prevalence of migraine in females 
compared to males. Migraine is more common in women than in men during 
adulthood, with a prevalence peak in women’s fertile age. However, this imbalance 
in terms of prevalence between sexes does not occur in childhood and old age, 
when the disorder tends to affect the same percentages of males and females [11]. 
Fluctuation of female sex hormones levels have been proposed as the more 
plausible endogenous factor responsible for variations of migraine prevalence 
throughout female life span [12]. Consistent with this, stable and low levels of 
ovarian hormones, characterizing childhood as well as natural menopause, emerged 
to be correlated with lower migraine frequency. On the contrary, reduced levels of 
estradiol and progesterone, typical of menstruation, resulted triggering frequent 
migraine attacks [13]. In addition to hormonal causes, sex differences in pain 
perception and stress response have been proposed as additional plausible factors 




From a physiological viewpoint, a migraine attack could be defined as a complex 
sequence of brain events that can last from hours to days. For descriptive purposes, 
several “phases” can be simplistically identified in a migraine attack, each of them 
corresponding to specific chemical, biological and anatomical mechanisms 
partially overlapping in the sequence of migraine phases themselves. These phases, 
chronologically ordered, are named premonitory, aura (if present), headache and 
postdrome phase. It must be highlighted that not all aforementioned phases are 
manifested by all migraineurs or present in all attacks. 
More than 80% of adults and a slightly lower percentage of children experience 
premonitory symptoms, which can occur up to hours before headache. The most 
commonly reported premonitory symptoms preceding headache are mood changes, 
fatigue, irritability, difficulty concentrating, stiff neck, phonophobia and nausea. 
Other symptoms that have been reported in this phase include change in appetite, 
bloating, piloerection and change in facial expression or body perception. Some 
symptoms can resolve before the headache phase, whereas others can increase in 
intensity in headache phase and furthermore persist during the postdrome phase 
[15]. 
 
A consistent proportion of migraineurs also manifests a set of neurological 
symptoms, called aura, which usually occur after premonitory signals and before 
the headache phase. Sometimes, migraine aura begins after the pain phase has 
commenced or continues into the headache phase. The most common type of aura 
is the visual one, characterized by visual symptoms ranging from the most common 
scintillating scotoma to the rarest visual hallucination. Some subjects can also 
subsequently experience sensory and language aura, respectively characterized by 
migrating paresthesias and altered language capacity [16]. 
The migraine headache phase properly named is characterized by headache pain, 
usually described as of pulsating quality and with unilateral localization. Headache 
4 
 
pain tends to occur in a gradual manner till reaching a stable moderate or severe 
intensity during the remaining part of headache phase. Photophobia, phonophobia, 
nausea and vomit can frequently accompany headache pain [17]. 
After headache resolution, symptoms such as tiredness, weakness, cognitive 
difficulties, mood changes, residual head pain, dizziness and gastrointestinal 
symptoms are frequent among migraineurs. These symptoms characterize migraine 
postdrome phase, which can occur from hours to days after resolution of headache. 
The overlapping between premonitory and postdrome symptoms fostered the 
hypothesis that postdromal signs could be present throughout the attack, probably 
disguised by headache, nausea or, if present, aura [18]. 
 
1.1 Clinical presentation 
 
The International Classification of Headache Disorders, version III beta (ICHD-
IIIb) recognizes two major subtypes of migraine, which are migraine without aura 
and migraine with aura [17]. These migraine types are not exclusive but can co-
occur in the same migraineur, either alternating or at different phases of patient’s 
life [19]. 
 
Migraine without aura (MwoA), previously named “common migraine” or 
“hemicrania simplex”, is defined as a recurrent headache disorder with headache 
attacks lasting between 4 and 72 hours and characterized by headache pain having 
at least two of the following characteristics: typical unilateral location, moderate or 
severe intensity, pulsating quality and aggravation by routinary physical activity, 
such as walking or climbing stairs. Nausea, vomiting, photophobia and 













At least five attacks fulfilling criteria B–D 
B: Headache attacks lasting 4-72 hours (untreated or unsuccessfully 
treated) 
C: Headache has at least two of the following four characteristics: 
 1. unilateral location 
2. pulsating quality 
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical 
activity (e.g. walking or climbing stairs) 
D: During headache at least one of the following: 
1. nausea and/or vomiting 
2. photophobia and phonophobia 
E: Not better accounted for by another ICHD-3 diagnosis. 
 
In both men and women, migraine without aura is more common than migraine 
with aura and often seems to correlate with menstrual status in women [11]. On the 
contrary, the frequency of migraine without aura attacks usually decreases during 
pregnancy, when the levels of ovarian hormones in serum are stable and high [14]. 
In children and adolescents aged under 18 years and affected by MwoA, the 
headache pain is more often bilateral than in adults and unilateral pain usually 
emerges in late adolescence or in early adult life [17]. 
 
Around 20-30% of migraineurs experience an additional complex of transient 
neurological symptoms, called aura, which can precede or accompany headache 
pain. [19]. Migraine with aura (Mwa), previously also named “classic or classical 
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migraine” “ophthalmic, hemiparaesthetic, hemiplegic or aphasic migraine” or 
“complicated migraine”, is defined by ICHD-IIIb as a migraine characterized by 
“recurrent attacks, lasting minutes, of unilateral fully reversible visual, sensory or 
other central nervous system symptoms that usually develop gradually and are 
usually followed by headache and associated migraine symptoms” [17]. 
More precisely, migraine aura is defined as a fully reversible neurologic 
dysfunction, characterized by a gradual onset of specific symptoms, which usually 
last between 5 and 60 minutes. Visual aura is the most common type of aura, 
occurring in 99% of migraineurs [20]. Migraineurs describe visual impairments 
symptoms characterized by “a zigzag figure near the point of fixation that may 
gradually spread right or left and assume a laterally convex shape with an 
angulated scintillating edge, leaving absolute or variable degrees of relative 
scotoma in its wake” [17]. Posphenes, white or coloured dot, curved lines or other 
geometric forms may also be seen by migraine aura patients. 
Sensory aura is the next more frequent aura symptoms, affecting around 54% of 
MwA patients [21], followed by language aura, which is experienced by 32% of 
MwA subjects [22]. Sensory aura, is often described as migrating paresthesias, 
with numbness typically occurring in the hands and then affecting arms, face, lip 
and tongue (cheiro-oral sensory changes). Language aura may consist of impaired 
language comprehension and speaking, accompanied or not by decreased ability to 
read or write. It should be noted that sensory aura may lead to stuttering words and 
should not be confused with language aura [23]. If co-occurring, aura symptoms 
types usually follow one other in succession, starting from visual and ending with 
















At least two attacks fulfilling criteria B and C 
B: One or more of the following fully reversible aura symptoms: 
      1. visual 
      2. sensory 
      3. speech and/or language 
      4. motor 
      5. brainstem 
      6. retinal 
C: At least two of the following four characteristics: 
       1. at least one aura symptom spreads gradually over ≥ 5 minutes, 
and/or two or more symptoms occur in succession  
      2. each individual aura symptom lasts 5-60 minutes 
      3. at least one aura symptom is unilateral 
      4. the aura is accompanied, or followed within 60 
minutes, by headache 
D: Not better accounted for by another ICHD-3 diagnosis, and transient 
ischaemic attack has been excluded. 
 
Aura symptoms may worsen or appear for the first time during pregnancy, 
highlighting the role of high estrogen levels in the development of migraine with 
aura [11].  
Some patients may also experience migraine aura followed by a less distinct 
headache or even without headache. In the first case, they may suffer from typical 
aura with headache, characterized by aura accompanied or followed within 60 
minutes by headache with or without migraine characteristics. In the latest case 
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patients are diagnosed as having had typical aura without headache, in which aura 
is neither accompanied nor followed by headache of any sort within 60 minutes 
[17]. 
 
1.2 Pathophysiology  
 
Migraine pathophysiology has greatly evolved in the last century till currently 
describing migraine as a “neurovascular” disorder, resulting from the interaction 
between vascular and neurological events.  
The exact cause of migraine is still not completely understood but some key events 
characterizing migraine pathophysiology have emerged, such as the phenomenon 
of cortical spreading depression and the activation of trigeminovascular systems 
accompanied by neurogenic inflammation [24]. 
 
Historically, two independent theories explaining migraine etiology were proposed. 
The “vascular theory” was initially introduced by Thomas Willis in 1664, who 
suggested, for the first time, the involvement of vasodilatation of cerebral and 
meningeal arteries in migraine onset [25]. In the 20th century Graham and Wolff 
refined the aforementioned theory, highlighting that the vascular event was 
mediated by an initial intracranial vasoconstriction subsequently followed by a 
rebound vasodilatation of the extracranial terminal branches of the external carotid 
artery. Consistent with this hypothesis was the observed pulsating quality of 
migraine pain, which they attributed to the amplitude of pulsation of the occipital 
and superficial temporal branches of the external carotid artery [26].  
The alternative theory subsequently proposed was the “neurogenic” one, which 
reported neuronal networks dysfunctions as key mechanisms underlying migraine 
pathogenesis. Support for the neurogenic theory came from the fact that typical 
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neurological symptoms of migraine aura could not be explained by a vascular 
pathophysiological model alone. In 1944, Aristides Leão, described for the first 
time the phenomenon of cortical spreading depression (CSD), defined as “a self-
propagating wave of depolarization that begins in the neuronal/glia cells of local 
areas of the brain and subsequently spread in all directions at a rate of ≈ 3 mm/min” 
[27]. Milner in 1958 and then Olsen in the 1980s caught, for the first time, 
similarities between CSD phenomenon and aura symptoms (previously described 
in 1941 by the psychologist Karl Spencer Lashley) and fostered pathogenic theories 
changing from primary vascular to primary neuronal mechanism [28]. 
However, even if aura is a symptom exclusive for a specific migraine subtype, the 
observation of the possible co-occurrence of the two subtypes of migraine in the 
same subject suggested that these two conditions could share at least some 
mechanisms involved in the initiation and resolution of attacks. 
In this context, Moskowitz and collegues, in the 1980s, integrated the vascular 
theory with the neurogenic one and proposed the “trigeminovascular theory”. They 
hypothesized that probably CSD could depolarize the trigeminocervical nerve 
terminals innervating meninges which in turn may release pro-inflammatory 
peptides responsible for “neurogenic inflammation”, consisting in meningeal 
vessels vasodilatation and plasma protein extravasation. Such neurogenic 
inflammation was hypothesized to lead to migraine pain [29]. 
 
Nowadays, migraine is viewed as a complex neurological disorder that affects 
multiple cortical, subcortical and brainstem areas that regulate several functions, 
including autonomic, affective, cognitive and sensory ones. The interaction 
between neurons, glia and blood vessels still appears to be crucial in migraine 
pathogenesis, with CSD phenomenon and activation of trigeminovascular system 
accompanied by neurogenic inflammation being recognized as key events 
implicated in migraine pathogenesis. 
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In more detail, trigeminovascular system consists of trigeminal nerve and nerve 
fibers innervating intra- and extra- cranial meningeal blood vessel as well as 
brainstem [30]. The trigeminovascular system role is to regulate both 
neurotransmission of pain signals and vascular tone. The transmission pathway 
originates in trigeminal ganglion neurons whose central axons reach the 
nociceptive dorsal horn laminae of the spinal trigeminal nucleus. Here, the 
nociceptors converge on neurons receiving additional inputs from the periorbital 
skin and precranial muscles. The ascending axons of spinal trigeminal nucleus 
neurons convey nociceptive signals to brainstem, hypothalamic and basal ganglia 
nuclei, which overall seem to be crucial in mediating symptoms typical of migraine 
attacks, such as nausea initiation, vomiting, yawning, loss of appetite, anxiety, 
irritability and lacrimation [7]. Trigeminal sensory nerves store several vasoactive 
neuropeptides, including substance P, calcitonin gene-related peptide (CGRP), 
neurokinin A, nitric oxide (NO) and pituitary adenylate cyclase-activating peptide 
(PACAP). These neuropeptides, when released, are crucial in provoking an 
increase in blood flow and vasodilation in meningeal vascular system, where 
edema and inflammation occur, conceivably causing headache pain. Supporting the 
hypothesis of trigeminovascular system activation is the evidence of increased 
levels of CGRP both in external and internal jugular blood of migraineurs during 
headache attack [31]. 
Recently Amin and colleagues identified, through a magnetic resonance 
angiography imaging technique, that the release of neuropeptides and 
proinflammatory substances (e.g. histamine, bradykinin, serotonin and 
prostaglandins) from trigeminal afferents in the meningeal vessels, results in an 
altered molecular environment causing sensitization of both peripheral and central 
neurons of trigeminovascular system. Once sensitized, peripheral 
trigeminovascular neurons begin to respond to stimuli to which they showed 
minimal or no response at baseline [32].  
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Endogenous events that may trigger trigeminovascular system, and so 
neuropeptides release, are still largely unknown. Several experimental models 
report CSD as an important upstream trigger of trigeminovascular system 
activation. Cortical SD seems to activate trigeminovascular pathway, leading to a 
prolonged neurogenic inflammation around meningeal vessels [33]. Even if it is not 
clear how CSD begins in human brain, genetic factors are likely to play a 
substantial role in modulating individual CSD susceptibility by regulating brain 
excitability.  
 
1.3 Genetic basis of migraine 
 
The current knowledge of genetic basis of migraine has come from different 
scientific approaches, encompassing linkage studies in family pedigrees and 
candidate genes or genome-wide association studies. 
Much interest of geneticists has been initially focused on the study of genetic basis 
of familial hemiplegic migraine (FHM), a rare subtype of migraine with aura, 
characterized by a prolonged visual aura typically accompanied by hemiparesis 
[24]. FHM is inherited in an autosomal dominant fashion and was identified as the 
first primary headache disorder with a genetic basis. The substantial overlapping 
between phenotypes of FHM and migraine with aura fostered FHM to be 
considered a good model to study the genetic architecture of migraine. In this 
context, CACNA1A, ATP1A2 and SCNA1A have been identified as causative 
genes in FHM. More precisely, the proteins encoded by these three genes form 
channels involved in the regulation of ions flow across neuronal and glial cell 
membranes. Collectively, these genes regulate glutamate availability in the 
synaptic cleft by means of a fine tuning of glutamate release and re-uptake as well 
as the generation of action potentials. It has been hypothesized that mutations in all 
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three genes may result in an increased efflux of glutamate and potassium in the 
synaptic cleft, in turn leading to an increased susceptibility to cortical spreading 
depression. Mutations in these genes specifically identify three different forms of 
FHM, named, respectively, FHM1, FHM2 and FHM3 [7]. However, these 
identified genetic variants do not account for the totality of FHM cases and it has 
been suggested that additional genetic variants resulting in altered ions flow may 
lead individuals to be more susceptible to FHM [34] [35]. 
Strongly supporting the hypothesis of common genetic basis between FHM and 
other migraine subtypes is the subsequent evidence provided by Cuenca-Leon and 
colleagues which, in 2009, reported 14q32 locus as a shared susceptibility locus in 
a Spanish family affected by FHM, MwoA and MwA [36]. 
 
Numerous linkage studies were also performed on families of different ethnic 
origin. Several migraine susceptibility loci have been identified in a wide range of 
chromosomes, suggesting how migraine could be substantially considered as a 
polygenic disease [37]. However, many of the findings in the field have not been 
replicated in populations of different origin. Heterogeneity of analyzed cohorts, 
both in terms of phenotype and diagnosis, or the existence of rare high-impact 
family specific markers may explain, almost in part, inconsistency of results 
between studies.  
 
Another commonly used approach to identify genetic variants potentially 
influencing migraine susceptibility is represented by the conduction of candidate-
genes association studies performed in a case-control setting. These studies 
generally attempted to investigate genetic basis of migraine through the analysis of 
tagging SNPs or selected functional variants located on specific genes plausibly 
involved in migraine susceptibility. On the basis of available evidences regarding 
migraine pathophysiological mechanisms, the majority of studied SNPs were 
located in genes primarily involved in neurological, hormonal and vascular 
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functions. Among neurological candidate genes, genes involved in serotonin 
neurotransmission have been extensively studied. Even if the exact mechanisms of 
the serotoninergic system in migraine are still unknown, a deficit on 5-HT 
descending pain inhibitory system is still probably today the most implicated in 
migraine pathophysiology [38]. These genes included 5-HT1B, 1D and 2C 
receptors, SLC6A4 (encoding for SERT, a serotonin transporter), TPH2 (encoding 
for tryptophan hydroxylase, a rate-limiting enzyme in the synthesis of serotonin), 
and MAOA (encoding for monoamine oxidase A enzyme which degrade 
serotonin). Similarly, genes regulating dopaminergic neurotransmission were 
studied, such as DRD2 (dopamine receptor D2), DRD3 (dopamine receptor D3), 
SLC6A3 (encoding for the dopamine active transporter), DBH (encoding for 
dopamine beta hydroxylase, an enzyme converting dopamine into noradrenaline), 
TH (tyrosine hydroxylase) and COMT (catechol-O-methyltansferase). In the same 
way, genes implicated in glutamate transmission, such as GRIA1 (glutamate 
receptor 1) and GRIA3 (glutamate receptor 3) were considered  as well good 
candidate genes [37].  
As previously mentioned, fluctuations of hormonal levels, in particular estrogen, 
seem to trigger migraine attacks. In this context, genetic variations on ESR1 
(encoding for estrogen receptor 1) and PGR genes (progesterone receptor gene) 
emerged as potential predictors of migraine susceptibility [39] [40]. Being vascular 
events also crucial in migraine pathogenesis, genetic variations in CGRP 
(calcitonin gene related peptide), ACE (angiotensin I-converting enzyme), MTHFR 
(methylenetetrahydrofolate reductase) and NOTCH3 were analyzed in correlation 
with migraine risk [37].  
However, even if several replication studies were performed to validate significant 
associations between SNPs in all aforementioned genes and migraine risk, a 
consistent part of these results still remains controversial or inconclusive. The 
small effect size of these genetic variants, the generally small sample size of studies 
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as well as the strong heterogeneity among migraineurs included in the patient sets 
may explain, almost in part, the difficulty in replicating such results. 
 
A recent advance in the knowledge of genetic basis of migraine has been provided 
by genome-wide association studies (GWAS). More precisely, two GWAS were 
performed on clinic based collections of patients affected by MwA [41] or MwoA 
[42] whilst two other were conducted on population-based collections of 
migraineurs [43] [44]. A meta-analysis performed by Anttila and colleagues in 
2013 quantitatively summarized previously reported results in the four GWAS 
added together with unreported GWAS findings for migraine susceptibility 
obtained in additional 9 population-based collections [45]. A total of 12 loci 
emerged as significantly associated with migraine susceptibility. Among them, 5 
loci were new (near AJAP1, near TSPAN2, FHL5, c7orf10, and near MMP16) 
while 7 confirmed previously found migraine loci (PRDM16 [43], MEF2D [42], 
TRPM8 [41] [43], near TGFBR2 [42], PHACTR1 [42], ASTN2 [42], and LRP1 
[43]). More in detail, LRP1 modulates synaptic transmission through the NMDA 
receptor while MEF2D is involved in glutamatergic excitatory synapse. AJAP1, 
TSPAN2 and MMP16 (whose encoded protein cleaves LPR1) seem to regulate 
activity of metalloproteinase, which are responsible for the breakdown of 
extracellular matrix in normal physiological processes. ASTN2 and FHL5 are 
involved in neuronal neurodevelopment and synaptic plasticity.  
Overall, these results support the importance of glutamatergic neurotransmission 
and neuronal development/plasticity in migraine pathogenesis and, in conjunction 
with all evidences retrieved from other genetic studies, make conceivable the 








1.4 Pharmacological treatment 
 
The pharmacological treatment of migraine traditionally includes: 
i) the acute/symptomatic treatment, able to relieve headache pain and corollary 
symptoms accompanying migraine; 
ii) the prophylactic therapy, aimed to reduce intensity and frequency of headache 
attacks. 
 
The Italian guidelines for primary headache (revised version 2012) recommend the 
symptomatic treatment alone when migraine attacks are not-disabling or if they 
occur < 4 days per month. On the contrary, preventive therapy is suggested when 
disabling migraine attacks are present for ≥ 4 days per month or in case of poor 
response to symptomatic drugs [46]. 
 
Acute treatment 
Nowadays, several drugs are available for symptomatic pharmacological treatment 
of migraine. Antimigraine drugs can be divided in specific antimigraine drugs, 
characterized by being effective only for headache pain (i.e. triptans and ergot 
derivates), and non-specific antimigraine drugs, resulting effective in relieving pain 
of several origins, including headache (e.g. non-steroidal anti-inflammatory drugs, 
simple analgesics and antiemetics) [47]. 
The Italian guidelines for primary headache (revised version 2012) propose a 
“stratified approach” when the initial pharmacological acute treatment of migraine 
attacks must be outlined. More precisely, specific drugs are recommended for the 
treatment of moderate or severe attacks while non-specific drugs should be 
administered for the therapy of migraine attacks of mild/moderate intensity. 
Moreover, preparations with only one active principle should be preferred and the 
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most appropriate drug should be taken at the lowest effective dosage and as early as 
possible from migraine attack onset [46]. 
 
As mentioned before, specific antimigraine drugs include triptans and ergot 
derivates. 
Triptans are considered by many specialists as the gold-standard therapy of 
migraine. However, there’s a lack of knowledge regarding the complexity of their 
hypothesized multiple mechanisms of action. Their action is primarily attributed to 
their agonist effect on serotonin 5HT1B/D/F receptors, resulting in the 
vasoconstriction of meningeal vessels and in the inhibition of the neurogenic 
inflammation. In addition to this well-known mechanism, recent evidences support 
the potential action of triptans on modulating calcium and potassium currents in 
dural-projecting trigeminal neurons in vitro [48]. 
Nowadays, six triptans are on Italian market: sumatriptan, frovatriptan, eletriptan, 
rizatriptan, almotriptan, zolmitriptan. All triptans are available in conventional oral 
formulations. Sumatriptan is also marketed in other several formulations, such as 
nasal spray, suppository and subcutaneous, the latest one being considered the most 
effective one [49]. Zolmitriptan has also the nasal spray formulation and, as 
rizatriptan, is available in rapid-dissolving formulations (RPD), which have an 
effectiveness similar to that of tablet formulations of the same drugs at the same 
dosages [50], [51]. 









Table 3: Pharmacokinetic parameters and lipophilicity of oral triptans available on 


























almotriptan 1.5-2.0 3 70 -2.1 low 
frovatriptan 2.0-3.0 26 24-30 -1.0 high 
rizatriptan 1.0-1.5 2 40-45 -0.7 high 
zolmitriptan 1.5-2.0 3 41-48 -1.0 high 
eletriptan 1.0-1.5 4 50 +0.5 high 
T max: time to maximum concentration; t1/2: biological half-life; Log D ph=7.4 quantifies triptan 
lipophilicity (increasing numbers indicate greater lipid solubility). 
 
 
They are all effective on relieving migraine pain, associated symptoms and 
functional disability, without provoking common relevant side effects in patients. 
Only the 4-5% of migraineurs treated with subcutaneous sumatriptan experience 
the “triptan syndrome”, characterized by chest pain and chest and neck tightness, 
while the 2-4% of subject also complaint symptoms such as somnolence, dizziness, 
paresthesia, asthenia, nausea and facial flush [46]. Myocardial infarction and ictus 
related to triptan use were rarely reported. Contraindications to triptans are 
uncontrolled blood hypertension, coronary artery disease, history of ischemic 
stroke, peripheral artery disease, pregnancy, lactation and age <18 years and > 
65years. 
Despite the well documented efficacy of triptans, about one third of migraineurs do 
not respond to a specific triptan [53]: in this case, other triptans can be 





Ergot derivates have been used for many years in migraine treatment before the 
advent of triptans. These drugs are partial agonists of α-adrenergic and 
dopaminergic receptors and interact with 5HT1B,D,F receptors, so resulting in 
vasoconstriction of meningeal vessels and inhibition of pro-inflammatory 
neuropeptides release. 
Ergotamine (not available in Italy) and dihydroergotamine are the most common 
used ergot derivates and have emerged to be more effective vs placebo in migraine 
treatment, but less effective compared to triptans [55]. Their use should be 
restricted to migraineurs which fail to be responsive to other drugs. Ergot derivates 
may worsen nausea and vomiting in migraineurs, so contemporary administration 
of antiemetic drugs is generally indicated. Major side effects include nausea, 
vomiting, diarrhea and ergotism. Cardiovascular and cerebrovascular diseases, 
uncontrolled blood hypertension, Raynaud disease, renal failure, pregnancy and 
lactation represent contraindications for ergot derivates treatment. 
 
Non-specific antimigraine drugs include non-steroidal anti-inflammatory drugs, 
simple and combination analgesics, antiemetics, barbiturates, lidocaine and 
steroids. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are indicated for the treatment of 
migraine attacks of mild or moderate intensity or when triptans resulted ineffective 
or contraindicated [46]. Acetaminophen, acetylsalicylic acid, ibuprofen, naproxen 
sodium, and diclofenac potassium have good evidence supporting their use for 
migraine. Among the latest, acetaminophen is considered less effective than other 
NSAIDs and is generally administered for the treatment of relatively mild migraine 
attacks [56]. Acetylsalicylic acid is recommended in subjects with cardio- and 
cerebrovascular comorbidities. Only ibuprofen (the most commonly used one), 
ketoprofen and morniflumate can be used in patients under 14 years of age. Due to 
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their well-known mechanisms of action, adverse events mainly consist in 
gastrointestinal toxicities (e.g. gastric pain, gastric or duodenal ulcer).  
Concerning simple analgesics, paracetamol has a good efficacy on mild-moderate 
migraine pain and corollary symptoms and it is the first-choice drug for migraine 
treatment during pregnancy. 
Analgesics in combination have the same indication of NSAIDs and simple 
analgesics. Analgesic combinations available in Italy include: acetylsalicylic acid + 
acethaminophen + propyhenazone, acetylsalicylic acid + acethaminophen + 
indomethacin (with/without caffeine), and acetaminophen + propyphenazone and 
acetaminophen + codeine. Side effects and contraindications of combinations are 
the same as those for each component [46]. 
Antiemetics are considered adjuvant drugs in migraine therapy, especially during 
attacks characterized by prominent nausea and vomiting. The association between 
antiemetics and other classes of antimigraine drugs, such as NSAIDs, ergotamine 
or triptans, may result in a major absorption of antimigraine drugs and in the 
effective treatment of nausea and vomiting. Among common used antiemetics, 
metoclopramide emerged effective in reducing headache pain if intravenously 
administered alone in migraineurs [57]. 
Barbiturates are usually prescribed in addition to other antimigraine drugs. 
However, this class of drugs should in principle be avoided because barbiturates 
may induce intoxication, addiction and dependence. 
Steroids, such as dexamethasone and prednisone, seem also to be effective in 
migraine treatment but available findings are conflicting. Only one study 
demonstrated the superiority of the association dexamethasone-rizatriptan 





New specific drugs for the abortive treatment of migraine: a focus on CGRP as a 
therapeutic target 
In the light of the substantial abundance of non-responders among migraineurs 
treated with triptans, a digression concerning new developed drugs representing a 
valid alternative to triptans is mandatory.  
The evidence of CGRP involvement in the transmission of pain [58] as well as its 
release during migraine attack [31], fostered the hypothesis that CGRP could be a 
potential good target for new drugs. In this context, CGRP receptor antagonists 
emerged as effective molecules compared to placebo. CGRP receptor antagonists 
include, telcagepant, olcegepant, rimegepant, MK-3207, BI 44370 TA and MK-
1602. However, despite the promising results in term of efficacy, the drug 
development programmes of all these new drugs terminated because of different 
reasons, including toxicity evidences and commercial decision. Only MK-1602 is 
in phase 2 study [59]. 
In addition to CGRP receptor antagonist, four CGRP monoclonal antibodies 
(mAbs) were developed, of which three targeting CGRP ligand (LY2951742, 
ALD-403 and TEV-48125) and one targeting CGRP receptor (AMG 334). The 
mAbs against the ligand are thought to remove CGRP that is released at 
perivascular trigeminal sensory nerve fibers, while the receptor mAbs block CGRP 
signalling. Preliminary data showed positive results in terms of efficacy and safety 
for all four mAbs. However, subcutaneous and intravenous administration routes, 
that are mandatory for mAbs, represent a significant limitation for their everyday 
use in clinical practice [60]. 
 
Prophylactic therapy 
As previously mentioned, preventive therapy is recommended when disabling 
migraine attacks are present for ≥ 4 days per month or in case of poor response to 
symptomatic drugs. A wide range of drugs have been studied for the purpose of 
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reducing both frequency and intensity of migraine attacks. However, the majority 
of preventive medications currently available were not specifically design for 
migraine treatment and their use is often limited by their toxicities or eventual 
inefficacy.  
Preventive drugs must be chosen on the basis of patient’s comorbidities, with a 
particular attention to drug-drug and food-drug interactions. To minimize side 
effects, the most appropriate drug should be administered at the lower dose and 
preferentially as a monotherapy. The preventive therapy will be considered 
effective if the frequency of migraine attacks will be reduced by at least half and if 
a significant improvement in quality of life will be reached. Clinical benefit may 
take some time to be obtained, so preventive treatment should be maintained for at 
least 3 months. Due to the teratogenic effect of the majority of prophylactic drugs, 
preventive treatment during pregnancy should be limited to special situations for 
which the use of drugs with the lowest teratogenic effect should be preferred [46]. 
 
Preventive drugs include beta-blockers, calcium channel blockers, antidepressants, 
antiepileptic drugs, angiotensin inhibitors, botulinum toxin A and other 
supplements. However, few evidences clearly stated their efficacy and no 
universally accepted guideline unequivocally suggest the preventive treatment of 
choice for migraine. Depending on the methodological assessment underlying 
guidelines development, the levels of recommendation reported for every single 
active principle broadly vary among national and international guidelines. 
Table 4 simplistically summarized the most commonly recommended preventive 
drugs on the basis of two Italian [46] [61] and five international guidelines [62] 
[63] [64] [65] [66] for preventive migraine treatment. No emphasis was herein put 
on the levels of recommendation for single drugs reported by each guideline. 













Molecule Indications [46] 
 
Beta-blockers metoprolol [46] [61] [62] [63] [64] [65] [66] 
propranolol [46] [61] [62] [63] [64] [65] [66] 
atenolol [46] [62] [63] [65] [66] 
nadolol [46] [61] [63] [65] [66] 
bisoprolol [46] [62] [64] [65] 
timolol [63] [65] [66] 
nebivolol [65] [66]  








candesartan [46] [64] [65] [66] 
lisinopril [46] [64] [65] 
 
Second-choice treatment 






flunarizine [46] [61] [63] [66] 
 
Particularly indicated for 
patients with concomitant 




topiramate [46] [61] [62] [63] [64] [65] [66] 
 
First choice treatment of 
high-frequency migraine 
attacks, chronic migraine, 
MOH and in migraineurs 
with concomitant 
epilepsy 
sodium valproate [46] [61] [62] [63] [64] [65] 
[66] 
gabapentin [46] [63] [64] [65] [66] 




amitriptyline [46] [61] [62] [63] [64] [65] [66] 
venlafaxine [46] [61] [63] [64] [65] [66] 
fluoxetine [46] [61] 
 
Indicated for patients 














onabutlinum toxin A [46] [61] [64] [65]  




NS: not specified 
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1.5 Pharmacogenetics of migraine 
 
Pharmacogenetics is the study of the influence of individual genetic background on 
drug response, in terms of both therapeutic effect and drug safety. The 
identification of subpopulations inadequately responding to a specific drug may 
lead to a personalized pharmacological therapy, resulting in improved patients’ 
quality of life and optimization of healthcare resources. 
Despite rigorous pharmacogenetic studies have been carried out for a multitude of 
diseases with interesting and clinical-relevant results, surprisingly a very few 
pharmacogenetic evidences have been reported in migraine. Nevertheless, strong 
clinical evidences have highlighted a significant individual variability in response 
to all drugs routinely used for the acute treatment of migraine. A recent network 
meta-analysis, aimed to compare relative efficacy of triptans with respect to other 
acute antimigraine drugs, reported that the proportions of responders to abortive 
antimigraine drugs were 42-76% for triptans, 38% for ergots, 46-52% for NSAIs 
and paracetamol, and 62-80% for combination therapies [67]. In this context, non- 
response to acute medications can be hypothesized not to be only influenced by 
factors such as altered drug absorption, inadequate dosing or incorrect time of drug 
administration, but also by individual genetic background, plausibly impacting on 
both pharmacokinetic and pharmacodynamic drug variability. In addition to this, 
the observation that migraineurs may experience adverse reactions more frequently 
than other groups of patients [68] further supports the need of improving 
pharmacogenetic knowledge in migraine, which in turn may allow to unravel 
subpopulations of migraineurs that, at present, are inadequately treated by 
antimigraine drugs on the market. 
 
With the aim of collecting all available pharmacogenetic evidences in episodic 
migraine, we performed in 2012 a systematic review of literature concerning 
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genetic predictors of response to acute or preventive drugs commonly used in 
migraine treatment 1. We identified only 7 candidate-gene association studies 
investigating the correlation between genetic polymorphisms and clinical response 
to acute antimigraine drugs [69] [70] [71] [72] [73] [74] [75]. Despite the wide 
range of symptomatic drugs available for migraine therapy, all 7 pharmacogenetic 
studies were performed on patients exclusively treated with triptans. Triptan 
efficacy was always included as the primary outcome while four out of seven 
studies also investigated the potential correlation between gene polymorphisms and 
triptan-induced side effects as secondary endpoint [70] [71] [72] [75]. The 
polymorphisms studied were related to 5HT1BR (serotonin receptor 5HT1BR) [69] 
[71] [72] [73] [75], SLC6A4 (serotonin transporter SERT) [69] [73] [74], DRD2 
(D2 subtype of dopamine receptor) [69] [73] [74], MAOA (monoamine oxidase A) 
[69] [73], GNB3 (guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-
3) [69] [74], 5HT2A (5HT2A receptor) [69], 5HT1F (5HT1F receptor) [70] , 
MTHFR (methylene tetrahydrofolate reductase) [69], ACE (angiotensin-converting 
enzyme) [69], ESR1 (estrogen receptor alpha) and TNF-B (tumor necrosis factor-
beta) genes [69]. Among them, only DRD2 rs6275 and SLC6A4 Stin2 VNTR 
genetic variations have been reported to be potentially associated with triptan 
response, evaluated in terms of drug efficacy. More precisely, Asuni and colleagues 
reported that carriers of DRD2 rs6275 C/C genotype showed a better response to 
triptans compared to other DRD2 rs6275 genotypes [73]. Conversely, Ishii et al 
found an association between rs6275 C/C genotype and a lack of response to 
triptan class [69] whereas our group did not confirm any correlation between the 
aforementioned genetic variant and triptan response [74]. Moreover, we found a 
significant association between SLC6A4 Stin2 VNTR and response to triptans [74] 
but Ishii and collegues subsequently fail to replicate our results [69]. 
                                                 




Four additional pharmacogenetic studies investigating potential genetic predictors 
of triptan response were published after our database search for the systematic 
review of literature was performed. More precisely, three out of four studies were 
performed by our group 2, whereas the remainder was conducted by Christensen 
and colleagues in 2015 [76]. Christensen et al aimed to test the role of 12 SNPs, 
previously emerged to be correlated with migraine susceptibility [45], as genetic 
predictors of response to both acute antimigraine drugs (triptans and ergotamine) 
and prophylactic medications (beta-blockers, calcium antagonists, angiotensin II 
receptor antagonists and anti-epileptics) in two large cohorts of migraineurs. A 
number of tested SNPs showed a trend of association with the efficacy of triptans 
or some of the prophylactic drugs. Among them, only the genetic variant PRDM16 
rs2651899 resulted significantly associated with the efficacy of triptans in the 
exploratory cohort. However, this correlation failed to be replicated in the 
validation cohort. 
 
As previously mentioned, pharmacological treatment of migraine includes also 
preventive therapy. Through our systematic review of the literature, we identified 
only two pharmacogenetic studies investigating the role of genetic variants as 
predictors of preventive therapy response [77] [78]. One study did not report any 
correlation between ACE I/D polymorphism and the response to ACE inhibitors 
(i.e. lisinopril and candesartan) [77]. The other one found a potential association 
between non-H mitochondrial DNA haplotypes and better response to riboflavin 
[78]. No replication cohorts were present in these two studies.  
After the publication of our systematic review, only one pharmacogenetic study 
investigating the role of genetic background in modulating the response to 
preventive drugs was reported in the literature [79]. This study included 80 
migraine patients treated with tricyclic antidepressants (the molecules were not 
                                                 




specified). Being nitric oxide involved in migraine pathogenesis, the genetic variant 
Glu298Asp of NOS3 gene was investigated as genetic predictor of tricyclic 
antidepressants response. As results, they found that homozygous carries of T allele 
of the Glu298Asp SNP showed a better response to tricyclic antidepressants 
compared to other genotypes. However, the absence of a replication cohort as well 
as the limited sample size of the study do not allow to consider these results as 
conclusive. 
 
The data reported herein highlight that only little information is still available in the 
field of migraine pharmacogenetics. Given the high burden of migraine, in terms of 
high prevalence, disability and healthcare costs, it is surprising that a tool aimed to 
tailor and optimize antimigraine therapies has not received enough attention. 
Moreover, the absence of genome-wide association studies in the field emphasizes 





2. Medication overuse headache 
 
Epidemiological evidences report that each year about 2.5% of people with 
migraine show a progressive worsening of headache clinical presentation, in terms 
of both increased frequency and severity of migraine attacks [80]. This “migraine 
transformation” usually takes place gradually over months to years [81] and leads 
to the development of chronic migraine, defined by the International Classification 
of Headache Disorders, version III- beta (ICHD-IIIb) as a “headache occurring on 
15 or more days per month for more than 3 months, which has the features of 
migraine headache on at least 8 days per month” [17]. 
Chronic migraine has an estimated worldwide prevalence ranging from 1.2% to 
2.2%, with a prevalence peak in women aged 18-49 years [82]. It mainly affects 
people during their most productive years of life, resulting in greater disability and 
higher direct/indirect costs than episodic migraine [83]. It is often comorbid with 
fatigue, sleep disorders, cerebrovascular disease, cardiovascular disease, and 
gastrointestinal problems. Compared to subjects affected by episodic migraine, 
patients with chronic migraine are twice as likely to have depression, anxiety, other 
chronic pain, bipolar disorders and respiratory illness, such as asthma and chronic 
obstructive pulmonary disease [84]. 
Epidemiological studies have identified several modifiable risk factors associated 
with chronic migraine, including  obesity, depression, female sex, snoring, 
comorbid pain disorders, stressful life events (e.g. divorce, marriage, or change of 
employment status) and lower socioeconomic status [85]. However, the ICHD-IIIb 
reports that the most common risk factor for migraine chronicization is 
paradoxically represented by the overuse of any one or more antimigraine drugs 
routinely taken for acute headache pain relief. If some degree of medication 
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overuse co-occurs in chronic migraine patients, their headache disorder is 
specifically defined by ICHD-IIIb as medication overuse headache.  
 
2.1 Clinical classification 
 
Medication overuse headache (MOH), previously named “rebound headache”, 
“drug induced headache” or “medication-misuse headache”, is defined by ICHD-
IIIb as a secondary chronic “headache occurring on 15 or more days per month 
developing as a consequence of regular overuse of acute or symptomatic headache 
medication (on 10 or more, or 15 or more days per month, depending on the 
medication) for more than 3 months. It usually, but not invariably, resolves after 
the overuse is stopped.” [17].  
 









Headache occurring on ≥ 15 days per month in a patient with a pre-
existing headache disorder 
B: Regular overuse for >3 months of one or more drugs that can be 
taken for acute and/or symptomatic treatment of headache 
C: Not better accounted for by another ICHD-3 diagnosis. 
 
It is now accepted that all symptomatic medications may lead to MOH in 
susceptible patients. The ICHD-IIIb accurately report diagnostic criteria for each 













Regular intake of ergotamine on ≥ 10 days per month for > 
3 months. 
  
Triptan-overuse headache Regular intake of one or more triptans, in any formulation, 
on ≥ 10 days per month for > 3 months. 
  
Simple analgesic-overuse headache 
(acetylsalicylic acid or paracetamol) 
Regular intake of acetylsalicylic acid on ≥ 15 days per 
month for >3 months. 
  
Other non-steroidal anti-inflammatory drug 
(NSAID)-overuse headache 
Regular intake of one or more NSAIDs other than 
acetylsalicylic acid on ≥ 15 days per month for > 3 months. 
  
Opioid-overuse headache Regular intake of one or more opioids on ≥ 10 days per 
month for > 3 months 
  
Combination-analgesic-overuse headache  
(intended as formulations combining drugs of two or 
more classes, each with analgesic effect or acting as 
adjuvants) 
Regular intake of one or more combination analgesic 
medications on ≥ 10 days/month for > 3 months. 
  
Medication-overuse headache attributed to 
multiple drug classes not individually overused 
Regular intake of any combination of ergotamine, triptans, 
simple analgesics, NSAIDs and/or opioids on a total of ≥ 10 
days per month for > 3 months without overuse of any 
single drug or drug class alone. 
  
Medication-overuse headache attributed to 
unverified overuse of multiple drug classes 
Regular intake of any combination of ergotamine, triptans, 
simple analgesics, NSAIDs and/or opioids on ≥10 days per 
month for > 3 months. The identity, quantity and/or pattern 
of use or overuse of these classes of drug cannot be reliably 
established. 
 
Overall, it is estimated that MOH affects around 1% of general population, with a 
male to female ratio of 1:3-4 [1]. It’s prevalence peaks in the forties and then 




Chronic analgesic consumption rarely induce MOH in non-headache patients, 
suggesting that MOH may results from an interaction between the overuse of acute 
medications and a susceptible patient [87]. 
The most common headache types affecting patients before MOH development are 
migraine (65%), tension-type headache (27%) and mixed/other headaches (8%) 
[88]. The desire to relieve pain and to normally carry out daily activities may lead 
these subjects to overuse migraine acute medications. The fear of experiencing 
severe pain and disability may also foster them to preemptively take acute 
medications at the first weak warning or, even worse, in anticipation of an attack 
[89]. In this context, it must be underlined that over-the-counter drugs are the most 
commonly overused antimigraine medications in primary care while triptans and 
other more potent, centrally acting, drugs emerged as the most overused ones by 
secondary e tertiary care patients [86]. Among overused drugs, triptans cause MOH 
faster and with fewer doses compared with ergots and analgesics [90]. In Europe, 
MOH is rarely cause by opioids overuse cause their prescription is largely 
discouraged in the medical environment [91]. 
 
Clinical presentations of MOH strongly vary among patients in terms of 
localization, quality and intensity of headache attacks. A plausible explanation 
underlying this variability in headache characteristics may consist in the fact that 
more than 90% of patients tend to concomitantly use different painkillers [88]. 
Common traits in MOH subtypes are morning headaches (possibly due to overnight 
drug withdrawal) and accompanying symptoms such as neck pain, cutaneous 
allodynia, rhinorrhea, lacrimation and gastrointestinal symptoms [92]. 
Risk factor for migraine transformation to MOH other than anti-migraine drug(s) 
overuse include tobacco smoke, sedentary lifestyle, low socioeconomic status and 
gastrointestinal complaints [93]. Chronic musculoskeletal pains, anxiety, 
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The pathophysiological mechanisms underlying the development of MOH are not 
completely known. 
As in migraine, the development of MOH seems to be triggered by cortical 
spreading depression (CSD). Neurophysiological studies demonstrated that an 
increased in neuronal excitability, at least in somatosensory and visual cortices, is 
identifiable in MOH patients. Supporting this, the electrical stimulation on the 
forehead or limb in MOH patients resulted in increased sensory-evoked cortical 
potentials that reverted/normalized after withdrawal from acute medications [96]. 
Moreover, chronic paracetamol or ergot use emerged leading to augmented 
frequency of CSD in rats [97]. 
Cortical changes are evident in MOH. More precisely, Coppola and colleagues in 
2010 reported that MOH patients, especially those overusing NSAIDs, had an 
increased sensitization of somatosensory cortex [98]. By measuring glucose 
metabolism with 18-FDG PET, Fumal et al identified several areas of 
hypometabolism in MOH patients, including bilateral thalamus, orbifrontal cortex 
and insula/ventral striatum. All dysmetabolic areas recovered to almost normal 
glucose uptake after withdrawal of analgesics, except for the orbifrontal cortex 
[99]. Alterations of gray matter volume in cortical areas were also reported by 
anatomical studies. More precisely, increased volumes of periacqueductal grey, 
bilateral thalamus and ventral striatum as well as decreased volumes of orbifrontal 




Another mechanism underlying pathogenesis of MOH is represented by peripheral 
and central sensitization via the trigeminal pain pathway. De Felice and colleagues 
demonstrated that rats who overused triptans had cutaneous allodynia (an index of 
central sensitization in trigeminal nucleus caudalis) and increased CGRP levels 
[101]. Moreover, chronic ergot and paracetamol administration seem to facilitate 
trigeminal nociception [102].  
 
MOH may also be considered a bio-behavioral disorder. Patients affected by this 
condition show dysfunctions in the ventromedial prefrontal cortex of the 
mesocorticolimbic dopamine circuit, which plays a crucial role in reward circuit 
and in drug dependence [103]. 
 
Serotonin, endocannabinoids, orexin A and corticotrophin-releasing factor 
neurotransmission systems are altered in MOH patients.  
A suppression of serotonin function has been described in MOH. More precisely, 
MOH patients had lower levels of platelet serotonin (which revert after withdrawal) 
and higher density of 5-HT2A receptors in platelets [104] [105]. Moreover, 
Ayzenberg and colleagues in 2008 demonstrated that activity of the platelet 
serotonin transporter was increased in patients with analgesic- and triptan induced 
MOH [106]. Serotonin neurotransmission is closely linked to cortical spreading 
depression and trigeminovascular system. Supporting this, cortical spreading 
depression emerged leading to an increased 5-HT2A receptors expression in 
cerebral cortex in rats chronically treated with paracetamol [107]. In addition to 
this, animals with low levels of serotonin also showed an increase in CGRP 
expression in trigeminal ganglion as well as an augmented release of CGRP 
induced by cortical spreading depression [102]. 
Platelets levels of anandamide and 2-acylglicerol, two endogenous cannabinoids, 
were decreased in MOH patients compared to controls [108]. The endocannabinoid 
system seems to inhibit the trigeminovascular system antagonizing the 
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development of neuronal sensitization [92]. Lastly, augmented concentration of 
orexin A (a protein involved in regulating sleep cycles) and corticotropin-releasing 
factors were found in cerebrospinal fluid in MOH patients compared to controls 
[108]. 
However, because several alterations herein reported are also observed in patients 
affected by chronic migraine that did not show medication overuse, it is plausible 
that these anatomical, functional and biochemical changes may reflect headache 




Due to the lack of knowledge concerning MOH pathophysiology, there’s still a 
lack of mechanism-based therapies aimed to effectively treat patients affected by 
this pathological condition. Nevertheless, the scientific community agrees that 
withdrawal from overused drug(s) is the first mandatory approach able to lead to an 
improvement of headache in the majority of MOH patients, irrespective of the 
drug(s) previously overused. However, no internationally accepted guidelines for 
the clinical management of MOH are currently available.   
Detoxification protocols broadly vary among centers and include home treatment 
with simple advice of withdrawal, hospitalization or day hospital. Nevertheless, 
contrasting results have emerged from clinical studies investigating the 
efficacy/superiority of each different detoxification settings.  
Few evidences suggest that simple advice to withdrawal could be effective [109] 
[110]. For example, two Italian studies performed on MOH patients showed that 
the efficacy of simple advice in reverting MOH at 2 months were of 78-92% in 
MOH patients with low medical needs (previously defined by ICHD-II “simple 
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MOH” ) and 60% in MOH patients presenting also psychological problems or 
medical comorbidities (defined by ICHD-II “complicated MOH”) [111] [112]. 
However, several experts are in favour of a more robust support to patients 
undergoing detoxification program. Indeed, it must be acknowledged that drug 
detoxification may result in withdrawal symptoms in the majority of MOH 
patients. Withdrawal symptoms may last 2-10 days and include rebound headache 
(described as an initial worsening of headache pain), nausea, vomiting, 
hypotension, anxiety, tachycardia and sleep disturbances [113]. The duration of 
rebound headaches varies according to the specific drug overused. More in detail, 
triptan overuse, when interrupted, may lead to withdrawal headache lasting 4.1 
days while ergotamine and NSAIDS detoxification may induce rebound headaches 
lasting, respectively, 6.7 days and 9.5 days [114]. Pharmacological therapies for 
withdrawal symptoms are so needed and broadly vary among centers.  In this 
context, the most commonly used drugs include intravenous hydration, NSAIDs 
with a long duration of action (i.e. naproxen and piroxicam, if not previously 
overused), corticosteroids (prednisone), antiemetics, benzodiazepines and eventual 
rescue medication (i.e. other analgesics than overused one) [115] [116]. 
Among robust detoxification programs, the inpatient setting emerged as the most 
effective approach, with a 70% rate of reported success [113]. Hospitalization may 
last from 2 days to 2 weeks and should be preferred to other settings in patients 
with opioids and barbiturate overuse, in subject with psychiatric comorbidities and, 
in general, in patients having difficulties in stopping the overuse. On the contrary, 
motivated patients without psychiatric comorbidities or subjects with NSAIDs- or 
analgesic-overuse headache seem to better benefit from an outpatient setting [91]. 
A day hospital regimen also emerged as effective in reducing long-term headache 




Abrupt vs gradual suspension of the overused drug(s) is an another aspect of 
detoxification protocols largely debated by specialists. Even if no studies directly 
compared efficacy of abrupt versus gradual withdrawal, clinical practice suggests 
that abrupt detoxification may be preferred for triptan-, ergot- and  NSAID-overuse 
headache while a gradual washout is indicated for patients overusing barbiturates, 
opioids, benzodiazepine or compounds containing caffeine [113]. 
 
Preventive therapies are often initiated when MOH treatment begins and include 
the same classes of drugs administered for migraine prophylaxis (i.e. beta-blockers, 
calcium channel blockers, anticonvulsants, ACE inhibitors) [115]. The most 
effective prophylactic drugs include topiramate and onabotulinum toxin A, 
resulting in significantly reduced headache days per month [119] [120]. However, 
two studies did not found a superior efficacy of withdrawal combined with 
prophylactic therapy compared to withdrawal alone, suggesting that a preventive 
therapy should be initiated in MOH patients who did not previously benefit from 
detoxification alone [109] [121].  
 
Medication overuse headache usually, but not invariably, resolves after the overuse 
is stopped. At short term, the withdrawal intervention has good outcomes, with 
only the 25% of patients not responding to the treatment [116]. However, the long 
term prognosis of patients initially responding to the withdrawal worsens over 
time. In fact, a consistent proportion of patients, varying from 22 to 75%, relapse 
again into medication overuse headache within 1 year from an initially effective 
withdrawal [122][123][124][125]. The risk of relapse fortunately tends to decrease 
if medication overuse is avoided for at least 12 months after withdrawal. Risk 
factors for relapse into medication overuse headache include: male sex, primary 
tension type headache, higher severity of migraine condition, longer duration of 
overuse, higher number of prophylactic medication previously administered to the 
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patient, intake of combination analgesic products made up of NSAIDs and caffeine 
or codeine, smoking, alcohol consumption, poor improvement after drug 
withdrawal and reduced sleep quality [126] [127]. Moreover, the type of drug 
overused before withdrawal seems to impact on the risk of relapse: more precisely, 
triptans emerged as conferring a lower risk of relapse compared to analgesics 
[125]. Psychiatric comorbidities have also been suggested to be predictors of a poor 
prognosis after withdrawal [94].  
 
2.4 Genetics and pharmacogenetics of MOH 
 
As previously mentioned, several risk factors for migraine transformation into 
MOH have been identified in the last years. In this context, the observation that 
MOH subjects with a familiar history of MOH tended to have a threefold increased 
risk of developing MOH, fostered the hypothesis that individual genetic 
background might also contribute to influence MOH susceptibility [128].  
Nowadays, the body of knowledge about genetic predisposition to MOH is still 
relatively recent and sparse. The first study aimed to assess the role of genetic 
polymorphisms as predictors of migraine transformation into chronic daily 
migraine accompanied by drug overuse was performed by Cevoli and colleagues in 
2006 [129]. More precisely, in the light of alterations in mesocorticolimbic 
dopamine circuit of MOH patients [103], they conducted a genetic association 
study aimed to assess the role of 4 dopamine metabolism related genes (DRD4, 
DAT, MAOA and COMT) in the genetic liability to MOH. As results, they found 
that the allele 10 of a 40-base-pair tandem repeat in 3’ untranslated region of the 
SLC6A3 gene dopamine transporter (DAT chromosome 5p15-3), was significantly 
underrepresented in patients with chronic migraine accompanied by drug abuse 
compared to migraineurs without drug abuse. 
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Besides dopamine, a number of neurotransmission systems have been postulated to 
be involved in MOH susceptibility. Among them, serotonin primarily emerged as a 
neurotransmitter playing a crucial role not only in migraine and headache but also 
in the sensitization induced by drugs [104] [105] [106] [130]. In this context, four 
genetic association studies were performed with the aim of identifying potential 
correlations between polymorphisms in genes involved in serotoninergic 
neurotransmission and the risk of developing MOH. Cevoli and colleagues in 2010 
investigated the role of six SNPs in five serotonin metabolism-related genes 
(SLC6A4 STin2 VNTR, 5-HT1A A82G, 5-HT1B G861C and T261G, 5-HT2A 
T102C, 5HT6 C267T) as predictors of MOH susceptibility [131]. As results, 
genotypic and allelic distribution of all polymorphisms investigated did not differ 
among MOH patients and healthy controls. A further study performed by our group 
specifically focused on the analysis of 2 polymorphisms in the serotonin 5HT2A 
receptor gene (A1438G and C516T) as plausible risks factors for MOH [132]. In 
this context, we did not find significant differences in genotype distributions 
between MOH patients and healthy controls. However, C516T polymorphism 
emerged as a predictor of the number of symptomatic drug doses taken per month 
by MOH patients. In 2012, we also conducted an association analysis between 3 
genetic variants in SLC6A4 (5HTTLPR, STin2 VNTR and rs1042173) and MOH 
susceptibility [133]. None of the analyzed SNPs were nominally associated with 
MOH susceptibility but the haplotype-based analysis suggested that the haplotype 
STin2 VNTR-rs1042173 might have a trend of association with MOH.  Lastly, 
Ishii and colleagues in 2013 investigated the plausible role of 3 SNPs (rs4570625, 
rs4565946 and rs4341581) in the TPH2 gene as predictors of migraine 
transformation into MOH [134]. More precisely, TPH2 encodes for tryptophan 
hydroxylase 2, which is a rate-limiting enzyme in the synthetic pathway for brain 
serotonin. Despite valid assumptions, genetic distributions of analyzed SNPs did 
not differ between migraineurs and patients affected by MOH. 
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On the basis of the aforementioned disparate results concerning genetic 
susceptibility of MOH, Onaya et al in 2013 analyzed the potential correlation 
between migraine transformation into MOH and 12 SNPs in 12 candidate genes 
involved in the onset of migraine and/or depression, including SLC6A4, 5HT2A, 
5HT1B, MTHFR and DRD2 [135]. More precisely, genotypic distributions for all 
analyzed SNPs were compared between 47 migraine patients and 22 MOH 
patients. Among all studied SNPs, only MTHFR C677T and DRD2 C939T resulted 
significantly associated with the development of MOH in migraineurs. 
Overall, this results are clearly inconclusive and do not support a validated role of 
specific genetic variants in influencing MOH susceptibility. Further studies with 
larger sample sizes and independent replication cohorts are so needed to clarify the 
impact of genetic background on MOH. Moreover, the performance of genome-
wide association studies may potentially allow to identify new genetic variants 
involved in MOH susceptibility, giving the chance to spread light on still unknown 
pathogenic mechanisms underlying this neurological condition.  
 
If little is known about genetic susceptibility to MOH, then even less has been 
discovered concerning genetic predictors of the prognosis of MOH patients.  Di 
Lorenzo and colleagues in 2009 evaluated the role of BDNF Val66Met as a 
worsening factor in the progress of MOH disease [136]. More precisely, due to the 
fact that MOH shares some pathophysiological mechanisms of drug addiction and 
that BDNF Val66Met is involved in substance abuse, they hypothesized that this 
genetic variant in BDNF might influence the number of doses taken by MOH 
patients. As results, they found that homozygous wild-type subjects for Val66Met 
(GG) showed a lower consumption of monthly drug doses compared to other 
genotypes (non-GG). 
As previously mentioned, withdrawal from overused drug(s) is to date the best 
available treatment for MOH patients. Surprisingly, even if several studies have 
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been conducted with the aim of identifying clinical predictors of short- and long-
term outcomes after detoxification, no evidences are now available regarding the 
influence of genetic background on the response to withdrawal therapy in MOH 
patients. In our opinion, the identification of genetic predictors for the prognosis of 
MOH patients underwent withdrawal is strongly needed because it may allow 
clinicians to identify subjects that may benefit or not from a specific detoxification 
protocol. In addition to this, the choice of a more or less robust withdrawal setting 
according to genetic predictors may, in principle, result in improved MOH patients’ 
quality of life and optimized health-care resources. 
 
2.5 Pharmacoepidemiology of triptan-overuse headache 
 
Migraine chronicization into medication overuse headache is a clinical issue of 
primary importance in the field of therapeutic management of migraine. Indeed, 
MOH is a costly disease, both in terms of social burden and high direct and indirect 
economic costs. Recently, a comprehensive estimation of expenditure for headache 
disorders in Europe was conducted in eight European countries representing the 
55% of adult European population. Mean per-person annual costs emerged to be 
three times higher for MOH (€ 3561, 92% of indirect costs) compared to those 
estimated for episodic migraine (€ 1222, 93% of indirect costs). What is more is 
that, despite MOH low prevalence, its annual costs resulted to account for the 21% 
of total annual expenditure for all headache types (€173 billions) [137]. In the light 
of the aforementioned results, there is clearly a need of still performing multiple 





In the interest of lightening migraine and MOH burdens, the analysis of the 
utilization patterns of anti-migraine drugs in a real setting has represented a key 
step in drawing a more comprehensive picture of the actual use or overuse of these 
drugs in unselected populations. 
In general terms, the study of the utilization and effects of drugs in large 
populations is provided by the pharmacoepidemiology research, recently defined 
by the World Health Organization as “the application of epidemiological methods 
and reasoning to the study of the use and effects/side-effects of drugs in large 
numbers of people, with the purpose of supporting the rational and cost-effective 
use of drugs in the population, thereby improving health outcomes”. More 
precisely, the pharmacoepidemiologic description of the extent, quality and 
determinants of drug use is specifically performed by drug utilization studies, 
which are aimed to facilitate and promote the rational use of drugs, “giving special 
emphasis on the resulting medical, social and economic consequences” [138]. 
Hence, drug utilization studies focusing on the dispensing of anti-migraine drugs 
could allow not only to trace use and overuse of the aforementioned drugs in large 
communities but also to promote drugs’ appropriate use in the interest of patients’ 
quality of life and optimization of health resources. 
 
As previously mentioned in Chapter 2.1, all symptomatic medications for migraine, 
if overused, can trigger migraine transformation into MOH. 
At this stage, the question that arises is whether is possible to trace the use/overuse 
of all anti-migraine symptomatic drugs available on the market. The response to 
this question directly depends on the data available for the pharmacoutilization 
analysis. Indeed, the data sources of drug utilization studies broadly vary among 
countries depending on the level of record keeping and data collection, and usually 
include in-field collected data, disease registries and large healthcare databases. 
Due to their reliability and worldwide diffusion, healthcare databases are nowadays 
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commonly used in drug utilization studies and are defined as “electronic systems 
design to store, on an ongoing basis, disease related data (e.g. drug prescription, 
hospital diagnoses, outpatients visits and so forth) from a well-defined dynamic 
population” [139]. More precisely, healthcare databases can be classified into: 
i) databases collecting information for administrative purposes (healthcare 
utilization databases - HCU), which were initially born as simple electronic 
storages of data pertaining patient’s demography, healthcare procedures and 
other health services (e.g. drug prescription/dispensation data, hospital 
admission and diagnoses, laboratory examinations, surgical and other 
interventions) for supplying payments to providers of health services; 
ii) databases generated by medical records (MRs), which allow physicians to 
easily collect and retrieve data concerning the clinical picture of their 
patients. 
HCU databases have a major real life clinical practice representativeness compared 
to MRs, with larger sizes of the covered populations (often up to million patients) 
and lower costs for the information obtaining. Prescription/dispensation data 
recorded in HCU databases are particularly suitable for investigating drug-use 
profiles, in terms of prevalence, incidence and duration of drugs’ use. In fact, 
accurate information regarding drug name, formulation, dose, frequency of 
administration and duration of treatment may be provided by each prescription 
form recorded in the database. With respect to Italy, data concerning all prescribed 
drugs reimbursed by the Italian National Health Service are recorded into 
administrative databases by regional health authorities. 
 
On the basis of the aforementioned, it’s clear that prescription data cannot trace the 
pattern of use of all routinely used antimigraine drugs. Most of the commonly used 
non-specific drugs for migraine (i.e. simple or combination analgesics and 
NSAIDs) are over-the-counter drugs. Their uncontrolled dispensation may 
42 
 
obviously result in unlimited drug consumptions potentially triggering MOH; 
nevertheless, their pattern of use during time cannot be traced by means of drug 
prescription data. 
Contrary to NSAIDs, triptans are prescribed by general practitioners in a number of 
countries, including Italy, and so, in principle, the analysis of individual triptan 
prescription may allow to accurately estimate the real prevalence of triptan use and 
overuse in large communities. Moreover, since triptans are specific anti-migraine 
drugs and migraine is their only therapeutic indication, the analysis of triptan use 
and overuse may surely allow to identify only subjects affected by migraine and 
potentially at risk of developing triptan-induced MOH. Conversely, other non-
specific antimigraine drugs (e.g. NSAIDs and analgesics) cannot be considered 
unequivocal tracers of migraine condition because they may be used and overused 
for treating pain conditions other than migraine. 
On the basis of the aforementioned reasons, several drug utilization studies have 
been performed worldwide in the last 20 years with the aim of describing use and 
overuse of triptans in large and unselected population samples.  
Different methods and different threshold have been used to define triptan overuse. 
According to the International Classification of Headache Disorders, version III-
beta, MOH induced by triptans overuse (named “triptan-overuse headache”) is 
defined as a secondary chronic headache due to a “regular intake of one or more 
triptans, in any formulation, on ≥ 10 days per month for at least 3 consecutive 
months” [17]. Assuming that patients takes all the triptans prescribed, but not more 
than one dose per day, the minimum threshold used to define triptan overuse is the 
prescription/dispensation of at least 10 DDDs 3 of triptans every month for at least 
three consecutive month. More stringent definitions of triptan overuse (set on the 
                                                 
3 DDD (Defined Daily Dose): the assumed average maintenance dose per day for a drug used for its 
main indication in adults. DDD is a comparison unit and does not necessarily correspond to the 
recommended dose. According to World Health Organisation, DDD as a measuring unit has become 
the gold standard for international drug utilization research. 
43 
 
basis of higher thresholds of monthly dispensed DDDs of triptans) have been often 
used, allowing the identification of more serious triptans overusers. 
Overall, the results emerged from these drug utilization studies suggest that the 1-
year rate of triptan users among general population ranged from 0.55% to 1.4% of 
general population. The most commonly used threshold for defining triptan overuse 
was set at the dispensing of more than 120DDDs per year [140] [141] [142] [143]. On the 
basis of this definition, the prevalence of triptan overuse in triptan users varied 
between 3.2 and 14.3%. 
Among this studies, two were performed on prescription data recorded by the 
Italian Regional Health Authority of Tuscany and Emilia-Romagna [142] [143]. 
The first one was conducted on prescription data covering around 225,000 resident 
of Tuscany in 2005 [142]. The 0.55% of general population resulted using triptans 
in that period. Among them, the 3.2% emerged overusing at least 120 DDDs of 
triptans per year; an even more intense overuse (≥216 DDDs/year) was observed 
only in the 0.9% of triptan users. 
A subsequent study was performed on prescription data recorded by the Regional 
Health Authority of Emilia Romagna (4,249,533 inhabitants) [143]. In this 
community, triptan users represented the 0.8% of the population, a percentage 
consistent with that one reported in the previous study conducted on a Tuscany 
population. Herein, the rate of users being dispensed more than 120 DDDs/year 
reached the 14.3% of triptan users and the 7,5% of triptan users showed an overuse 
of at least 180 DDDs per year. 
Overall, the rates of triptan overuse emerged from the studies conducted on these 
two Italian communities are inconsistent. In addition to this, available data run 
back in time and so it would be important to have an updated snapshot of triptan 
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Outlines of the thesis 
 
The pharmacogenetics of migraine 
 
Migraine is a highly disabling primary headache disorder that affects around 10% 
of the worldwide adult population, with a male to female ratio of 1:3. Despite 
several symptomatic and preventive drugs are currently commonly used in the 
clinical management of acute migraine, this neurobiological condition still remains 
under-diagnosed and under-treated, placing a substantial burden on society. The 
relatively recent advent of triptans in acute migraine treatment has greatly 
ameliorated the societal impact of the disease to the extent of leading triptans to be 
considered by many experts as the gold-standard therapy for acute migraine. 
Nevertheless, clinical evidences have reported a significant interpatient variability 
in the response to all drugs routinely used for migraine treatment, including 
triptans. Non-response to each anti-migraine drugs classes was hypothesized not to 
be fully explained by altered pharmacokinetic parameters or incorrect drug 
administration, suggesting that genetic individual variability could also account for 
pharmacokinetic and pharmacodynamic drug variability. Surprisingly a very few 
pharmacogenetic studies have been performed in migraine. With the aim of 
comprehensively collecting all available pharmacogenetic evidences in episodic 
migraine, we conducted in September 2012 a systematic review of literature 
concerning genetic predictors of response to all available acute or preventive 
antimigraine drugs. As expected, we reported sparse and inconclusive 
pharmacogenetic evidences exclusively supporting potential correlations between 
few genetic variants and triptan response in migraineurs. 
In order to fill the lack of pharmacogenetic knowledge into migraine therapeutics, 
we further performed three candidate gene association studies investigating the role 
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of common genetic polymorphisms on the response to triptans in large cohorts of 
migraineurs enrolled at specialized headache centers. More precisely, the 
polymorphism COMT rs4680 emerged as a potential genetic predictor of triptan 
response in both an exploratory and a validation cohort of migraineurs. Conversely, 
genetic variants in GRIA1 (rs548294, rs2195450) and CGRP-related genes 
(CALCA rs3781719, RAMP1 rs3754701, RAMP1 rs7590387) were found not to 
be correlated with triptan response in migraineurs. 
 
The pharmacogenetics of medication overuse headache 
 
Medication overuse headache (MOH) is a daily or almost daily type of headache 
which results from chronicization of episodic migraine or tension-type headache as 
a consequence of symptomatic drug overuse. Withdrawal of the overused 
medication/s is at present recognized as the treatment of choice for MOH. At short 
term, the withdrawal intervention results in good outcomes, with only the 25% of 
patients not responding to the detoxification. However, the long term prognosis of 
patients, initially responding to the withdrawal, worsens over time, with the 22-
75% of patients relapsing again into MOH within 1 year from the withdrawal. Even 
if several studies have been conducted with the aim of identifying clinical 
predictors of short- and long-term outcomes after detoxification programs, no 
evidences are reported regarding the influence of genetic background on the 
response to withdrawal therapy in MOH patients. In the light of this, we conducted 
two exploratory pharmacogenetic studies assessing the role of several 
polymorphisms as genetic predictors of both short-term prognosis (14 
polymorphisms in 8 candidate genes) and long-term prognosis (COMT rs4680, 
COMT rs6269, SLC6A4 STin2 VNTR) of MOH patients underwent in-patient 
withdrawal therapy. More precisely, DRD2 NcoI emerged as a plausible genetic 
determinant of detoxification outcome in MOH patients at 2 months of follow-up. 
In addition to this, the combination of multiple genetic markers among the tested 
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ones resulted to be clinically useful for the identification of MOH patients at higher 
risk for poor short-term prognosis. As regards to the identification of genetic 
predictors of long-term prognosis, COMT rs4680G allele carriers or subjects with 
COMT rs6269G-rs4680G haplotype were found to be at lower risk of relapse into 
MOH within one year from successful detoxification therapy, compared, 
respectively, to rs4680AA carriers or COMT rs6269A-rs4680A carriers. 
 
The pharmacoepidemiology of migraine chronicization into medication overuse 
headache 
 
In the interest of lightening migraine and MOH burdens, the analysis of the 
patterns of triptans utilization in a real setting has represented a key step in drawing 
a more comprehensive picture of the actual use or overuse of these drugs in 
unselected populations. In Italy, drug utilization studies performed on prescription 
data recorded by administrative databases of two Regional Health Authorities 
suggested that the 0.6-0.8% of general population used triptans during the study 
period. Among triptan users, the 3.2-14.3% emerged to overuse these drugs, so 
being at risk of developing MOH. Since this data ran back in time, we aimed to 
have an updated snapshot of triptan use/overuse in Italy. We performed a drug 
utilization study on 1-year prescription data (1 Jan 2012- 31 Dec 2012) derived 
from the drug dispensation monitoring system of the Local Health Authority of 
Vercelli (about 175,000 inhabitants) and of the Umbria region (about 885,000 
inhabitants). Our findings suggested that triptans were used by the 0.7-1.0% of the 
population and that the 10% of triptan users showed triptan overuse during the 
study period. Moreover, about two-thirds of triptan users who overused triptan in 
the first semester of 2012 persisted in this behavior in the following six months. 
Given the need of reducing prevalence and duration of MOH, our data suggest that 
an approach based on drug prescription databases could be useful for early 
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Abstract 
Background: Migraine is a disabling condition characterized by a heterogeneous 
behavior of response to drug assumption. In the recent years many resources have 
been invested in studies attempting to unravel the genetic basis of migraine, while 
the role of genetics in preventive or symptomatic responses to currently available 
drugs has received less attention.  
Methods: We performed a systematic literature search identifying original articles 
pertaining to pharmacogenetics of episodic migraine.  
Results: Seven primary studies on the pharmacogenetics of symptomatic 
medication and two primary studies on pharmacogenetic aspects of preventive 
medication in episodic migraine were found. The number of patients studied in the 
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individual articles ranged between 40 and 130. There was a strong heterogeneity 
among these studies.  
Conclusion: We believe that Pharmacogenetic studies, if properly designed, could 
give a contribution in optimizing the treatment and reducing the burden of 
migraine, in turn helping patients and optimizing resources. Yet, our knowledge on 
the pharmacogenetics of migraine is growing too slowly, and concerted measures 
should be undertaken to speed up the process.  
 
Keywords 






Migraine is a highly prevalent and disabling condition, with high socioeconomic 
and quality of life impact. In the World Health Organization’s study on the global 
burden of disease, migraine was ranked among the first diseases causing worldwide 
disability, with a high incidence in more active age [1]. 
In recent years, a number of studies have focused on attempting to unravel the 
genetic basis of migraine [2]. These attempts have also included genome-wide 
association studies [3] which have indeed found an association between common 
genetic variants and the risk of migraine with or without aura [4-6]. The 
investigation of the genetic backgrounds that confer a higher or lower possibility to 
respond to single drugs used in migraine has not, instead, received as much 
attention. This is surprising, given also the high number of preventive or 
symptomatic treatments available and the well-known fact that there is a great 
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inter-patient variability of response. Moreover, migraineurs may have side effects, 
or adverse events, to treatments, more frequently than other groups of patients [7]. 
Pharmacogenomic studies in this respect would be warranted to allow for a more 
tailored therapeutic approach, as well as to unravel sub-populations that at present 
are inadequately treated by drugs on the market [8,9]. Yet, despite rigorous 
pharmacogenomic studies have been carried out in many other diseases with 
interesting and clinical-relevant results, our impression is that in migraine they are 
very few, with many methodological limitations, different study designs and finally 
contrasting results. The lack of shared and appropriate “guidelines” to carry out 
these studies, interpretation the data and write the manuscript, is so deep that even 
a non-univocal choice of the key words makes it difficult to find these few original 
studies in PubMed using the keywords ((“pharmacogenomics” OR 




The aim of this work was to evaluate, by a systematic review to identify articles 
dealing with pharmacogenomic studies in episodic migraine, the quality of what 
has been produced so far in terms of number of manuscripts, methodology, results 
and translationality. With this in hand, secondary we will propose some suggestion 
to design proper and shared guidelines for such studies. These should avoid that 
other efforts will be produced to perform non-comparable, underpowered, or not 





To perform this systematic review the principles of the PRISMA statement were 
used. To retrieve the relevant articles, we used the database Pubmed and the last 
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search was performed on September the 6th 2012. We used three groups of 
combination of terms: (i) “(pharmacogenetic OR pharmacogenomic) AND 
migraine”; (ii) a symptomatic treatment (ST) search that combined any drug ranked 
at least at “level C” or “weak” recommendation in at least one of the most updated 
European, U.S. and the most recent national (Canadian and Italian) guidelines for 
the symptomatic treatment of migraine [10-13] AND the terms “(gene OR genetics 
OR genomics OR polymorphism OR polymorphisms OR SNP OR SNPs) AND 
migraine”; and (iii) a preventive treatment (ST) search that combined any drug 
ranked at least at “level C” or “weak” recommendation in at least one of the most 
updated European, U.S. and the most recent national (Canadian and Italian) 
guidelines for the preventive treatment of migraine[10-13]) AND the terms  “(gene 
OR genetics OR genomics OR polymorphism OR polymorphisms OR SNP OR 
SNPs)” AND migraine”.  A full list of terms used in the symptomatic treatment 
(ST) and preventive treatment (PT) search is present in Table 1. We also 
considered articles from the reference lists of relevant papers and reviews on 
pharmacogenomics of migraine. 
 
Table 1: Search strings used to specify drugs used in symptomatic or preventive 






‘(sumatriptan OR rizatriptan OR zolmitriptan OR almotriptan OR eletriptan OR naratriptan OR 
frovatriptan OR ‘acetylsalicylic acid’ OR aspirin OR NSAID OR ‘non-steroidal anti-inflammatory drugs’ 
OR ibuprofen OR diclofenac OR ketoprofen OR naproxen OR paracetamol OR acetaminophen OR 
ketorolac OR metamizol OR indometacin OR flurbiprofen OR piroxicam OR pirprofen OR ‘mefenamic 
acid’ OR butalbital OR ergotamine OR DHE OR dihydroergotamine OR ‘ergot alkaloids’ OR codeine OR 
tramadol OR meperidine OR butorphanol OR isometheptene OR lidocaine OR corticosteroids OR 
dexamethasone OR chlorpromazine OR metoclopramide OR prochlorperazine OR domperidone OR 
phenazon OR ‘tolfenamic acid’) AND (gene OR genetics OR genomics OR polymorphism OR 






‘(metoprolol OR propranolol OR timolol OR atenolol OR nadolol OR bisoprolol OR nebivolol OR 
pindolol OR candesartan OR lisinopril OR clonidine OR guanfacine OR flunarizine OR cinnarizine OR 
valpro* OR divalproex OR topiramate OR carbamazepine OR amitriptyline OR venlafaxine OR 
cyproheptadine OR petasites OR butterbur OR naproxen OR acetylsalicylic OR gabapentin OR 
magnesium OR tanacetum OR feverfew OR parthenolide OR riboflavin OR ‘Coenzime Q10’ OR 
methysergide) AND (gene OR genetics OR genomics OR polymorphism OR polymorphisms OR SNP OR 




Studies investigating the association between common genetic variants 
(polymorphisms) and the clinical response (in terms of efficacy and/or tolerability) 
to symptomatic or preventive medications in episodic migraine patients of any age 
were retrieved. Only original articles were considered in the analysis while review 
articles were excluded but their reference list was scanned for further articles of 
interest. No language, publication date or publication status were imposed. Studies 
on patients with chronic migraine (with or without medication overuse) or cluster 
headache were excluded. 
 
Study selection and data extraction 
Eligibility assessment of manuscripts was performed independently of each other 
by two investigators (M.V. and C.D.L) who examined all the abstracts found in the 
literature search. Disagreement between reviewers was solved by consensus. 
Whenever the abstract suggested that the publication was relevant, the entire 
manuscript was retrieved and examined. 
Two investigators (M.V. and C.D.L.) independently extracted data from the articles 
and entered them into a customized database. In case of disagreement, a consensus 
agreement was reached by involving the third person (A. A. G.). This was the case 
in the review of two abstracts. The extracted data included: publication information 
(authors, year of publication, Country), population characteristics (number of 
patients, gender distribution, age, BMI, overlapping sample among studies), 
clinical information (diagnosis - diagnostic system by which the diagnosis was 
performed, headache frequency, duration of illness, previous exposure to the 
medication - or class of medications – studied, other concomitant medications), 
study methodology (prospective/retrospective, exclusion criteria, use of an 
headache diary, number of attacks treated for the symptomatic medication), genetic 
polymorphisms, medication(s) studied, clinical endpoint (primary and secondary 
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outcomes, measures and results), statistical analysis (type of analysis, calculation of 
Hardy-Weinberg equilibrium, use of effect size measures, application of any post 
hoc correction) and results of the genotype-phenotype association analysis. We 
contacted two authors (corresponding authors of 4 manuscripts [14-17]) for further 
information, in particular relating to the study methodology. Both responded fully 




The search strategy identified a total number of 412 published studies: 28 for the 
“(pharmacogenetic OR pharmacogenomic) AND migraine” search, 257 for the ST 
search and 127 for the PT search (Figure 1). Of these, 46 articles were duplicated in 
more than one search, nine were reviews on pharmacogenetic/genomics of 
migraine [18-26], one was an original article concerning a pharmacogenetic study 
in chronic migraine and/or MOH [27], whereas 350 did not meet the main 
inclusion criteria. Six articles were considered for a full text reading (4 for ST [15-
17, 28] and 2 for PT [29, 30]). The reference list of these six papers and of the nine 
reviews mentioned above were scanned for further articles, and three additional 
studies [14, 31, 32] (all relating to ST) were identified. It has to be noted that 
during this latter search we found also four papers regarding pharmacogenetic 
studies in MOH [33-36] that were therefore excluded. The nine articles were all in 
the English language. Key findings of these studies are summarized in 
Supplementary tables 1 & 2. Only a single eligible study [17] was found by the use 







Figure 1: Review process 
 
†By checking the references of relevant papers and reviews. ‡Four articles were not taken into account as they were 
only related to the pharmacogenomics of medication overuse in headache. 
MOH: Medication-overuse headache; PT: Preventive treatment; ST: Symptomatic treatment. 
 
Symptomatic Treatment 
In all the seven studies the Authors investigated the association between genetic 
polymorphisms and clinical response to triptans [14-17, 28, 31, 32]. These seven 
studies, spanning from 1998 to 2012, stemmed from 4 groups. One group 
performed different genetic analyses from 1998 to 2012 on the same sample of 
patients that underwent the same clinical trial [15-17]. One group performed 
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different genetic analyses on overlapping patients [31, 32]. The number of patients 
studied in the individual articles ranged between 40 and 130. The cumulative 
number of patients studied was 480, but the unique patients enrolled were 280. All 
the studies reported the age and gender distribution (see supplementary table 2); 
none reported data on BMI of the patients. With respect to the diagnosis only the 
study by Asuni et al [28] was performed on a homogenous sample: 40 patients 
affected by migraine without aura. In three studies the sample population presented 
either migraine without aura or migraine with aura [14, 31, 32], while three studies 
reported that the population was composed by “migraine patients” without further 
specifications [15-17]. Headache frequency and the age of onset of migraine were 
lacking in three studies [14, 31,32], the presence of a preventive therapy was 
reported just in two out of seven studies [31,32], concomitant use of other 
medications was not reported in any of the papers. Whether patients were naïve to 
triptan use was not reported in any paper. Exclusion criteria such as the presence of 
a psychiatric comorbidity or contraindication to the use of a triptan compound were 
reported only in two studies [14,31]. The symptomatic treatment evaluated was a 
single triptan in four studies (rizatriptan 10mg per os on 40 patients [28] and 
sumatriptan 6 mg subcutaneous in other 40 patients [15-17]), while in three studies 
a pool of different triptans were used: four in one case [14] and six in two studies 
[31, 32] (in all the three studies each patient used for all the three attacks tested the 
same triptan). 
With respect to the study design of the clinical assessment, four studies were 
retrospective [14-17] while three were prospective (with a specific diary to fulfill 
during the attacks) [28, 31, 32]. 
Polymorphisms studied were related to 5HT1B in five studies [14, 16, 17, 28, 32], 
SLC6A4 in three studies [14, 28, 31], DRD2 in three studies [14, 28, 31], MAOA 
in two studies [14, 27, 28], GNB3 in two studies [14, 31], 5HT2A [14], 5HT1F 
[15], MTHFR, ACE, ESR1, TNF-B in one article [14]. Triptan efficacy was always 
75 
 
included as the primary outcome, yet the clinical measures were different among 
the studies (including studies performed by the same group). Considering these 
differences the response rate ranged from 66.9 to 76.6%. Four out of seven studies 
investigated also an association between gene polymorphisms and the presence of 
side effects as a secondary endpoint [15-17, 32]. 
The Hardy-Weinberg equilibrium was not reported in 2 studies [14, 32]. None 
adopted an a priori power analysis to detect the sample size of the study whereas 
three studies adopted a post hoc power analysis [17, 31]. 
Statistical analysis was conducted by Fisher's exact test or chi-square test alone [16, 
28, 32] or followed by multivariate logistic regression analysis [14, 31] while two 
studies did not mention the statistics used [15, 17]. All studies analyzed a single 
cohort of patients and no replicatory cohort was used. 
In these studies, DRD2 rs6275 (also known as C939T or NcoI) and SLC6A4 Stin2 
VNTR polymorphisms have been reported as associated to the response to triptans 
in terms of efficacy [14, 28, 31]. Only one study applied correction for multiple 
testing [31]. Asuni et al [28] found that rs6275 C/C carriers were associated with a 
good response to rizatriptan. Yet, in a similar size population sample, Ishii et al 
[14] found in the multivariate analysis an association of the C/C genotype with a 
lack of response to triptans as a class. In a third study, no association was found 
between DRD rs6275 and response to triptans, albeit the patient characteristics, the 
triptans used, and the efficacy end-point were different [31]. Terrazzino et al [31] 
found a significant association between the variable number of tandem repeats 
polymorphism in intron 2 (Stin2 VNTR) of the serotonin transporter gene 
(SLC6A4) and the clinical response to triptans. However, this finding was not 
replicated in a subsequent study by Ishii et al [14]. No study found any association 






The two studies concerning the pharmacogenetics of preventive treatment (PT) in 
migraine investigated the role of the angiotensin converting enzyme (ACE) 
genotype on response to ACE inhibitors/sartans [30] and the role of mtDNA 
haplogroups on the response to riboflavin [29]. The number of patients was 104 
and 64, respectively. Yet, the largest study recruited from two previous 
randomized, double-blind, placebo-controlled crossover studies and the patients 
were stratified in two groups: lisinopril (on 47 patients) and candesartan (in 57 
patients) in migraine prophylaxis [37, 38]. Both studies reported the age and gender 
of patients but neither reported the BMI of patients. Both studies included patients 
suffering from migraine with and without aura. In respect to clinical data, headache 
frequency was reported in both studies while age of onset of migraine was reported 
only in the study by Di Lorenzo et al. In the riboflavin study [29] and in the 
candesartan group of the ACE polymorphism study [30, 37] it was specified that 
only patients naïve for the tested medication were enrolled while. Just in one study 
only patients who were not under any chronic medication (except for contraceptive 
pill) were enrolled [29]. 
Both studies were prospective and a headache diary was used. As reported above, 
the candesartan and lisinopril studies were randomized, double-blind, placebo-
controlled crossover studies, while the riboflavin study was an open study where 
the pharmacogenetic side was blinded. The primary outcome measure was the 
efficacy in migraine prevention but with some differences: in the riboflavin study 
the Authors used as the reduction in monthly attack frequency of at least 50% 
between the month preceding inclusion and the fourth month of treatment whereas 
in the candesartan and lisinopril studies the treatment period was compared to the 
placebo period (responders being patients with at least 50% reduction of headache 
days). Responder rates were 62.5% for riboflavin [29], 32.1% for candesartan and 
24.4% for lisinopril [30]. 
77 
 
The Hardy Weinberg equilibrium was only tested in one paper [30] since it is not 
required in haplogroup analysis [29]. Power analysis was performed in both studies 
(a priori analysis in the riboflavin study [29], not specified in candesartan/lisinopril 
study [30]).  
In the study that investigated the association between ACE genotypes and the 
response to candesartan or lisinopril there was no significant association [30], 
while in the study by Di Lorenzo et al. riboflavin appears to be more effective in 
patients with a particular cluster of mitochondrial haplogroups [29]. No replication 
cohorts were present in these studies and no further studies investigating these 




The data presented above confirms our hypothesis, highlighting a number of key 
flaws in the field of migraine pharmacogenomic studies. 
First, the manuscripts presenting primary data on the pharmacogenomics of 
migraine is extremely slim. This is highly surprising, given that a tool to tailor 
therapy to migraineurs is badly needed. Furthermore, it would be expected that a 
disease with such high incidence would have presented an ideal setting to recruit 
patients.  
Second, all the articles so far published in the field are hypothesis-driven, and there 
is no GWAS at present available. As this latter technique is costly, this fact may 
suggest that funding is one of the limiting steps in the pharmacogenetics of 
migraine. Part of this might be due to the lack of industrial interest given the patent 
expiry of most molecules used. Yet, it is paradoxical that public funding is limited 
for a situation that could greatly improve health while decreasing treatment costs. 
Third, population sizes in the published manuscripts are small (albeit adequate in 
most circumstances). Once again, this is surprising, given that migraine has such a 
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high prevalence and that the study designs are particularly simple and of an 
observational nature. 
Fourth, no manuscript presents a replication cohort, which at present is becoming 
the norm for pharmacogenetic associations in most fields. The replication cohort 
improves the quality of the result, reducing significantly false positives. Indeed, 
when comparing the published studies, the study designs appear largely 
heterogenous, suggesting that no consensus on how to best approach the problem 
has been reached. 
Fifth, studies facing preventive treatments are substantially absent (no studies on 
first choice treatments are present in literature), despite the high number of 
pharmacological classes involved migraine prophylaxis. Pharmacogenomic of 
migraine prophylaxis is a very interesting field of research, with a high 
translational impact. In fact, the response to a prophylaxis is often late and patient 
has to face a long, frequently expensive and non-free of side effects treatment 
before to understand if the therapy is effective or not. 
Sixth, the importance of common comorbid medical conditions is almost neglected 
by authors, even if they may influence treatment efficacy and side effects. It is, for 
instance the case of BMI that may influence results of such studies in at least two 
ways: it could modify the pharmacokinetics of drugs [39] and could worsen 
frequency, severity and clinical features of migraines [40]. Recent data evidenced 
that another important comorbidity that has to be taken into account in 
pharmacogenomics studies is psychiatry. In fact, the genetic background of 
migraine comorbid to major depressive disorder seem to be different from migraine 
alone [41]. Different genetic backgrounds could account for different 
pharmacogenomics consequences. 
To summarize all our considerations, we can assert that the field of 
pharmacogenomics in migraine is still at its year zero. The distance between 
research in migraine genetics and in pharmacogenetics is at present immense. To 
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give an example, the most recent high impact paper published on the genetics of 
migraine without aura included a GWAS on a total of 2300 patients from two 
separate cohorts and the results were replicated in four independent patient datasets 
(including 2500 patients) [42]. 
We feel that the time for a step forward in the search for genetic determinants of 
drug response in migraine has come. Indeed, it must be acknowledged that, at 
present, the choice of which preventive and/or symptomatic treatment to administer 
to a single patient is mainly guided by contraindications, side effects, and personal 
clinical experience and therefore an index of a priori efficacy would be badly 
needed. In this respect, it would be helpful to harmonize future studies around a 
few key pillars, to make studies comparable. This could also help form consortia in 
the future with similar databases. As an example, a simple scheme as that presented 
in Box 1 could be a good starting point. 
Yet, the use of such restrictive inclusion/exclusion criteria raises a crucial concern: 
the difficulty in patient recruitment. In fact, some of the authors of this manuscript 
have started a pharmacogenomic study in symptomatic treatment in migraine 
(triptans) for 18 months, following these guidelines (Box 1). Yet, out of 2000 
patients referred to Mondino Headache Center (tertiary university based center), 
just 40 patients were eligible and finally enrolled. Wordwide, most of the research 
in headache is run in tertiary / University based centers. Yet, these are the centers 
where most complicated cases are seen and therefore they might not be the ideal 
settings in which to recruit naïve patients. This point is more dramatic in the case 
of studies regarding over the counter drugs or nonsteroidal anti-inflammatory 
drugs, since it is virtually impossibile to find naïve patients for these treatments and 
it is unknown if the prolonged consumption of these drugs will have some 
influence on triptan response. We feel that best option to reach an adequate number 
of patients is to perform a multicenter study and to eventually involve local general 
practitioners in the referral of selected patients.  
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Box 1: Possible observational protocol for pharmacogenetic studies in episodic 
migraine.  
 
Collect demographic & clinical information that might affect drug response  
Examples: age, duration of illness and BMI, among others.  
 
Collect headache characteristics that might affect drug response  
Examples for symptomatic treatment (ST) studies: frequency, attacks upon waking, menstrual-
related attacks and delay of intake of the symptomatic medication, among others.  
Tool: use a headache diary to record triggers, headache phenotype and patient’s behavior/use of 
symptomatic medication.  
 
Collect pharmacological history of medications that might affect response  
Example: concomitant nonmigraine medication and other symptomatic treatment or preventive 
medication (recommendation for ST studies: only patients without prophylaxis).  
Consumption of cigarettes, caffeine, herbs or other substances.  
 
Population  
Homogeneous for diagnosis (at least second level of International Classification of Headache 
Disorders, beta release of 3rd version [46]; e.g., 1.2 code = migraine without aura).  
Sample size at least sufficient to detect medium effect sizes (clinically relevant).  
Exclude patients with comorbid conditions known to affect response to treatment (i.e., psychiatric 
disorders).  
Only patients naive for the tested medication (it should be better to enroll patients that have never 
taken drugs of the same pharmacological class of the medicine that is being studied).  
 
Study design  
Prospective assessment of the clinical response to drug.  
Use a headache diary.  
Challenge one medication in one formulation for line of treatment (and consider the patient that had 
no benefit: nonresponder to that single compound in that formulation). Consider the patient a 
nonresponder to the whole class when he had no benefit from all the compounds in all the 
formulations available [42].  
 
Outcome measures  
Use a primary end point that is least affected by the placebo effect (i.e., in ST studies, the pain free 
2 h in at least two attacks out of three, is more trustworthy than pain relief for 2 h in one attack).  
Use a primary end point that is least affected by other variables that cannot be controlled (in studies 
about efficacy of preventive treatments, it is better to chose as primary outcome the reduction of 
attack frequency as it is less influenced by use of STs than headache days per month, duration or 
disability).  
 
Statistical analysis  
Appropriate statistics based on the nature of the outcome measured (both univariate and multivariate 





A second crucial issue that still remain in migraine studies, is that in a number of 
fields pharmacogenomic analysis is now strengthened by side-by-side 
pharmacokinetic analysis [43]. Whether this would be feasible in migraine remains 
to be established. 
Nonetheless, also by using harmonized, agreed-upon protocols, a few issues in the 
pharmacogenomic of migraine will remain to be established. For example, most 
pharmacogenomic studies usually compare groups taking the same medication but 
exhibiting different effects (e.g. responders vs. non-responders; presence vs. 
absence of side effects). In a disease such as migraine, in which patient response 
may be inconsistent intra-patient, which clinical end-point is best and more 
clinically relevant remains to be established. Furthermore, it must be acknowledged 
that the placebo effect is relevant in most end-points used, and it remains to be 
decided whether to consider these patients responders, or whether to control for 
them with a more complex study design [44]. 
Certain limitations of the present review should be acknowledged. First, our last 
PubMed search was performed in September 2012. In that period we have prepared 
a lecture on this topic for a conference. We have decided to not perform new 
research because the possible inclusion of a few further studies would not have 
modified the outline of the situation: the poorness of study in the examined topic. 
Second, we have limited our observations to only episodic migraine, excluding 
chronic forms. Chronic migraine is very often complicated by MOH. In a lot of 
cases, the discontinuation of overuse of symptomatic drugs is enough to revert 
chronic headache to an episodic form [45]. Therefore, the pharmacogenomics of 
MOH could be completely different to the pharmacogenomics of chronic migraine 
without medication overuse: the first concerns the pharmacogenomics of a side 
effect [46], the second of a drug response. Studies regarding chronic migraine are 
often not clear about the presence of medication overuse, thus we decided to 
exclude this topic from our overview. Third, even if it was not our intention to 
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nullify the positive outcomes of pharmacogenomics studies in this review, 
discussion of so far published articles was limited to highlight flaws and criticisms. 
This choice was in accordance with the objectives of this work, which aimed to 
identify articles dealing with pharmacogenomics studies in episodic migraine and 
to propose suggestions for designing proper and shared guidelines for future 
studies. 
 
Conclusions and future perspective 
 
Since our knowledge on the pharmacogenomic of migraine is growing at a very 
low pace, only concerted measures should be undertaken to speed up the process. 
By collaborative efforts and through support by adequate funding we will try to 
move this important field of research forward, actually fading by an excess of 
indifference, approximation and absence of common guidelines. For this reason, 
there is a need for a consensus conference and for the birth of specific study 
groups. 
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Supplementary Table 1. Relevant data from accepted articles about symptomatic treatment. Pt: patient; F: Female: M: 
Male; Dx: Diagnosis; Ys: Years; MA: Migraine with aura; MO migraine without aura; TRPT: triptan; Suma: Sumatriptan; 
Zolmi: Zolmitriptan; Ele: Eletriptan; Riza: Rizatriptan; NR: Not reported; R: retrospective; Frova: Frovatriptan; Almo: 
Almotriptan; P: prospective; *(at time 0, after 2h and if recurrence occurred) indicating headache intensity; ^ (responder 
with or without headache recurrence and non responders); # and who experienced headache recurrence within 24 hours in 
less than 1 out of 5 successfully treated attacks (for other clinical groups - patients with headache recurrence, non-
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Supplementary Table 2. Relevant data from accepted articles about preventive treatment. Pts: patients; F: Female: M: 
Male; DX: diagnosis; Ys: Years; MA: Migraine with aura; MO migraine without aura; NR: Not Reported; P prospective; * 
overuse of antimigraine medications, pregnancy or lactation, presence of severe organic or psychiatric comorbidities, and 
concomitant drug treatment except for the contraceptive pill. § Some of the data were collected by reading the original paper 
of the two previous randomized, double-blind, placebo-controlled crossover studies that evaluated the efficacy of either 
lisinopril (on 47 patients) or candesartan (in 57 patients) in migraine prophylaxis; NOS: Not otherwise specified; # Lisinopril 
group: use of prophylactic drugs for migraine in the four weeks before randomization, pregnancy or inability to use 
contraceptives, decreased renal or hepatic function, hypersensitivity to ACE inhibitors, history of angioneurotic edema, and 
psychiatric disorder; Candesartan group: pregnancy, nursing, or inability to use contraceptives in women, decreased renal or 
hepatic function, use of prophylactic drugs for migraine in the four weeks before randomization, previous history of 
angioneurotic edema, hypersensitivity to active substance, psychiatric illness preventing full participation, use of daily 
migraine prophylactics in 12 weeks, having used more than 1 migraine prophylactic prior to study and cardiac problems or 
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Abstract 
Genetic variation in the COMT gene is thought to have clinical implications for 
pain perception and pain treatment. In the present study, we first evaluated the 
association between COMT rs4680 and the analgesic response to intrathecal 
morphine in patients with chronic low back pain to provide confirmation of 
previously reported positive findings. Next, we assessed the relationship between 
rs4680 and headache response to triptans in two independent cohorts of migraine 
patients. In patients with chronic low back pain (n=74), logistic stepwise regression 
analysis showed that age (OR: 0.90, 0.85-0.96, P=0.002) and the presence of the 
COMT Met allele (vs Val/Val, OR: 0.21, 0.04-0.98, P=0.048) were predictive 
factors for lower risk of poor analgesic response to intrathecal morphine. 
Intriguingly, in migraine patients, the COMT rs4680 polymorphism influenced 
headache response to triptans in the opposite direction. Indeed, in an exploratory 
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cohort of migraine patients without aura (n=75), homozygous carriers of the 
COMT 158Met allele were found at increased risk to be poor responders to 
frovatriptan when compared to homozygous patients for the Val allele (OR: 5.20, 
95% CI: 1.25-21.57, P=0.023). In the validation cohort of migraineurs treated with 
triptans other than frovatriptan (n=123), logistic stepwise regression analysis 
showed that use of prophylactic medications (OR: 0.43, 95%CI: 0.19-0.99, 
P=0.048) and COMT Met/Met genotype (vs Val/Val, OR: 4.29, 95% CI: 1.10-
16.71, P=0.036) were independent risk factors for poor response to triptans. 
Perspective: This study highlights the importance of COMT rs4680 in influencing 
the clinical response to drugs used for chronic pain, including opioid analgesics and 
triptans. These findings also underline a complex relationship between COMT 
genotypes and pain responder status. 
 





The catechol-O-methyltransferase (COMT) enzyme metabolizes catecholamines 
such as dopamine, adrenaline and noradrenaline that are involved in modulation of 
pain.35,36,57 Genetic variation in the COMT gene may therefore contribute to the 
interindividual variability in human pain phenotypes such as pain sensitivity, 
chronicity, severity and response to analgesics.1,19 The rs4680G>A variant 
(Val158Met) in the COMT gene causes a substitution from a valine (Val) to a 
methionine (Met) at amino acid position 158, leading to a three- to four-fold 
reduced enzymatic activity and higher dopamine availability (Met/Met > Val/Met > 
Val/Val).5,26 The COMT rs4680 variant has been shown to influence efficacy of 
95 
 
morphine used for cancer pain, for which the Met/Met genotype group needs lower 
morphine doses than Val/Val genotype group,28,41,43 possibly explained by an 
increased density of -opioid receptors in Met/Met genotype individuals.4,58 
However, some other reports were unable to demonstrate an involvement of rs4680 
on the opioid dose requirement in cancer patients.20,25 Failure to confirm such an 
association may be explained by several confounding factors which are inherent 
features of these studies on cancer patients, including the presence of both 
neuropathic and somatic pain. Hence, pharmacogenetic studies in non-cancer 
patients may contribute to clarify the relationship between rs4680 and the analgesic 
response to opioids. 
Dopaminergic system hypersensitivity has been suggested in the pathogenesis of 
migraine on the basis of pharmacological evidences supporting the clinical use of 
dopamine antagonists in the treatment of acute migraine, either as an adjunct 
treatment for nausea or for migraine itself.7,27 Although rs4686 does not appear to 
be involved in the predisposition to migraine,51 this genetic factor has been 
involved in the phenotypic expression of migraine without aura (MwoA), with 
158Met-allele carriers displaying a higher pain intensity of headache and a higher 
incidence of the accompanying nausea/vomiting compared to MwoA patients 
without 158Met allele.32 Therefore, it is possible that inter-individual differences in 
COMT activity might influence efficacy of drugs used for the treatment of 
migraine pain, including the triptan class of serotonin 5-HT1B/1D receptor 
agonists.11,50 While controversial results have been reported on the role of the 
DRD2 NcoI polymorphism on the variability in the therapeutic effects of 
triptans,3,16,53 no data are available as to whether an increased dopaminergic tone, 
as expected in COMT Met/Met individuals, might affect headache response to 
triptans in migraine sufferers.  
In the present study we assessed the value of COMT rs4680 as a predictive factor 
for the response to opioids or triptans, two classes of medication used to assist in 
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the management of chronic pain. More specifically, we evaluated the association 
between rs4680 and the analgesic response to intrathecal morphine in patients with 
chronic low back pain to provide confirmation of previously reported positive 
findings, while the relationship between rs4680 and headache response to triptans 
was assessed in two independent cohorts of migraineurs: one exploratory cohort of 
exclusively MwoA patients treated with frovatriptan and one validation cohort of 
migraineurs patients treated with other types of triptans. 
 
Methods 
Patients with persistent chronic low back pain 
Patients suffering from chronic low back pain who received intrathecal morphine 
were enrolled in this study at the Pain Therapy U.O. of Rimini Hospital. The study 
was approved by the local Ethical Committee. These patients received intrathecal 
morphine as a trialing method to evaluate suitability to having an intrathecal drug 
delivery system implanted.9,23,38,39 A total of 74 subjects were enrolled between 
2008 to 2012 according to the following inclusion/exclusion criteria: Inclusion 
criteria: a) patient able to read, understand and voluntarily sign the informed 
consent to participation before undergoing any procedure for the study; b) age 18 
years or older, at study entry; c) patient affected by chronic low back pain 
secondary to  spinal stenosis and failed back surgery, and eligible to receive 
implantation of an intrathecal drug delivery system;9,23,38,39 d) patient receiving an 
intrathecal morphine trialing protocol at a dose of 0.030 mg. Exclusion criteria 
were: a) patient who is pregnant or breast-feeding; b) patient who received an 
investigational drug within 30 days prior to screening; c) patient with a known 
hypersensitivity to opioid drugs; d) patient for which the use of opioid analgesia is 
contraindicated; e) patient with pre-existing history of psychosis; f) patient with a 
history of drug addiction. 
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Pain levels were assessed using a visual analog scale (VAS) of 0–10 (0= “No 
pain”, 10= “worst pain possible”) based on patient self report at the time of initial 
assessment (baseline), and at 1 hour after intrathecal administration of morphine. 
The intrathecal administration of 0.03 mg of morphine has been previously 
demonstrated to be effective in inducing pain relief in patients with chronic 
noncancer pain.14,40 The presence of side effects commonly associated with opioids 
was also assessed. Patients were considered good responders to intrathecal 
morphine if pain reduction was ≥ 60 %, moderate responders if it was ≥ 40 % and 
< 60 %, and poor responders if pain reduction was < 40 %. 
 
Patients with migraine pain 
A total of 198 Caucasian migraine outpatients of the Novara and Pavia headache 
centers were enrolled in the study. All patients were diagnosed by a neurologist 
after neurological examination and direct interview according to the diagnostic 
criteria set by the International Headache Society (Headache Classification 
Subcommittee of the International Headache Society, 2004) for migraine without 
aura (MwoA) (IHS code 1.1) and migraine with aura (MwA)—typical aura with 
migraine headache (IHS code 1.2.4). Exclusion criteria were a headache that 
fulfilled the diagnostic criteria for a probable medication—overuse headache (IHS 
code 8.2.7) and contraindication to triptan use. Tension type headache patients and 
patients with double diagnosis were not enrolled in this study. In the first visit, 
patients were prescribed one of the six triptans commercially available in Italy 
according to the clinician's judgement and were given a diary on which to record 
the clinical response to the drug in three consecutive migraine attacks. If indicated, 
they were also prescribed a migraine prophylactic therapy. For each of the migraine 
attacks, the patient was asked to record on the diary the intensity of pain (on a scale 
from 0 to 3; 0=absent pain, 1=mild pain/no disability, 2=moderate pain/partial 
disability and 3=severe pain/total disability) at the moment of the triptan intake and 
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after 120 min, and the presence and intensity (on a scale from mild-to-severe) of 
side effects. The second visit took place after three attacks. Good responders were 
defined as the migraineurs who experienced a ≥2 point reduction in a 4-point scale 
intensity of pain from 3 (severe) to 0 (absent) 2 h after triptan administration in at 
least two attacks out of the three,54 otherwise patients were defined as poor 
responders. 
This study was approved by the local Ethics Committees of the institutions 
involved (Istituto C. Mondino Pavia and Ospedale Maggiore della Carità, Novara) 
and it met the requirements of the Declaration of Helsinki. Informed consent was 
obtained from all patients before participation in the study. 
 
COMTVal158Met genotyping 
Genomic DNA was extracted from peripheral blood by using the QiaAmp DNA 
Mini Kit (Qiagen Valencia, California, USA). Polymerase chain reactions (PCRs), 
conducted in a total volume of 30 μl containing 100 ng of genomic DNA, were 
performed using 0.4 μM of each couple of the following primers: FW: 5’-TCG 
TGG ACG CCG TGA TTC AGG-3’; Rev: 5’-AGG TCT GAC AAC GGG TCA 
GGC-3’. After 33 cycles of PCR amplification (denaturation at 94 °C for 30 s, 
annealing at 55 °C for 30 sec, extension at 72 °C for 30 sec), amplification products 
of 217 bp in length were electrophoresed in 2% agarose gel and visualized after 
staining with ethidium bromide. The PCR products (10 μl) harboring the SNPs 
were digested overnight at 37°C by 2 U of NlaIII (New England Biolabs, Milano, 
Italy). Wildtype COMT Val/Val was characterized by 136, 81 bp fragments, 
heterozygotes (Val/Met) by 138, 96, 81 and 40 bp fragments, and homozygotes for 
the Met allele (Met/Met) by 96,81,40 bp sized fragments. All PCR reactions were 
set up in a dedicated PCR area with dedicated pipettes and reagents. For quality 
control purposes, each PCR and restriction enzyme digestion included negative as 
99 
 
well as positive controls. For validation, about 10% of the samples were re-




Data were summarized and presented in the form of mean, standard deviation and 
percentage as descriptive statistics. The Hardy-Weinberg equilibrium was verified 
in each patient cohort using the chi-square test as implemented in the Finetti 
program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Patients were dichotomized in two 
groups on the basis of drug response status: responders (good- and moderate-) and 
poor responders. In a preliminary analysis, the Armitage test for linear trend in 
proportions was performed on genotype frequency data to assess the dosage effect 
of possessing zero, one or two copies of the Met allele (i.e. an additive effect) on 
drug responses rates (analgesic response to intrathecal morphine or headache 
response to triptans). Next, the magnitude of the effect (effect size) of categorical 
or continuous variables (age) on the risk of poor drug responses was evaluated by 
unconditional logistic regression analysis (univariate analysis). Odds ratios (ORs) 
and their 95% confidence intervals (CIs) were used as estimates of relative risk. 
Finally, a binary logistic regression model, weighted for multilevel data and with 
forward stepwise selection of the variables (with input p-values set at 0.15), was 
performed to investigate the dependence of drug response status on a set of 
explanatory variables. A P<0.05 was considered statistically significant. All 
clinical and genotype data were managed with the statistical software package 








Analgesic response to intrathecal morphine in patients with chronic low back 
pain. 
Of the 74 patients with persistent chronic low back pain (age: 60.7 ± 16.1 years), 
34 (45.9%) were males and 40 (54.1%) females (Table 1). The percentage of 
patients with good, moderate and poor analgesic response to intrathecal morphine 
was 74.3%, 9.5% and 16.2%, respectively. Distribution of COMT genotypes 
(Val/Val: n=19; Val/Met: n=44; Met/Met: n=11) was in Hardy–Weinberg 
equilibrium (P=0.08). The analgesic response rate according to COMT Val/Met 
genotype distribution is presented in Fig 1A. The analysis on dichotomized 
responses (good- and moderate- vs poor response) showed a significant better 
response across the three genotypes according to the number of copies of the Met 
allele carried (Armitage trend test; P=0.018) with 100% of the patients with 
Met/Met experiencing response (good or moderate) to intrathecal morphine 
compared to 68.4% of responders in patients with Val/Val genotype (P=0.037). As 
none of patients with Met/Met responded poorly to intrathecal morphine, Val/Met 
and Met/Met genotypes were combined to estimate the impact of COMT genotypes 
on the risk of poor intrathecal morphine response. The univariate logistic 
regression analysis (Table 1) showed that patients with poor response to intrathecal 
morphine differed from responders (good- or moderate) for younger age (OR: 0.91, 
95%CI: 0.86-0.96, P=0.001) and lower frequency of the Met allele compared to 
Val/Val genotype (OR: 0.26, 95%CI: 0.07-0.96, P=0.043). Given that COMT 
activity may be under hormonal control17,56 and our cohort was composed by a 
similar proportion of males and females, we conducted separate analyses for each 
gender. The sex-specific analysis of the data showed a trend in both male and 
female carriers of the Met allele towards a lower risk to be poor responders to 
intrathecal morphine (Table1), but in both groups the effect of COMT genotype did 
not reach statistical significance, probably due to the small number of patients. The 
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two-way ANCOVA analysis adjusted for age revealed that the interaction between 
COMT genotype (Met carriers vs Val/Val) and gender on the analgesic response to 
intrathecal morphine was not significant (P=0.515). In the logistic stepwise 
regression analysis (Table 1), age (OR: 0.90, 0.85-0.96, P=0.002) and the presence 
of the COMT Met allele (vs Val/Val, OR: 0.21, 0.04-0.98, P=0.031) were selected 
as significant independent predictors for lower risk of poor analgesic response to 




Table 1. Logistic regression analysis evaluating the association between COMT 
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  Age at study entry (year) 
     mean ± SD  60.7 ± 16.1 63.8 ± 14.4 44.4 ± 15.4 0.91 (0.86-0.96) 0.001 
      
  COMT rs4680 (total sample) 
     Val/Val 
     Val/Met 
















      
COMT rs4680 (females only) 
     Val/Val 
     Val/Met 

















COMT rs4680 (males only)  
     Val/Val 
     Val/Met 

















Multivariate stepwise logistic regression analysis 
    Age    0.90 (0.85-0.96) 0.002 
    COMT_Met allele carriers vs Val/Val 0.21 (0.04-0.98) 0.048 
Note: some percentages may not add up to 100% due to rounding. 
*Met allele carriers vs Val/Val. 
P values ≤0.05 are in boldface. 
 
Headache response to frovatriptan in patients without aura (MwoA) 
Demographic and clinical data of MwoA patients treated with frovatriptan, in the 
overall cohort (n=75) and after stratification for headache response status, are 
shown in Table 2. Eighty-four percent of the study population was female (63/75), 
the average age in the cohort was 40.9 years ± 11.3 and fifty-six percent of patients 
(42/75) used prophylactic medications. Thirty-four out of the 75 patients (45.3%) 
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were poor responders to frovatriptan. Distribution of COMT genotypes was in 
accordance with Hardy-Weinberg equilibrium (P=0.72). Sex, age and use of 
prophylactic medications were similarly distributed between good and poor 
responders to frovatriptan (P=0.78, P=0.31, P=0.36, respectively). The headache 
response rate of MwoA patients to frovatriptan after stratification for COMT 
Val/Met genotypes is shown in Fig 1B. The Armitage trend test showed a 
significant worse headache response across the three genotypes according to the 
number of copies of the Met allele carried (P= 0.017) and 31.6 % of migraine 
patients with Met/Met experienced response to frovatriptan, while the response rate 
was higher in the Val/Val group (70.6% of responders, P= 0.019). In the univariate 
analysis (Table 2), homozygous carriers of the COMT 158Met allele were found at 
increased risk to be poor responders to frovatriptan when compared to homozygous 
patients for the Val allele (OR: 5.20, 95% CI: 1.25-21.57, P=0.023). Similar results 
were obtained when analysis was restricted to women. The relationship between 
rs4680 polymorphism and poor response to frovatriptan remained significant after 
adjustments for sex, age and use of prophylactic medications (Met/Met vs Val/Val, 




Table 2. Univariate logistic regression analysis evaluating the association between 
COMT rs4680 and clinical variables with response to frovatriptan in migraine 
patients without aura. 
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    0.781 
  
  Age at study entry (year) 
    mean ± SD  40.9 ± 11.3 41.9 ± 11.1 39.3 ± 11.5 0.98 (0.94-1.02)     0.309 
      
  Use of prophylactic medications 
    No 










    0.361 
  
  COMT rs4680 (total sample) 
    Val/Val 
    Val/Met 














    0.411 
    0.023 
      
COMT rs4680 (females only) 
     Val/Val 
     Val/Met 














    0.193 
    0.019 
 
Note: some percentage may not add up to 100% due to rounding. P values ≤0.05 are in boldface.  
 
Headache response to other triptans in migraineurs 
In order to validate the generality of our findings we studied an independent cohort 
of migraine pazients treated with triptans other than frovatriptan. Demographic and 
clinical data of the second cohort of migraineurs (n=123) are shown in Table 3. 
Seventy-seven percent of the study population was female (95/123), the average 
age in the cohort was 38.3 years ± 10.2, 90.2% of which affected by MwoA and 
9.8% by MwA. The triptans prescribed were: rizatriptan (n=34), eletriptan (n=34), 
almotriptan (n=25), sumatriptan (n=21) and zolmitriptan (n=9). Sixty-five of 123 
patients (54.2%) were on prophylactic medication, while for three patients the data 
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on the use of preventive medication were lacking. Poor response to triptans was 
observed in 30.1% of migraine patients (37/123). The genotype frequency 
distribution of rs4680 was in accordance with Hardy-Weinberg equilibrium 
expectations (P=0.12). Fig 1C shows headache response rates after stratification for 
the COMT Val/Met genotypes, in the validation cohort of migraineurs. The 
analysis revealed again a significant worse headache response across the three 
genotypes according to the number of copies of the Met allele carried (Armitage 
trend test; P= 0.013) and 53.8 % of the patients with Met/Met experienced response 
to triptans other than frovatriptan while the response rate was higher in the Val/Val 
genotype (85.5% of responders, P= 0.013). In the univariate analysis (Table 3), 
patients undergoing prophylactic treatment (n=120) were found at lower risk to be 
poor responders, as compared to patients who were not on prophylactic treatment 
(OR: 0.44, 95% CI: 0.2-0.99, P=0.046). All other demographic and clinical 
variables considered were similarly distributed when comparing good and poor 
responders to triptans (Table 3). In addition, homozygous carriers of 158Met allele 
were more frequently poor responders to triptans when compared to homozygous 
patients for the Val allele (OR: 4.93, 95%CI: 1.33-18.31, P=0.017) and similar 
results were obtained when analysis was limited to women (Table 3). In the logistic 
stepwise regression analysis (Table 3), use of prophylactic medications (OR: 0.43, 
95%CI: 0.19-0.99, P=0.048) and COMT Met/Met genotype (vs Val/Val, OR: 4.29, 
95%CI: 1.10-16.71, P=0.036) were selected as independent risk factor for poor 




Table 3. Logistic regression analysis evaluating the association between COMT 
rs4680 and clinical variables with response to triptans other than frovatriptan in 
migraine patients. 
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    mean ± SD  38.3 ± 10.2 38.0 ± 10.3 38.8 ± 10.4 1.007 (0.97-1.04)   0.715 
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  Use of prophylactic medications (n= 120) 
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  0.134 
  0.017 
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     Val/Val 
     Val/Met 














  0.195 
  0.013 
Multivariate stepwise logistic regression analysis 
   Prophylaxis_Yes 
   COMT_Val/Met 
   COMT_Met/Met 
  0.43 (0.19-0.99)   0.048 
  2.27 (0.69-7.51) 
4.29 (1.10-16.71) 
  0.180 
  0.036 
 







Fig 1: A) Analgesic response rate to intrathecal morphine according to COMT Val158Met 
genotype distribution in patients with chronic low back pain. Comparison of responders (good and 
moderate) with Armitage trend test across the three genotypes (P=0.018). B) Headache response 
rate to frovatriptan according to COMT Val158Met genotypes in migraine patients without aura 
(Armitage trend test across the three genotypes, P= 0.017). C) Headache response to triptans other 






Experimental pain studies have consistently shown that individuals with low 
COMT activity have low tolerance to pain. For instance, healthy volunteers with 
the COMT Met/Met genotype displayed higher sensory and affective ratings of 
pain and a higher regional density of -opioid receptors in the brain as measured by 
ligand-PET (positron emission tomography).58 Moreover, in a functional 
neuroimaging study, homozygous subjects for the Met-allele exhibited a higher 
blood oxygen level-dependent response in the anterior cingulate cortex to painful 
laser stimulation compared to carriers of the Val-allele.29 In chronic clinical pain, 
the effect of COMT on pain sensitivity and modulation has been suggested to 
depend on the pain conditions.51 Indeed, in neuropathic and cancer-related pain, 
COMT variation does not play a large role, 2,41,45 while in chronic musculoskeletal 
pain and migraine low COMT activity appears to increase incidence and/or pain 
symptoms.19,32 On the other hand, the genetic background may also influence the 
analgesic response to various pharmacotherapies, however the specific genetic 
variations underlying inter-individual differences in analgesic drug responses 
remain poorly elucidated. As genetic variation in the COMT gene may have 
clinical implications not only for pain perception but also for pain treatment, in the 
present study we have addressed a possible contribution of rs4680 in the COMT 
gene to the individual variability in the response to morphine or triptans, two 
classes of medication used to control pain in patients with chronic low back pain 
and migraine, respectively. 
Our results provide evidence in patients with chronic low back pain that rs4680 
significantly influences the response to intrathecal morphine, with the analgesic 
outcome being inversely proportional to the enzyme activity: better response rate in 
patients with lower COMT activity (Met/Met), worse response in patients with 
higher COMT activity (Val/Val). These results support a higher efficacy of 
intrathecal morphine therapy in patients with Met/Met genotype. Therefore, our 
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findings are in the same direction of previous studies reporting that cancer patients 
with Met/Met genotype require less morphine than patients with Val/Val genotype 
to achieve the same level of analgesia.28,41,43  
The use of intrathecal drug delivery systems in chronic non-malignant pain is 
indicated in those patients in which traditional administration routes are poorly 
effective or in those who cannot tolerate high doses because of systemic side-
effects.9,23,39 However, the efficacy of intrathecal morphine treatment is hampered 
by the large variability and unpredictability in individual response. Although the 
factors explaining variability in opioid efficacy are still largely unknown, clinical 
features and types of pain,8,38 as well as polymorphisms in genes encoding drug 
targets,47 drug metabolizing enzymes, and/or drug transporters,48 have been 
suggested to contribute to the large interindividual variability in the efficacy of 
intrathecal morphine administration. At present, there is no agreement regarding 
the intraspinal screening method that will be most predictive of patients' long term 
response to intrathecal morphine. Thus, given the results presented here, we 
propose that COMT Val158Met polymorphism should be evaluated further to 
investigate whether it can predict efficacy of chronic intrathecal morphine therapy. 
We also provide for the first time evidence that allelic variation of the COMT 
rs4680 polymorphism affects headache response to triptans in patients with 
migraine pain. Intriguingly, the impact of rs4680 on headache response to triptans 
was in the opposite direction. Indeed, frovatriptan-treated patients with the 
Met/Met genotype showed a poorer headache response than patients with the 
Val/Val genotype and similar results were obtained in a second cohort of 
migraineurs treated with other types of triptans. Altogether, our results highlight a 
role of rs4680 as response-modifying gene variant in relation to morphine or to 
triptan therapy. In addition, our study suggests that the COMT rs4680 variant, 
affecting catecholaminergic neurotransmission, may influence the individual 
response to different classes of drugs used for chronic pain, irrespective of their 
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primary molecular target. The better response to opioids in Met/Met carriers has 
been previously explained by an increased amount of regional μ-opioid 
receptors4,58 as a compensatory mechanism in response to lower content of 
enkephalin within the peripheral neurons of these individuals.22,41 In contrast, the 
lower rate of response to triptans in migraineurs with Met/Met genotype is an 
entirely novel finding, for which data on possible molecular mechanisms are 
missing. We can speculate that, in migraine subjects, the lower activity of COMT 
is associated with a reduced metabolization of cathecolamines, such as 
norepinephrine and epinephrine, thereby leading to a potentiation of pain signaling 
through the downstream stimulation of β2- and β3-adrenergic receptor pathways.31 
The more aggressive phenotype described by Park  et al32 in Met/Met migraineurs 
may therefore represent a consequence of a genetic predisposition, and the poorer 
response to triptans just reflects the failure to control more intense attacks. 
Alternatively, a complex interplay between enhanced adrenergic and dopaminergic 
activity in different parts of the nociceptive system might explain the complicated 
actions of low COMT.1,19 On the other hand, the possible contribution of COMT 
rs4680 in migraine pain therapy stems from reports supporting the usefulness of 
dopamine antagonists in the treatment of acute migraine, either as an adjunt 
treatment for nausea or for the migraine itself.7,27,49 Given that COMT inactivates 
NE and DA, but not 5-HT, our data support the possibility that triptans are less 
effective in migraine patients with a higher catecholaminergic tone, as expected in 
patients with Met/Met genotype. Noteworthy is that the combination of sumatriptan 
with the dopaminergic antagonist metoclopramide has been reported to provide 
relief in some migrainers who failed to achieve adequate relief with a triptan 
alone.46 It is therefore tempting to speculate that COMT rs4680 genotyping could 
be useful to identify patients at higher risk of poor response to triptan monotherapy 
which can benefit from a combination therapy (triptan + DRD2 antagonist).34 
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Although the similarities of 5-hydroxytryptamine (5-HT) 1B/1D receptor agonists 
outweigh their differences, important differences exist in the pharmacokinetic 
profile of triptans. For instance, bioavailability of oral formulations ranges between 
14% (sumatriptan) and 69% (almotriptan), and their elimination half-life ranges 
from 2 h (sumatriptan and rizatriptan) to 26 h (frovatriptan).37 In addition, the 
beneficial effect of triptans in patients with migraine may be related to their 
multiple mechanisms of action at either peripheral and/or central sites implicated in 
the pathophysiology of migraine.13 In this regard, triptans as a class display a poor 
brain-blood barrier penetration with brain/plasma partition coefficients (Kp,brain) 
well below 1, when compared with typical CNS marketed drugs (e.g. 
diphenhydramine with a Kp,brain of 9).
18,33 In contrast, the relatively hydrophilic 
triptan, sumatriptan, has been regarded either to be incapable of crossing the brain-
blood barrier or to cross it to a lower extent compared to other triptans.55 Given the 
wide variety of drug treatments received by migraine patients due to the naturalistic 
setting of our study, it was not possible to conduct a rigorous analysis of the 
possible differential effect of COMT rs4680 on headache response to the different 
triptans. However, it should be noted that the effect size of COMT genotype in 
patients treated with to the long-acting triptan (frovatriptan) was similar to that 
observed in patients treated with the fast-acting triptans (eletriptan, rizatriptan, 
almotriptan, sumatriptan, zolmitriptan). In addition, the significance of COMT 
genotype was retained in both univariate (Met/Met vs Val/Val, OR: 5.04, 95% CI: 
1.87-13.60, P=0.001) and fully adjusted multivariate analysis (Met/Met vs Val/Val, 
OR: 4.09, 95% CI: 1.43-11.67, P=0.008), when patients receiving sumatriptan were 
excluded from the combined analysis of the two migraine cohorts. 
We recognize some limitations in our study. First, the COMT Val158Met 
polymorphism alone cannot fully account for the variation in enzyme activity as 
COMT haplotypes have been shown to influence COMT function30 and to explain 
the effects on pain perception or opioid efficacy to a greater extent than rs4680 
112 
 
alone.10,42,52 In addition, rs740603 and haplotypes containing SNPs in intron 1, but 
not rs4680, have been associated to adverse effects of morphine.45 Thus, further 
studies in larger populations in which COMT haplotype analyses can be better 
evaluated are required to replicate and extend the current findings. In addition, we 
also recognize that polymorphisms in other genes encoding for drug metabolizing 
enzymes, drug transporters or drug targets may be also involved in the individual 
variability of clinical response to opioids or triptans.6,12,21,24,44 Therefore, 
approaches based on multiple genetic markers, along with demographic and 
clinical characteristics of patients, are required to characterize the joint effects of 
multiple genes in predicting the clinical response to opioid analgesics or triptans. 
Another potential limitation of this study is the absence of placebo-treated groups. 
Since we do not know the rate of non-specific or non-drug attributable responses, 
we cannot exclude the possibility that some patients in the responder group were 
subjected to a placebo effect, which in a very recent paper has also been observed 
with rs4680.15 Nonetheless, given the confirmatory nature of the study conducted 
in morphine-treated patients and the consistent association emerged in the 
exploratory/validation study of triptan-treated migraineurs, we feel that the 
presence of placebo groups may not have significantly affected our results. In 
addition, the observational design of the study conducted in triptan-treated patients 
reflects the conditions of migraine managing in primary care, in which triptans are 
the first-line treatment and placebo is not used. Finally, given the limited number of 
male patients in our cohorts, larger studies are required to evaluate gender-specific 
effects of COMT Val158Met polymorphism on the efficacy of morphine or 
triptans. 
In conclusion, the current results highlight the importance of COMT rs4680 
genotype in influencing the clinical response to drugs used for chronic pain 
including opioid analgesics and triptans. The opposite direction of rs4680 effect on 
the clinical response to these classes of drugs in two different pain conditions 
113 
 
reveals a complex relationship between COMT genotypes and pain responder 
status which appears to be drug-specific and likely to reflect the multifaceted 
interaction between different pain states and the cathecolaminergic 
neurotransmission. 
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Abstract 
The present study was designed to replicate previous findings reporting a 
significant association between the rs548294 polymorphism at the glutamate 
receptor subunit GluR1 gene (GRIA1) with migraine without aura, either as a 
single marker or in haplotype combination with rs2195450. In addition, the role of 
GRIA1 polymorphisms and haplotypes was evaluated in migraine patients without 
aura as predictive factors for consistency in headache response to triptans. Analysis 
of rs548294 and rs2195450 polymorphisms of GRIA1 was conducted by Real-time 
PCR allelic discrimination assay in 186 migraine patients without aura and 312 
healthy controls, respectively. In the logistic regression analysis adjusted for 
gender and age, genotype and haplotype frequencies for the two polymorphisms 
did not significantly differ between migraine patients without aura and controls. In 
addition, no evidence of association was found between GRIA1 
polymorphisms/haplotypes and consistent response to triptans. This study failed to 
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replicate previously reported association between GRIA1 rs548294 and migraine 
without aura, either as single marker or when analysed in haplotype combination 
with rs2195450. In addition, no evidence was found for a relevant role of GRIA1 
polymorphisms and haplotypes as modulating factors of headache response to 
triptans. 
 




Migraine is a common, painful and debilitating disorder with a strong genetic basis. 
About 50% of affected individuals have a first-degree relative also suffering from 
migraine [1-3], with estimates of heritability from family and twin studies ranging 
between 34 and 57% [2,4,5]. The involvement of glutamate in trigemino-vascular 
activation, cortical spreading depression and central sensitization [6,7] as well as 
the effectiveness of glutamate receptor-subtype antagonists in preclinical studies 
[8,9] argue for a primary role of the glutamatergic neurotransmission in the 
pathophysiology of migraine. Recent results of genome–wide association studies 
support a correlation between migraine and variants in glutamatergic system genes 
[10-12]. However, the effect estimates of all associations with genome-wide 
significance confer a small to moderate change in risk for migraine, a result which 
suggests that only a small part of the genetic background of migraine has been 
established so far. 
Glutamate exerts its actions through activation of ionotropic and metabotropic 
receptors [4]. Great interest was therefore aroused by results of a case-control study 
showing that rs548294 and rs2195450 SNPs of the glutamate receptor subunit 
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GluR1 gene (GRIA1) are significantly associated with migraine, either as single 
markers or in haplotype combination [13]. Intriguingly, stratified analysis of 
migraine subtype revealed that the rs548294 SNP was primarily associated with 
migraine without aura (MwoA), while rs2195450 was found associated with aura, 
but not with MwoA. More precisely, in the subgroup analysis comprising 109 
MwoA patients and 260 control healthy subjects, carriers of the minor allele of 
rs548294 were found at higher risk of developing MwoA than homozygotes wild-
type carriers (OR: 2.7, 95%CI: 1.6-4.3). Given that these GRIA1 SNPs are located 
in the same linkage disequilibrium (LD) block [13], in the present study we 
undertook a case-control association study on rs2195450 and rs548294 to validate 
their role, either as single SNPs or haplotypes, as genetic determinants of migraine 
without aura (MwoA). In addition, since the majority of glutamatergic neurons in 
trigeminal ganglion carry serotonin 5-HT1B/D/F receptors and glutamate has been 
implicated in the response mechanisms of 5-HT1B/1D agonists (triptans) [14], we 
also assessed whether GRIA1 polymorphisms and haplotypes may be predictive 
factors for consistency in headache response to triptans in MwoA patients. 
 
Materials and methods 
Patient selection 
All patients were diagnosed for migraine without aura (MwoA) (IHS code 1.1) by 
two headache specialists (M.V. and D.M.) after neurological examination and 
direct interview according to the diagnostic criteria set by the International 
Headache Society (Headache Classification Subcommittee of the International 
Headache Society, 2004). In the first visit, patients were prescribed one of the six 
triptans commercially available in Italy according to the clinician's judgement and 
were given a diary on which to record the clinical response to the drug in three 
consecutive migraine attacks. If indicated, they were also prescribed a migraine 
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prophylactic therapy. For each of the migraine attacks, the patient was asked to 
record on the diary the intensity of pain (on a scale from 0 to 3; 0= absent pain, 1= 
mild pain/no disability, 2= moderate pain/partial disability and 3= severe pain/total 
disability) at the moment of the triptan intake and after 120 min. The second visit 
took place after three attacks. Consistent responders to triptans were defined as the 
migraineurs who experienced a ≥2 point reduction in a 4-point scale intensity of 
pain from 3 (severe) to 0 (absent) 2h after triptan administration in at least two 
attacks out of the three, otherwise patients were defined as inconsistent responders 
[15]. Controls were randomly selected from a population of same regional 
background (northwest Italy) to minimize population heterogeneity and 
stratification. This study was approved by the local Ethics Committees of the 
institutions involved (Istituto C. Mondino Pavia and Ospedale Maggiore della 
Carità, Novara) and met the requirements of the Declaration of Helsinki. Informed 
consent was obtained from all patients before participation in the study. 
 
Genotyping 
Genomic DNA was extracted from peripheral blood by using the QiaAmp DNA 
Mini Kit (Qiagen Valencia, California, USA). Genotyping of rs548294 and 
rs2195450 SNPs of the GRIA1 gene was performed by real-time PCR using 
Applied Biosystems TaqMan Pre-Designed SNP Genotyping assays [rs548294 
Assay ID: C_318751_20; rs2195450 assay ID: C_15850372_10]. Real-time PCR 
amplification and detection was conducted on genomic DNA in 48-well PCR plates 
using a MiniOpticon Real–Time PCR Detection System (Bio-Rad, Milan, Italy). 
Thermal cycling was initiated with a denaturation step of 10 min at 95 °C, followed 
by 50 cycles of 15 s at 95 °C and 90 s at 60 °C. After PCR was completed, allelic 
discrimination was analyzed using the Bio-Rad CFX Manager Software (Version 
2.1, Bio-Rad). Genotype assignment was determined by plotting the end point 
relative fluorescent units (RFU) for one fluorophore (allele 1 on the x-axis) against 
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the RFU for the other fluorophore (allele 2 on the y-axis) on the allelic 
discrimination plot. All reactions of real-time PCR were set up in a dedicated PCR 
area with dedicated PCR pipettes and reagents. For quality control purposes, each 
Real-time PCR included negative as well as positive controls for the three 
genotypes. For validation, about 10% of the samples were re-genotyped. The 
results were reproducible with no discrepancies in genotyping. 
 
Statistical analysis 
Data were summarized and presented in the form of mean, standard deviation and 
percentage as descriptive statistics. Each polymorphism was tested for deviation 
from the Hardy-Weinberg equilibrium (HWE) by use of Pearson’s chi-square test 
as implemented in the Finetti’s program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The 
association between GRIA1 SNPs and clinical endpoints was assessed by logistic 
regression analyis with adjustment for confounding covariates using the SNPStats 
software [16]. Odds ratios (ORs) and their 95% confidence intervals (CIs) were 
used as estimates of relative risk. The SNPStats software was also used for the 
calculation of linkage disequilibrium (measured as Lewontin’s D′-values) between 
GRIA1 SNPs, for the estimation of haplotype frequencies and for the evaluation of 
haplotype association with the two clinical endpoints considered. As the haplotype 
test was a post-hoc analysis, we considered it to be an additional test. Therefore, for 
a Bonferroni correction on the P values we used P= 0.05/3 (total 2 polymorphisms 
+ 1 haplotype) = 0.017 as a threshold for significance. Power calculations were 
performed using Quanto version 1.2.4 (http://hydra.usc.edu/gxe/). Meta-analysis 
was performed with Open Meta-Analyst available at http://tuftscaes.org/open_meta 
(Joseph Lau, Boston, Massachusetts). Data were combined using random-effects 
(DerSimonian and Laird) models which incorporate the between-study 
heterogeneity and allow for a different effect in each population [17]. We estimated 
the between-study heterogeneity by using the Cochran’s Q chi-square test 
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(significant for P < 0.10) [18]. We also reported the I2 index, which quantifies 
heterogeneity irrespective of the number of studies (range, 0-100%; values ≥75% 
imply extreme heterogeneity). 
 
Results 
This study included a total of 186 Caucasian MwoA patients (79.0% of women) 
with a mean age of 39 years (standard deviation: 10.6) and 312 population-based 
controls (62.8% of women) with a mean age of 56 years (standard deviation: 18.1). 
Genotypic distributions of rs548294 and rs2195450 polymorphisms in the GRIA1 
gene in MwoA patients and control subjects are shown in Table 1. The two 
polymorphisms analyzed were in HWE both in MwoA patients (PHWE rs548294= 0.73; 
PHWE rs2195450 = 0.25) and in control subjects (PHWE rs548294=  0.57; PHWE rs2195450 = 
0.46). In addition, in control subjects, the observed minor allele frequencies 
(MAFs) of both SNPs (MAF of rs548294: 0.34; MAF of rs2195450: 0.27) were 
similar to those reported in HapMap-CEU population (MAF of rs548294: 0.36; 
MAF of rs2195450: 0.28). After adjusting for age and gender, rs548294 and 
rs2195450 polymorphisms did not emerge as factors significantly associated to 
MwoA when analyzed as single locus variants, either under the dominant model of 
inheritance (Table 1) or other genetic models (codominant, recessive, over-
dominant and log-additive). Pooled meta-analysis of the two studies (the present 
study and [13]) also found no statistically significant associations between 
rs548294 polymorphism and MwoA risk in the genetic dominant, codominant, 
recessive and additive models (Fig 1).  
As haplotype association analysis of polymorphisms in strong LD has more power 
than single locus tests to detect gene–disease associations, an approach based on 
haplotype combination of GRIA1 gene polymorphisms was also used to detect 
association with MwoA. To this end, we first estimated LD between the two 
polymorphisms of the GRIA1 gene. Haplotype analysis in both patients and 
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controls revealed a strong pairwise LD between rs548294 and rs2195450 
polymorphisms (D’= 0.86). In the logistic regression analysis adjusted for age and 
gender, no association was found between GRIA1 haplotypes and MwoA (Global 
haplotype association P-value: 0.34, Table 1).  
 
Table 1. Genotype distribution of GRIA1 SNPs in MwoA patients (n = 186) and 
control subjects (n= 312) and association results as single markers or haplotypes 
(rs548294 - rs2195450). 
 
SNP Controls n (%)       Cases  n (%)                                                                                                                   OR* (95% CI) P-
value 
































Haplotype †       Haplotype frequency___ 
  Controls              Cases                 





   0.381 
   0.334 
   0.271 













Abbreviations: D, dominant model of inheritance. *Logistic regression analysis adjusted for age and 
gender. †Global haplotype association P-value: 0.34. 
 
Next, we assessed the association between GRIA1 SNPs and haplotypes and 
consistent response to triptans in MwoA patients. Consistent response to triptans 
was observed in 64.5% of patients with MwoA (120/186). Patients receiving 
triptans other than frovatriptan (n=111, 59.7%) displayed higher consistent 
response rates than patients treated with frovatriptan (OR: 2.05, 95%CI: 1.11-3.78, 
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P=0.022, Table 2). All the other demographic and clinical variables were similarly 
distributed when comparing consistent responders with inconsistent responders. In 
the logistic regression analysis adjusted for triptan (frovatriptan vs other triptans), 
rs548294 and rs2195450 SNPs of the GRIA1 gene were not found significantly 
associated to response to triptans, either as single markers or when analysed in 




Table 2. Clinical variables and genotype distribution of GRIA1 polymorphisms in 
MwoA patients with consistent (CR) and inconsistent response (IR) to triptans and 





OR* (95% CI)  P 
value 
  Sex     
    Female 









  Age at study entry, year 
    Mean (SD) 39.4 (10.6) 39.4 (10.7) 1.00 (0.97-1.029) 0.97 
  Triptan 
    Frovatriptan 
    Rizatriptan 
    Eletriptan 
    Almotriptan 
    Sumatriptan 





















  Use of prophylactic medications (n= 183) 
    No 









     
GRIA1 rs548294 (G>A)    
    GG 
    GA 








D: 1.13 (0.61-2.08) 




GRIA1 rs2195450 (C>T) 
    CC 
    CT 








D: 0.76 (0.41-1.41) 




     
Haplotype † Haplotype frequency 
  IR                       CR 
OR# (95% CI)  
   G-C 
   A-C 
   G-T 

















Abbreviations: D, dominant model of inheritance; R, recessive model of inheritance. *Crude 
logistic regression analysis. #Logistic regression analysis adjusted for triptan (frovatriptan vs 




Figure1. Forests plot for the association of GRIA1 rs548294 with MwoA risk in 
the genetic dominant (GA + AA vs GG), codominant (GA vs GG or AA vs GG), 
recessive (AA vs GA + GG) and allele models (A vs G). Pooled estimates (OR, 
odds ratio) are from the random-effects model. 
 
  
GA+AA vs GG 
GA vs GG 
AA vs GG 
AA vs GA+GG 









The GWASs so far conducted have identified eight genetic variants that are 
associated with genome-wide significance with migraine [10-12,19]. Among these, 
rs1835740 is located between MTDH and PGCP genes, which are both involved in 
glutamate homeostasis, and rs11172113 is located within the LRP1 gene which 
may interact with neuronal glutamate receptors [20]. Together, these findings 
support a role of glutamatergic gene variants in the pathophysiology of migraine. In 
line with this hypothesis are therefore previous results showing that rs548294 and 
rs2195450 polymorphisms at the GRIA1 are significantly associated with migraine 
(with and without aura) [13]. Although a number of case-control studies have 
reported associations between particular candidate gene polymorphisms and 
migraine susceptibility, replication studies to confirm previous findings are 
generally lacking [21]. 
In the present study, we aimed to validate the role of GRIA1 rs548294 as genetic 
determinant of migraine without aura (MwoA), either as single marker or in 
haplotype combination with rs2195450. However, we were unable to confirm 
previous association of rs548294 SNP of GRIA1 gene as susceptibility factor for 
MwoA [13]. In addition, results of the haplotype combination of rs548294 and 
rs2195450 polymorphisms also provide evidence against an association of the 
GRIA1 gene with MwoA. Failure to confirm a previously identified association is 
not unusual in the search for genetic determinants of complex traits and 
multifactorial diseases such as migraine. Probably, the identification of genetic 
variants in migraine susceptibility remains challenging for several reasons, 
including population heterogeneity, environmental effects, and low sample size. 
Assuming a dominant model of inheritance, our study has >80% statistical power 
to detect an association of rs548294 with the effect size (OR) of 2.2 ( level of 
0.017, with a 34% of MAF in controls) or to detect an association of rs2195450 
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with an effect size of 2.1 ( level of 0.017, with a 27% of MAF in controls). Thus, 
the failure to confirm the association of rs548294 with MwoA in the dominant 
model is not probably due to insufficient statistical power of our study. A possible 
alternative reason of these contrasting findings may be the result of choice of 
controls, however genotype frequencies of control patients in the present study 
(GG: 43.3%, GA: 43.9%, AA: 12.8%) did not differ compared to the previous one 
(GG: 48.1%, GA: 39.2%, AA: 12.7%). In addition, when the two studies were 
combined for pooled analysis, none of the genetic models tested provided a 
significant association between rs548294 polymorphism and MwoA risk. While no 
obvious explanation exists for these discrepant results, it should be noted that in 
our study the two GRIA1 SNPs were found in HWE both in controls and in MwoA 
patients, while rs2195450 was not previously found in HWE either in controls and 
in MwoA patients [13], suggesting the possibility in the previous study of 
inappropriate population stratification and selection or other confounding factors. It 
should be also acknowledged that, in the time of writing this article, a further study 
reported no evidence of association between rs548294 or rs2195450 and risk of 
migraine, either with or without aura [22]. Pooled results of the three studies so far 
conducted [the present study and 13, 22] excluded a role for rs548294 or 
rs2195450 as risk factors for migraine, either with or without aura (see 
Supplementary Material). 
Several hypothetical ways have been suggested by which triptans might affect 
glutamate neurotransmission such as affecting the glutamate receptors binding site, 
inhibiting glutamate release, increasing the glutamate uptake by glial cells and/or 
by neuronal transporters, or decreasing the neuronal firing in the trigeminal nucleus 
[14,23-25]. In view of the facts that triptans may work in part by reducing 
extracellular glutamate as reflected by the decrease in CSF levels [14], and 
glutamate plays a significant role in the transmission of nociceptive information in 
the sensory thalamus [26,27], functional polymorphisms in glutamate receptors 
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binding sites including GRIA1 may affect the clinical response to triptans. 
However, our results obtained of either single SNP and haplotype-based analysis of 
rs548294 and rs2195450 exclude a possible involvement of GRIA1 SNPs in triptan 
response mechanisms in MwoA patients. Nonetheless, it should be noted that we 
did not perform a detailed LD-based association analysis with tagging SNPs 
covering a maximum amount of genetic variation in the GRIA1 gene, thus we 
cannot exclude the possibility that SNPs located in other LD blocks of the GRIA1 




The present results do not confirm previous association of rs548294 with MwoA, 
either as single marker or in haplotype combination with rs2195450 polymorphism. 
Our findings also do not support a role of GRIA1 SNPs and haplotypes in 
modulating the clinical response to triptan therapy. Although the presence of other 
risk variants in the gene studied cannot be excluded, the present study highlights 
the importance of replication before accepting an association between genetic 
variation and any complex trait. In addition, the present study provides further 
insight to the search of pharmacogenetic determinants in the field of triptan therapy 
in migraine. 
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Supplementary Figure 1. Forest plots for the association of GRIA1 rs548294 with 
migraine, either with or without aura, in the genetic dominant (GA+AA vs GG), 
codominant (GA vs GG or AA vs GG), recessive (AA vs GA+GG) and allele 
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AA vs GA+ GG 
A vs G 
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Supplementary Figure 2. Forest plots for the association of GRIA1 rs2195450 
with migraine, either with or without aura, in the genetic dominant (CT+TT vs 
CC), codominant (CT vs CC or TT vs CC), recessive (TT vs CT+CC) and allele 
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Abstract 
Objectives. We herein investigated the role of polymorphisms in calcitonin gene-
related peptide (CGRP)-related genes looking at the association of rs3781719 
(T>C) in the calcitonin gene-related polypeptide-alpha (CALCA) gene and of 
rs3754701 (T>A) and rs7590387 (C>G) at the receptor activity modifying 1 
(RAMP1) locus with triptan response in patients with migraine without aura 
(MwoA). In addition, their role was evaluated as risk factors for transformation of 
episodic migraine into medication overuse headache (MOH). Background. The 
calcitonin gene-related peptide (CGRP) has a central role in the pathogenesis of 
migraine, however few information is currently available concerning the role of 
polymorphisms in CGRP-related genes as determinants of clinical response to anti-
migraine drugs or as risk factors for migraine chronification. Methods. Genotyping 
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was conducted retrospectively by Real-time PCR allelic discrimination assay in 
219 patients with MwoA and 130 with MOH in whom migraine was the primary 
headache type. Gene variants association was evaluated by logistic regression 
analysis adjusted by confounding factors. The threshold of statistical significance 
was set according to the total number of polymorphisms analysed in the current 
study and in previous publications arising from overlapping datasets. Results. No 
evidence of association was found between the three polymorphisms tested and 
triptan response in MwoA patients. Conversely, carriers of RAMP1 rs7590387GG 
displayed a lower risk of episodic migraine transformation into MOH (vs C allele 
carriers, OR: 0.27, 95%CI: 0.13-0.57, P=0.0002; threshold of significance set at P< 
0.0029). When genotype distribution for RAMP1 rs7590387 was compared 
between healthy controls (n=209) and MOH patients, carriers of rs7590387GG 
were found at lower risk of developing MOH (OR: 0.43, 95%CI:  0.22-0.85, P= 
0.011). Conclusion. These results suggest that RAMP1 rs7590387 may have a role 
in the transformation of episodic migraine into MOH. 
 
Keywords: migraine, medication overuse headache, susceptibility, triptans, CGRP-
related genes, polymorphisms. 
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The neuropeptide calcitonin gene-related peptide (CGRP), a potent vasodilator 
agent involved in pain transmission, is recognised to play a central role in the 
pathogenesis of migraine.1 Clinical evidence shows that CGRP levels are elevated 
during migraine and reduced by triptans through action on 5-hydroxytryptamine (5-
HT)1B/1D presynaptic receptors.2,3 Although triptans represent the standard of care 
for migraine patients with mild-to-moderate attacks, up to 40% of treated patients 
do not respond to triptan therapy.4,5 Genetic factors have been postulated to be 
involved in interindividual variability of the therapeutic effects of triptans,6 
however no information is currently available on the role of single nucleotide 
polymorphisms (SNPs) in CGRP-related genes as pharmacogenetic determinants.   
On the other hand, the frequent use of triptans or other anti-migraine agents can 
lead to medication overuse headache (MOH) which is a daily or almost daily 
headache resulting from chronicization of episodic migraine or tension-type 
headache as a consequence of symptomatic drug overuse.7 The process of migraine 
chronification (i.e., progression from episodic to chronic migraine) is complex and 
involves comorbid risk factors such as depression, obesity, hypertension and 
stressful life events.8-11 Although genetic factors have been postulated to have a 
role in migraine chronification, only a few studies with limited number of patients 
have investigated the association with polymorphic gene variants.12-14 The 
observation of increased blood levels of CGRP outside migraine attacks in women 
with chronic migraine compared to women with episodic migraine15 raises the 
possibility that polymorphic genes in the signaling pathway of CGRP may be 
implicated in migraine chronification. Among these are the calcitonin gene-related 
polypeptide-alpha (CALCA) gene which encodes the two peptide hormones 
calcitonin and -CGRP, and the receptor activity modifying protein-1 (RAMP1) 
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gene encoding for the subunit of the CGRP receptor required for trafficking to the 
cell surface and for CGRP binding.16,17 
Given the central role of CGRP in migraine pathophysiology, we hypothesized that 
single nucleotide polymorphisms (SNPs) of CGRP-related genes may have an 
impact on triptan response rates or be involved in episodic migraine transformation 
into MOH. To test these hypotheses, in the present study we first investigated the 
effect of rs3754701 and rs7590387 at the RAMP1 locus and of rs3781719 in the 
CALCA gene on triptan response in patients with episodic migraine without aura 
(MwoA). Then, in the context of an association case-control study design, the role 
of the three SNPs was assessed as risk factors for trasformation of episodic 
migraine into MOH. 
 
Methods 
Study Subjects  
Adult patients with migraine without aura (MwoA), and patients with MOH 
referred to Headache Center of Mondino Institute of Pavia and the Headache 
Center of "Maggiore della Carità" University Hospital of Novara were eligible to 
participate. MwoA patients have been enrolled from May 2004 to March 2014 
while MOH patients have been recruited from March 2005 to September 2008. The 
inclusion criteria for enrollment of subjects with MwoA were i) headache fulfilling 
ICHD-II criteria for migraine without aura from at least one year, ii) age between 
18 and 65 years; exclusion criteria were i) previous or current diagnosis of MOH, 
ii) contraindications to be prescribed with triptans, iii) history of psychiatric 
disorders. The triptan response was assessed as previously reported.18 Briefly, 
MwoA patients were given a specific diary to record the clinical response to the 
triptan intake for three consecutive migraine attacks. For each of the migraine 
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attacks, the patient was asked to record on a  diary the intensity of pain (on a scale 
from 0 to 3; 0= absent pain, 1= mild pain/no disability, 2= moderate pain/partial 
disability and 3= severe pain/total disability) at the moment of the triptan intake 
and after 120 min. Consistent responders to triptans were defined as the 
migraineurs who experienced a ≥2 point reduction after triptan administration in at 
least two out of three consecutive attacks, otherwise MwoA patients were defined 
as inconsistent responders. The inclusion criteria for enrollment of subjects with 
MOH were i) headache fulfilling ICHD-2 criteria for MOH19,20 with migraine as 
primary headache type, ii) accurate compilation of the diary for a 3-month pre-
withdrawal period; exclusion criteria were: iii) history of psychiatric disorders that 
could sustain a chronic pain condition (psychotic and/or somatoform disorders; 
most patients also underwent an interview with a skilled psychologist and was 
administered the Minnesota Multiphasic Personality Inventory Test; MMPI-2 
Italian Version), iv) other major medical conditions. Control subjects were matched 
with MOH patients by age and sex and were randomly selected from general 
population of same ethnic background (north-west Italy) to minimize population 
heterogeneity and stratification. As no clinical evaluation has been performed on 
the control group, we cannot rule out the possibility that some individuals present 
in the control sample might be affected by MOH. However, this fraction of affected 
individuals is unlikely to be higher than that observed in the general population (1-
2%).7 This study was approved by the local Ethics Committees of the institutions 
involved (“C. Mondino” Institute, Pavia and “Maggiore della Carità” University 
Hospital, Novara) and it met the requirements of the Declaration of Helsinki. 
Informed consent was obtained from all patients before participation in the study. 
 
Genotyping 
Genomic DNA was extracted from peripheral blood by using the QiaAmp DNA 
Mini Kit (Qiagen Valencia, California, USA). Genotyping was performed by real-
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time PCR using Applied Biosystems TaqMan Pre-Designed SNP Genotyping 
assays [CALCA rs3781719 Assay ID: C_2698777_10; RAMP1 rs3754701 assay 
ID: C_27496443_10; RAMP1 rs7590387 assay ID: C_26481962_10]. Real-time 
PCR amplification and detection was conducted on genomic DNA according to 
previously described methods.21 For validation, about 10 % of the samples were re-
genotyped. The results were reproducible with no discrepancies in genotyping. 
CALCA rs3781719 was genotyped in all MOH patients also by polymerase chain 




Data were summarized and presented in the form of mean, standard deviation, and 
percentage as descriptive statistics. Each polymorphism was tested for deviation 
from the Hardy-Weinberg equilibrium (HWE) by use of the exact test implemented 
in the online Finetti’s program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The 
association between SNPs and the two clinical endpoints (risk of inconsistent 
response to triptans and risk of trasformation of episodic migraine to MOH, 
respectively) was assessed by logistic regression analysis with adjustment for 
confounding clinical covariates (cut-off of P-value <0.1 from univariate analyses). 
In addition, SLC6A4 STin2 VNTR and COMT Val158Met were included as 
covariates in the adjusted analyses, being found associated with triptan response in 
previous publications arising from an overlapping dataset.18,23 For all the selected 
polymorphisms, we considered either a log-additive, a dominant or a recessive 
mode of inheritance. The log-additive genetic model is a trend test for the 
genotypes, similar to the allele model, but comparisons are among subjects (N) 
instead of chromosomes (2N). In the log-additive model, estimates are based on a 
logistic regression model that coded the genotypes as 0,1, or 2 to reflect the number 
of minor alleles. Clinical and genotype data were managed with the statistical 
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software package SYSTAT for Windows (version 12; Systat Software Inc., 
Chicago, IL, USA) and SNPStats software.24 The SNPStats software was also used 
for the calculation of linkage disequilibrium (measured as r2-value) between 
RAMP1 SNPs. Due to the exploratory nature of this study, we reported nominal 
statistical associations (P value <0.05). Adjusted P values based on the Bonferroni 
correction were also considered to avoid chance findings due to multiple testing, 
and the threshold of statistical significance was adjusted according to the total 
number of polymorphisms analysed in the current study and in any previous 
publication arising from an overlapping dataset. Specifically, the significance level 
for the risk of inconsistent response to triptans was lowered to P<0.0035 to account 
for a total of 14 polymorphisms analysed, of which eleven in previous 
publications.18,21,23,25 The threshold of significance for the risk of episodic migraine 
transformation into MOH was set at P < 0.0029 to account for a total of 17 SNPs 
analysed including those reported in previous publications.26-28 Given our sample 
size of 138 MwoA patients with consistent response to triptans and 81 MwoA 
patients with inconsistent response and assuming a power of 80% and a nominal 
level of significance of 0.05, for the investigated gene variants (Minor allele 
frequency:  0.30 to 0.45) the minimal detectable odds ratio for inconsistence 
response to triptans was 1.8 under the log-additive model of inheritance, and 
ranged from 2.3 to 2.8 under the dominant model and from 2.6 to 3.1 under the 
recessive model of inheritance. The minimal detectable odds ratio for 
transformation of episodic migraine (n=207) into MOH (n=130) was 1.6 under the 
log-additive model, and ranged from 1.9 to 2.1 under the dominant and from 2.1 to 







This study included a total of 219 MwoA patients (79.9% of women) with a mean 
age of 38.4 years (standard deviation: 10.6), 130 MOH patients (75.4% of women) 
with a mean age of 47.8 years (standard deviation: 11.1) and 209 healthy subjects 
(75.6% of women) with a mean age of 50.0 years (standard deviation: 15.5). 
Among MOH patients, 20 (15.4%) overused exclusively 1, or more, types of 
triptan, 39 (30.0%) exclusively NSAIDs (1, or more, types of non-steroidal anti-
inflammatory drugs), 22 patients (16.9%) overused exclusively combination drugs 
(a single pharmaceutical product that contains more than 1 active principle), 47 
(36.2%) overused 2 or more classes of drugs (which we called association drugs), 1 
patient overused exclusively ergotamine (0.8%), and 1 patient exclusively opiates 
(0.8%).  
Clinical variables and genotypes distribution in the whole cohort of MwoA patients 
and after stratification according to their consistency status of headache response to 
triptans are shown in Table 1. Inconsistent response to triptans was observed in 
36.9% of patients with MwoA (81/219). Patients receiving triptans other than 
frovatriptan (n=108, 49.3%) displayed a lower risk of inconsistent response rates 
than MwoA patients treated with frovatriptan (OR: 0.49, 95%CI: 0.28-0.86, 
P=0.013, Table 1). All the other demographic and clinical variables were similarly 
distributed when comparing consistent responders with inconsistent responders. In 
MwoA patients, CALCA rs3781719, RAMP1 rs7590387 and RAMP1 rs3754701 
were in HWE (PHWE rs3781719 = 0.52; PHWE rs3754701= 0.77; PHWE rs7590387= 
0.41). The observed minor allele frequencies (MAFs) of the three SNPs (MAF of 
rs3781719: 0.30; MAF of rs3754701: 0.37; MAF of rs7590387: 0.45) were similar 
to those reported in Hap-Map-CEU population (MAF of rs3781719: 0.32; MAF of 
rs3754701: 0.37; MAF of rs7590387: 0.49). In addition, in our cohort of MwoA 
patients rs3754701 and rs7590387 were not found in linkage disequilibrium (LD) 
149 
 
(r2=0.006, p=0.092), a result in accordance with Caucasian HapMap LD data 
(r2=0.005).  
In the logistic regression analysis adjusted for triptan (frovatriptan vs other 
triptans), and for SLC6A4 STin2 VNTR and COMT val158met polymorphisms, 
which were found associated with triptan response in previous publications,18,23 
CALCA rs3781719, RAMP1 rs3754701 and RAMP1 rs7590387 were found not 
significantly associated to headache response to triptans, either under the log-
additive, the dominant or the recessive model of inheritance (Table 1). Given the 
confounding effect of frovatriptan on headache response rates and its unique 
pharmacokinetic profile, we also carried out subgroup analyses according to the 
use of frovatriptan. Similar results were obtained when analysis was conducted 
separately on patients treated with the long-acting triptan (frovatriptan) and patients 
treated with the fast-acting triptans combined (eletriptan, rizatriptan, almotriptan, 
sumatriptan, and zolmitriptan) (Table 2).  
In order to extend previous results showing lack of association of CALCA 
rs3781719, RAMP1 rs3754701 and RAMP1 rs7590387 with migraine 
susceptibility,22 we evaluated their role as risk factors for episodic migraine 
transformation into MOH. In MOH patients, RAMP1 rs3754701 and RAMP1 
rs7590387 but not CALCA rs3781719 were found in HWE (PHWE rs3754701= 0.56; 
PHWE rs7590387= 0.086; PHWE rs3781719= 0.009). Confirmation of genotypes for 
rs3781719 by PCR-RFLP in all MOH patients excluded that its deviation from 
HWE was a result of genotyping errors. The association of SNPs in CALCA and 
RAMP1 genes with the risk of episodic migraine transformation into MOH was 
assessed by comparing genotypes distribution in the whole cohort of MwoA 
patients and MOH patients. Given that the mean age of the MOH group was 
significantly higher than that in the MwoA group (P<0.001), we used the logistic 
regression method for adjustment of data to remove the effect of age variation as a 
confusing factor. No association was found with CALCA rs3781719 and RAMP1 
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rs3754701. Conversely, the RAMP1 rs7590387G allele (log-additive model: OR 
0.60, 95%CI 0.42-0.86, P=0.004) and carriers of rs7590387GG genotype (recessive 
model: 0.27, 95%CI: 0.13-0.57, P=0.0002) were found at lower risk of episodic 
migraine transformation into MOH (Table 3). It is noteworthy that the significance 
of rs7590387 under the recessive model of inheritance was retained even after 
lowering P-value threshold at < 0.0029 to account for a total of 17 SNPs analysed 
including those reported in previous publications.26-28 When analysis was restricted 
to MOH patients that, after withdrawal therapy, displayed chronic headache despite 
the interruption of the drug overuse and patients with chronic headache that still 
overused acute medication at the 2-month follow-up, conformation to HWE was 
observed for all three SNPs in this subgroup of MOH patients (n=30) (PHWE 
rs3781719= 0.18; PHWE rs3754701= 1; PHWE rs7590387= 0.69), and the nominal 
significance of RAMP1 rs7590387 was retained (recessive model, OR: 0.21, 
95%CI: 0.05-0.95, P=0.015). When comparing genotype distribution for RAMP1 
rs7590387 between healthy controls (n= 209, PHWE rs7590387= 0.16) and MOH 
patients, carriers of rs7590387GG genotype were found at lower risk of developing 
MOH (OR: 0.43, 95%CI:  0.22-0.85, P= 0.011, Table 4). Conversely, controls did 
not differ from MwoA patients in the distribution of rs7590387 genotypes (Table 
4), confirming previous results showing lack of association between RAMP1 




Table 1. Clinical variables and genotype distribution of SNPs in CALCA and 
RAMP1 genes in the whole set of MwoA patients and after stratification according 
to their consistency status of headache response to triptans. 






OR* (95% CI)  P 
value 
Sex      
    Female 











Age at study entry (year) 
    mean ± SD  38.4 (10.6) 38.6 (10.6) 38.1 (10.7) 0.99 (0.97-1.02) 0.73 
Triptan 
    Frovatriptan 
    Rizatriptan 
    Eletriptan 
    Almotriptan 
    Sumatriptan 





























Use of prophylactic medications (n= 209) 
   Yes 











      







OR# (95% CI) 
P 
value 
CALCA rs3781719 (T>C)   
    TT 
    TC 










A: 0.96 (0.62-1.48) 
D: 1.04 (0.59-1.85) 




RAMP1 rs3754701 (T>A) 
   TT 
   TA 










A: 0.90 (0.60-1.37) 
D: 0.73 (0.41-1.32) 




RAMP1 rs7590387 (C>G) 
   CC 
   CG 










A: 1.11 (0.75-1.65) 
D: 0.84 (0.46-1.54) 






Abbreviations: CR, consistent responders to triptans; IR, inconsistent responders; A, log-additive 
model of inheritance; D, dominant model of inheritance; R, recessive model of inheritance. 
*Univariate logistic regression analysis. #Logistic regression analysis adjusted for triptan (frovatriptan 
vs other triptans), and for SLC6A4 Stin2 VNTR and COMT val158met polymorphisms which were 





Table 2. Association analysis of SNPs in CALCA and RAMP1 genes in MwoA 
patients treated with the long-acting (frovatriptan) and fast-acting triptans 






OR* (95% CI)  
P value 
     
MwoA patients treated with frovatriptan (n=111) 
  CALCA rs3781719 (T>C) 
    TT 
    TC 







A: 0.94 (0.51-1.71) 
D: 1.10 (0.51-2.40) 




  RAMP1 rs3754701 (T>A) 
   TT 
   TA 







A: 1.03 (0.57-1.85) 
D: 1.02 (0.46-2.27) 




  RAMP1 rs7590387 (C>G) 
   CC 
   CG 







A: 1.08 (0.64-1.81) 
D: 0.77 (0.35-1.70) 




     
MwoA patients treated with triptans other than frovatriptan (n=108) 
  CALCA rs3781719 (T>C) 
   TT 
   TC 







A: 1.04 (0.54-2.02) 
D: 1.06 (0.44-2.54) 




  RAMP1 rs3754701 (T>A) 
   TT 
   TA 







A: 0.75 (0.41-1.39) 
D: 0.52 (0.21-1.24) 




 RAMP1 rs7590387 (C>G) 
   CC 
   CG 







A: 1.14 (0.61-2.12) 
D: 0.92 (0.35-2.40) 





Abbreviations: CR, consistent responders to triptans; IR, inconsistent responders; A, log-additive 
model of inheritance; D, dominant model of inheritance; R, recessive model of inheritance. 





Table 3. Association of SNPs in CALCA and RAMP1 genes with risk of episodic 
migraine transformation into MOH. 
 
SNP MwoA n(%) MOH, n(%) Genotypic model 
OR#(95% CI) 
P-value 










A: 0.97 (0.69-1.37) 
D: 0.81 (0.50-1.29) 




     










A: 0.81 (0.58-1.15) 
D: 0.75 (0.47-1.21) 




     










A: 0.60 (0.42-0.86) 
D: 0.71 (0.43-1.16) 




     
 
Abbreviations: A, log-additive model of inheritance; D, dominant model of inheritance; R, recessive 
model of inheritance. #Logistic regression analysis adjusted for age. The threshold of significance 
for Bonferroni correction was set at P < 0.0029 to account for a total of 17 SNPs analysed including 
those reported in previous publications.26-28 
 
 
Table 4. Association of RAMP1 rs7590387 (C>G) with migraine susceptibility or 
MOH risk. 
Genotypes Controls n(%) MwoA, n(%) Genotypic model 











A: 0.93 (0.69-1.26) 
D: 0.66 (0.41-1.06) 




Genotypes Controls n(%) MOH, n(%) Genotypic model 











A: 0.61 (0.43-0.86) 
D: 0.60 (0.37-0.95) 





Abbreviations: A, log-additive model of inheritance; D, dominant model of inheritance; R, recessive 
model of inheritance. #Logistic regression analysis adjusted for age. *Univariate logistic regression 






Despite clinical data supporting the involvement of CGRP in the clinical response 
to triptans in migraine patients29,30 or in migraine chronification,15 the possible 
contribution of polymorphisms in CGRP-related genes as pharmacogenetic 
determinants or as risk factors for chronification of episodic migraine has been 
poorly investigated. In the present study, we assessed the impact of rs3754701 and 
rs7590387 at the RAMP1 locus and of rs3781719 in the CALCA gene on triptan 
response rates in MwoA patients, as well as their role as risk factors for migraine 
transformation into MOH. We acknowledge that our study is underpowered to 
detect small genetic main effects, however it has sufficient power to detect 
medium-large effect sizes of clinical relevance. While our results exclude a 
clinically relevant impact of the SNPs tested on headache response to triptans, our 
findings suggest that RAMP1 rs7590387 may have a role in the transformation of 
episodic migraine into MOH.  
A few studies have addressed the genetic basis for variability in the therapeutic 
effects of triptans.6 Among the most interesting findings are associations with 
polymorphic variants in the SLC6A4,18 COMT23 and DRD231 and genes, however 
none of these associations has been independently validated. Polymorphisms in 
CGRP-related genes may be plausible pharmacogenetic candidates for 
interindividual variability of triptan response since administration of sumatriptan is 
effective in reversing the CGRP-induced migraine32 and elevation of salivary levels 
of CGRP predicts responsiveness to rizatriptan.30 In the present study, we found no 
association of the three SNPs in CALCA and RAMP1 genes on triptan response, 
either in the overall cohort of MwoA patients and in patients treated with the most 
frequently prescribed frovatriptan (a long-acting triptan). However, given the 
limited number of MwoA patients enrolled and the wide variety of triptans 
prescribed due to the naturalistic setting of our study, it was not possible to conduct 
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a stratified analysis of CALCA and RAMP1 gene SNPs according to all the triptans 
administered.33 Thus, further studies would be needed to evaluate the impact of the 
three SNPs tested on headache response to a specific fast-acting triptan.  
While polymorphisms in dopaminergic system genes have been involved with the 
prognosis of MOH patients after withdrawal therapy,28,34 the genetic basis for 
transformation of episodic migraine into MOH is not known. Early evidence of a 
genetic component for MOH comes from epidemiological studies showing a three-
fold increased risk of developing MOH in subjects with a family history of MOH.35 
Furthermore, MOH appears to share some pathogenic mechanisms with other kinds 
of addictive disorders36,37 and genetic factors are established contributors to drug 
addiction.38 Although serotonin has been implicated in the predisposition to 
substance-related disorders,39,40 no evidence of correlation has been reported 
between serotonergic gene variants and MOH risk.25-27,41 Despite lack of 
association between variants in CALCA and RAMP1 genes and migraine 
susceptibility,22,42,43 polymorphisms at these loci could have a role in migraine 
chronification. This possibility has been raised in a recent study with a three-stage 
design evaluating 144 SNPs selected from 48 candidate genes.44 Of these, eight 
SNPs including CALCA rs2956 and RAMP1 rs302680 were found nominally 
associated with chronic migraine in the two-stage discovery phase, although none 
was significant in the replication stage.44 
In the present study, we provide for the first time evidence that carriers of the 
major allele for rs7590387 are at higher risk for transformation of episodic 
migraine into MOH. Our findings are strengthened by confirmation of this 
association when analysis was restricted to MOH patients who continued to have 
daily headaches after drug withdrawal. However, it should be acknowledged that 
MwoA patients were younger than MOH subjects, therefore we cannot exclude that 
a percentage of included MwoA patients may develop MOH later. Although no in 
vitro or in vivo expression/functional data exists regarding the three SNPs analysed, 
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it should be noted that rs3781719 and rs3754701 are located in the promoter region 
of CALCA and RAMP1, respectively, while rs7590387 is localized 1.4 kb 
downstream of the RAMP1 gene. Thus, rs7590387 is not expected to be the true 
causal variant, and the association here reported may be due to linkage 
disequilibrium of rs7590387 with an unknown functional polymorphism which is 
the actual determinant factor for migraine transformation. Therefore, further studies 
are warranted, based on haplotype analysis of tightly linked SNPs in RAMP1 gene, 
to provide more conclusive evidence of association with migraine transformation. 
It is also noteworthy that a significant interaction has been reported between BDNF 
and CALCA genes in migraine susceptibility, showing an increased risk for the AT-
genotype of rs2049046 and the GC-genotype of rs1553005 for migraineurs.45 Thus, 
an approach based on SNP-SNP interaction analysis could also provide further 
insights in the genetic dissection of migraine transformation into MOH. Also 
noteworthy is the observation of lack of association beween rs7590387 and triptan 
response despite a correlation with migraine transformation. This deserves further 
study to investigate whether an inadequate response to triptans could entail the 
transformation of episodic migraine into MOH.  
In conclusion, although the present results exclude a clinically relevant impact of 
rs3754701 and rs7590387 at the RAMP1 locus and of rs3781719 in the CALCA 
gene on headache response to triptans, our findings support a role of RAMP1 
rs7590387 in the transformation of episodic migraine into MOH. However, the 
single institution and retrospective nature of the present study require our findings 
to be validated in larger, preferably multi-institutional prospective studies. In 
addition, further investigation based on haplotype analysis of tightly linked SNPs 
or on SNP-SNP interaction analysis is warranted to provide conclusive evidence of 
association of RAMP1 rs7590387, or of a linked functional SNP, with migraine 
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Abstract 
Purpose:  No information is currently available on genetic determinants of short-
term response to drug withdrawal in medication overuse headache (MOH). In the 
present study we aimed to evaluate the role of 14 polymorphisms in 8 candidate 
genes potentially relevant for drug addiction (OPRM1, DRD2, DBH, COMT, 
BDNF, SLC6A4, 5HT2A and SLC1A2) as predictors for detoxification outcome of 
MOH patients at 2 month of follow-up. 
Methods: Genotyping was conducted by PCR, PCR-RFLP analysis or real-time 
PCR allelic discrimination assay on genomic DNA extracted from peripheral 
blood. The association between gene variants and risk of unsuccessful 
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detoxification was evaluated by univariate and multivariate logistic regression 
analyses. 
Results: One hundred and eight MOH patients with effective drug withdrawal 
therapy and 65 MOH patients with unsuccessful detoxification were available for 
the analysis. In the multivariable logistic regressions analysis, triptan overuse (OR: 
0.271, 95% CI: 0.083–0.890, P= 0.031) and TT genotype carriage of DRD2 NcoI 
(OR: 0.115, 95% CI: 0.014–0.982, P= 0.048) emerged as independent predictors 
for unsuccessful detoxification. In addition, carriers of at least 4 of the 6 top-ranked 
gene variants (P<0.10) were found at higher odds for unsuccessful detoxification 
than patients with  3 high risk genotypes (OR: 3.40, 95%CI: 1.65-7.01, P=0.001).  
Conclusion: This exploratory study suggests that DRD2 NcoI may be a genetic 
determinant of detoxification outcome in MOH patients. Our findings also show 
that an approach based on the combination of multiple genetic markers could be 
clinically useful for identification of MOH patients at higher risk for unsuccessful 
detoxification. 
 
Keywords: medication overuse headache; drug withdrawal therapy; detoxification; 




Medication overuse headache (MOH) is a chronic secondary headache due to 
overuse of symptomatic headache drugs, including single and combination 
analgesics, barbiturates, opioids, ergot alkaloids and triptans [1, 2]. MOH has a 
prevalence of 1-2% in the general population [3] and a high economic burden on 
society, being estimated per-person annual costs three times higher than those of 
migraine and ten times higher than those of tension-type headache [4, 5]. Although 
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drug withdrawal therapy is performed very differently within and across countries, 
it represents the first choice treatment for MOH [6, 7]. In most MOH patients, 
chronic headache is resolved or reverted to its previous pattern within 2 months 
after drug withdrawal [8-10]. Despite a number of studies focusing on clinical 
predictors for detoxification outcome or evaluating brain metabolic changes in pain 
processing structures after drug withdrawal [9, 11], to date no information is 
available concerning the role of common genetic variants as determinants of short-
term outcome of MOH patients after drug detoxification treatment.  
A genetic susceptibility to MOH has been suggested on the basis of 
epidemiological studies showing a threefold increased risk of developing MOH in 
subjects with a family history of MOH or other substance abuse such as drug or 
alcohol abuse [12, 13]. Increasing evidences also suggest that MOH shares some 
pathogenetic mechanisms with other kinds of drug addiction [14], which has been 
postulated to be a complex phenotype influenced by either environmental and 
genetic factors [15]. The dopaminergic system has been most extensively studied in 
addiction research due to its strong association with reward and the observation 
that most drugs of abuse enhance dopamine levels [16]. For instance, the -141C 
Ins/Del polymorphism of the dopamine receptor D2 (DRD2) and the 
ANKK1/DRD2 Taq1A variant have been related to alcohol dependence [17, 18]. 
Moreover, the -1021C>T variant of the dopamine beta–hydroxylase (DBH) gene 
has been linked with the psychotic effects caused by cocaine [19], while a higher 
frequency of the Val allele of the catechol-O-methyltransferase (COMT) 
val158Met polymorphism has been found in polysubstance abusers [20] or 
methamphetamine users [21]. On the other hand, several studies have shown that 
118G allele carriers of the μ-opioid receptor gene (OPRM1) 118A>G SNP are at 
higher risk of alcohol or opiate dependency [22], while BDNF val66met has been 
linked to methamphetamine or heroin abuse [23]. Among serotonergic genes, the 
serotonin 2A receptor (5HT2A) -1438A>G gene polymorphism has been related to 
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alcoholism [24], while the STin2VNTR of the serotonin transporter (SLC6A4) has 
been reported to have an influence on treatment outcome in alcohol-dependent 
patients [25]. In addition, a dysregulation of excitatory glutamatergic system has 
been hypothetized to play a key role in the neuroadaptations associated with 
repeated drug use [26]. Although it is generally accepted that polymorphic genes 
may play a role in development of addictive diseases, only few studies have 
addressed the question of whether genetic variants may also contribute to treatment 
outcome in detoxification.  
Recently, we reported that COMT rs4680, alone or in haplotype combination with 
rs6269, is a determinant for relapse of MOH patients within the first year of follow-
up after successful drug withdrawal, suggesting a genetic basis for long-term 
outcome of successfully detoxified MOH patients [27]. In this exploratory 
‘‘hypothesis-generating’’ study, we evaluated the role of 14 polymorphic variants 
in 8 candidate genes (OPRM1, DRD2, DBH, COMT, BDNF, SLC6A4, 5HT2A 
and SLC1A2), potentially relevant for drug addiction, as predictive factors for 
unsuccessful detoxification of MOH patients 2 months after medication 
withdrawal. In addition, their role as risk factors for developing MOH was 




The medical records of 227 MOH patients who underwent withdrawal therapy 
between March 2005 and September 2008 at the inpatient Headache Unit of C. 
Mondino National Neurological Institute’ (Pavia, Italy) and who had given their 
informed consent to genetic analysis were retrospectively reviewed. Inclusion and 
exclusion criteria for MOH patients have been previously described [28]. All 
patients underwent a standard in-patient withdrawal protocol which was carried on 
according to previously described procedures [29]. At the 2-month follow-up visit, 
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the pattern of the headache was evaluated, on the basis of the information recorded 
by the patient in the diary, the number of days with headache and the use of 
symptomatic drugs. Withdrawal therapy was considered "successful" if, after 2 
months, the patients reverted to an episodic pattern of headache, stopped their 
overuse of symptomatic drugs and did not overuse another symptomatic 
medication (intake of NSAID/paracetamol on ≥15 days/month or other 
symptomatic medication or combination of symptomatic medications ≥10 
days/month). On the other hand response to withdrawal therapy was labeled 
“unsuccessful” if medication overuse had ceased within the last two months but 
headache had not resolved or reverted to its previous pattern or if overuse 
medication has not yet been withdrawn or if there was an overuse of another 
symptomatic medication (see above). The control sample consisted of 312 
unrelated subjects [196 women (62.8%) and 116 man (37.2%)] with a median age 
of 56 (range 18–100). Control subjects were randomly selected from general 
population of same ethnic background (north-west Italy) to minimize population 
heterogeneity and stratification. As no clinical evaluation has been performed on 
the control group, we cannot rule out the possibility that some individuals present 
in the control sample might be affected by migraine or MOH. However, the 
fraction of control subjects that may be affected by MOH is unlikely to be higher 
than that observed in the general population (1-2%).  
This study was approved by the local Ethics Committee and it met the requirements 
of the Declaration of Helsinki. Written informed consent was obtained from all 
patients before participation in the study. 
 
Genotyping 
The SNPs selected and their National Center for Biotechnology Information 
(NCBI) dbSNP ID (rs) were the following: DRD2 -141C Ins/Del (rs1799732); 
DRD2 TaqI A (rs1800497); DRD2 NcoI (rs6275); DBH -1021C>T (rs1611115); 
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COMT rs6269; COMT val158met (rs4680), BDNF val66met (rs6265); OPRM1 
118A>G (rs1799971); 5HT2A 516C>T (rs6305); 5HT2A -1438A>G (rs6311); 
SLC6A4 5-HTTLPR; SLC6A4 STin2 VNTR, SLC6A4 rs1042173; SLC1A2 -
181A>C (rs4354668). Genomic DNA was extracted from peripheral blood by use 
of the QiaAmp DNA Mini Kit (Qiagen Valencia, CA). Except COMT rs6269 and 
SLC1A2 rs4354668 polymorphisms, which were determined by real-time PCR 
allelic discrimination assay using Applied Biosystems TaqMan Pre-Designed SNP 
Genotyping assays [rs6269 Assay ID:  C_2538746_1; rs4354668 Assay ID: 
C__27142767_10], genotyping was performed according to PCR- RFLP methods 
by using the primers and restriction enzymes listed in Table S1 of Supplementary 
Material. All reactions of PCR/real-time PCR were set up in a dedicated PCR area 
with dedicated pipettes and reagents. For quality control purposes, each PCR run 
included negative as well as positive controls for the three genotypes. For 
validation, about 10% of the samples were re-genotyped. The results were 
reproducible with no discrepancies in genotyping. Genotyping was done blinded to 
MOH patient's outcome status. 
 
Statistical analysis 
Data were summarized and presented in the form of mean, standard deviation and 
percentage as descriptive statistics. For each polymorphism an exact test for 
Hardy–Weinberg equilibrium was performed for deviation from Hardy–Weiberg 
equilibrium by using the SNPstat software (available at 
http://bioinfo.iconcologia.net/snpstats/start.htm) [30]. The effect of clinical and 
genetic variables on the risk of unsuccessful detoxification was first evaluated by 
univariate logistic regression analysis. Odds ratios (ORs) and their 95% confidence 
intervals (CIs) were used as estimates of relative risk. The following clinical 
parameters were considered: gender, age at study entry, age of primary headache 
onset, familiarity for headache, primary headache diagnosis, drugs of abuse, 
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monthly drug number, headache per month and duration of MOH disease before 
withdrawal therapy. For all the selected polymorphisms, we considered either a 
log-additive, a dominant or a recessive mode of inheritance. The Akaike 
information criterion (AIC) was used to select the genetic model that best fits the 
data (i.e., the model with the lowest AIC score was the best fitting). The 
explanatory variables with a cut-off of P-value <0.1 from univariate analyses were 
used and included into the multivariate logistical regression model to identify 
independent predictors of unsuccessful detoxification. Clinical and genotype data 
were managed with the statistical software package SYSTAT for Windows 
(version 12; Systat Software Inc., Chicago, IL, USA) and SNPStats software. Due 
to the exploratory nature of this study, we reported nominal statistical associations 
(P value <0.05). Adjusted P-values based on the Bonferroni correction were also 
considered to avoid chance findings due to multiple testing of the 14 
polymorphisms, and the significance levels were lowered to P= 0.00357 (P= 
0.05/14). Details on power calculations are provided in Supplementary Material. 
 
Results 
Medical charts of 227 MOH patients undergoing inpatient drug withdrawal therapy 
were retrospectively evaluated. Distribution of clinical and demographic 
characteristics of MOH patients in the whole cohort and after stratification 
according to their detoxification status at 2 months of follow-up are shown in Table 
1. Outcome data was available in 173 MOH patients, of which 108 were MOH 
patients with effective drug withdrawal therapy and 65 were MOH patients with 
unsuccessful detoxification. In the univariate association analysis, triptan overuse 
(OR: 0.27, 95% CI 0.09–0.83, P= 0.022) and primary headache diagnosis (mixed 
type vs migraine type, OR: 2.06, 95% CI 1.04–4.10, P= 0.039) were found 
associated with unsuccessful detoxification. No other clinical factor was 
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univariately correlated to unsuccessful detoxification with a cut-off of P <0.1 
(Table 1).  
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Table 1. Clinical and demographic characteristics in the whole set of MOH 
patients and after stratification according to their detoxification status at 2-months 
of follow-up. 
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Combination drugsd 
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Monthly drug numberf  42.4 (27.3) 41.8 (26.9) 45.3 (27.7) 1.00 (0.99–1.02) 0.41 
Headache days  
per monthf 
25.2 (6.2) 25.06 (6.2) 25.5 (6.4) 1.01 (0.96–1.06) 0.67 
Duration of MOH 
desease (months)f 32.7 (40.9) 33.1 (46.8) 27.8 (34.3) 1.00 (0.99–1.01) 0.45 
 
aMigraine associated with episodic tension-type headache; b1, or more, types of triptan. c1, or more, 
types of NSAIDs; da single pharmaceutical product that contains more than 1 active principle, e 2 or 




All the polymorphisms analyzed were in Hardy–Weinberg equilibrium both in 
MOH patients (n=227) and control subjects (n=312) (all P > 0.05). Among MOH 
patients, at univariate analysis, carriers of COMT rs4680 AA (OR: 0.40, 95%CI: 
0.16–0.099, P= 0.047), carriers of DRD2 NcoI TT (OR: 0.14, 95% CI: 0.02–1.09, P 
= 0.061), DBH rs1611115 T allele carriers (OR: 0.57, 95%CI 0.30–1.09, P=0.091) 
and BDNF val66met in the log-additive genetic model (OR: 0.60, 95%CI: 0.36–
1.02, P=0.060) were found at lower risk of withdrawal therapy failure, while 
OPRM1 118G allele carriers (OR: 2.19, 95%CI 1.11–4.30, P=0.023) and 5HT2A 
516T allele carriers (OR: 2.22, 95%CI 0.90–5.48, P=0.084) displayed a higher risk 
of unsuccessful detoxification (Table 2).  
Table 2. Association analysis of top ranked gene variants (P 0.1) with the risk of 
MOH patients for unsuccessful detoxification: univariate logistic regression 
analysis. 
 
SNP Successful_withdrawal therapy 
Yes                      NO 
Genetic 
model 
OR (95% CI)          P value 










Dominant 2.19 (1.11–4.30) 0.023 










Recessive 0.40 (0.16–0.099) 0.047 










Log-additive 0.60 (0.36–1.02) 0.060 










Recessive 0.14 (0.02–1.09) 0.061 












2.22 (0.90–5.48) 0.084 










Dominant 0.57 (0.30–1.09) 0.091 
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None of the other polymorphisms investigated was found related by univariate 
analysis to treatment outcome with a cut-off of P-value <0.1 (Table S2, 
Supplementary Material). In both univariate and multivariate analyses, no 
polymorphism remained of statistical significance when the conservative 
Bonferroni correction was used for multiple testing (Bonferroni P value threshold 
<0.0036). Nevertheless, in the multivariable logistic regressions model including 
clinical and genetic factors found to be significant on univariate analysis at a P-
value <0.1, triptan overuse (OR: 0.271, 95% CI: 0.083–0.890, P= 0.031) and 
DRD2 NcoI (TT vs CT+CC, OR: 0.115, 95% CI: 0.014–0.982, P= 0.048) emerged 
as nominal independent predictors of unsuccessful detoxification (Table 3).  
 
Tables 3. Predictive factors for unsuccessful detoxification in MOH: multivariate 
logistic regression analysis. 
 
Variables OR (95%CI) P value 
Triptan overusea        
  No 





DRD2 NcoI   
  CC+CT 1 (Ref)  
  TT 0.115 (0.014–0.982) 0.048 
aof 1, or more, types of triptan. 
 
In order to evaluate the cumulative effect of the six top ranked gene variants (P<0.1 
in the univariate analysis) on the risk of unsuccessful detoxification, the number of 
high risk genotypes for each patient was considered. In the logistic regression 
analysis adjusted for triptan overuse and primary headache diagnosis, carriers of 4 
or more high risk genotypes were at higher odds for unsuccessful detoxification 
than were patients with  3 high risk genotypes (OR: 3.40, 95%CI: 1.65-7.01, 
P=0.001, Table 4). Noteworthy that the cumulative effect of the six high risk 
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genotypes remained significant after Bonferroni’s correction (threshold of 
significance required for Bonferroni correction for 14 polymorphisms analyzed, P< 
0.00357). In addition, when only the 3 dopaminergic gene variants were considered 
in the combined analysis (COMT val158met, DRD2 NcoI, DBH -1021C>T), 
nominal significance of this joint analysis was retained (3 vs 2 high risk 
genotypes, OR 2.316, 95%CI: 1.20-4.47, P=0.012, Table 4). The patients that 
displayed an unsuccessful detoxification were mainly composed of patients with 
chronic headache despite the interruption of the drug overuse (n=22) and patients 
with chronic headache that still overused acute medication at the 2-month follow-
up (n=35). The cumulative effect of genetic risk variants was significant in both 
groups when analysed separately (Table S3, Supplementary Material). 
 
Table 4. Cumulative effects of genetic risk variants on the risk of MOH patients 
for unsuccessful detoxification. 
N° of high risk 
genotypes 
Successful withdrawal therapy 
YES                     NO 
n (%)                   n (%) 
OR* (95% CI)  P value 
Combined analysis of six high risk genotypes  
 3 54 (50.0)              14 (21.5) 1 (Ref)  
4-6 54 (50.0)              51 (78.5) 3.403 (1.652–7.011) 0.001 
    
Combined analysis of three dopaminergic gene variants  
(COMT val158met, DRD2 NcoI, DBH -1021C>T) 
2 
3 
66 (61.1)                    27 (41.5) 





*Logistic regression analysis adjusted for triptan overuse and primary headache diagnosis.  
 
We have previously reported a lack of association between -1438A>G and 516C>T 
SNPs of 5HT2A with the risk for developing MOH [31] and a nominally 
significant association with SLC6A4 rs1042173 but not with SLC6A4 5HTT-LPR 
or SLC6A4 VNTR STin2 [28]. In the present study, we extended this association 
analysis to the other 9 gene variants investigated (OPRM1 118A>G, DRD2 NcoI, 
DRD2 -141C Ins/Del, DRD2 Taq1A, DBH -1021C>T, COMT rs6269, COMT 
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val158met, BDNF val66met and EAAT2 -181A>C). None of these polymorphic 




In the present study we found that 37% of MOH patients responded poorly to drug 
withdrawal therapy, a rate which is comparable to that reported by previous reports 
[9, 32]. It is not yet known why only about two-thirds of patients with MOH 
improve after drug withdrawal therapy, whereas the remainder continue to have 
chronic headache and/or to overuse symptomatic medication inspite of drug 
detoxification. A number of studies have been conducted so far to identify clinical 
predictors of short-term outcome of MOH patients after detoxification [9-11, 29]. 
However, the possibility of a genetic basis for variability in the response of MOH 
patients to medication withdrawal has not been investigated yet and, in our opinion, 
this issue is of clinical relevance as a personalized approach to individual patients 
could be implemented if the relative risk was known. The importance of this issue 
is also highlighted by the fact that, although in the new ICHD-III improvement 
after withdrawal is no longer required for the diagnosis of MOH [33], according to 
the previous ICHD-II criteria only patients that had undergone a successful 
detoxification were classified as “true” MOH patients, while nonresponders to 
detoxification were diagnosed as “probable” MOH (pMOH) [34].  
We here reported that MOH patients overusing triptans are at lower risk of 
unsuccessful detoxification, a finding consistent with previous results [9]. In 
addition, we showed for the first time that common gene variants influence short-
term outcome of MOH patients after medication withdrawal. Specifically, DRD2 
NcoI was found to be an independent predictor of unsuccessful detoxification, with 
T allele carriers of DRD2 NcoI found at lower risk compared to C allele 
homozygotes carriers. In addition, results of the analysis comprising the six top-
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ranking polymorphisms highlighted the notion that common gene variants with 
small effects can be clinically relevant when analysed in combination, being their 
cumulative effect found significant even after Bonferroni’s correction. Amongst 
the top-ranking gene variants are 5HT2A C516T and BDNF Val66Met, which have 
been reported to influence drug consumption in MOH patients [28, 35], and COMT 
rs4680, which we recently reported to be associated with relapse risk within the 
first year after successful detoxification therapy [27]. Furthermore, we found an 
increased risk of an unsuccessful detoxification in MOH patients carrying the 
OPRM1 118G allele, a result in line with previous observations showing a better 
response to detoxification among alcohol dependent patients with the 118AA 
genotype [36]. In addition, a role of dopaminergic pathway gene polymorphisms in 
detoxification of MOH patients is also suggested by the involvement of DBH -
1021 C>T, which has been previously reported to influence response to 
disulfuram’s efficacy in cocaine dependence [37]. It can be argued that the 
association of the aforementioned polymorphisms with detoxification outcome 
could be related to their possible involvement in MOH susceptibility. However, we 
failed in detecting evidence for a role of the polymorphisms investigated in the 
present study as risk factors for MOH. This lack of association confirms a previous 
finding for COMT rs4680 and patients with chronic daily headache associated with 
drug abuse (CDHDA) [38].  Intriguingly, the same article reported an 
underrepresentation of a particular dopamine transporter gene polymorphism in 
CDHDA patients, strengthening the link between MOH and dopamine. 
Several studies reported dysfunctions in the mesocorticolimbic dopamine circuit 
and in other pain-processing-related areas of MOH patients [39-42]. While most 
dysmetabolic regions have been shown to normalize after medication withdrawal, a 
persistent hypometabolism has been found in the orbitofrontal cortex (OFC) of 
MOH patients [11, 43]. A possible role of OFC in MOH is also supported by its 
implication in drug addiction [44, 45] and by the recent observation showing a 
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correlation between a decreased volume of gray matter of OFC at baseline and poor 
response of MOH patients to detoxification [46]. On the other hand, gene variants 
including COMT Val158Met [47], BDNF Val66Met [48], and a DRD2 SNP linked 
to NcoI [49] have been reported to influence regional gray matter volumes and 
cognitive performances in healthy subjects. Therefore, it is tempting to speculate 
that the risk genotypes identified in the present study may act cumulatively to 
affect gray matter volume of OFC, predisposing MOH patients to a higher risk of 
unsuccessful detoxification. Further preclinical and clinical investigations are 
warranted to test this hypothesis.  
Results of the present study should be interpreted in the light of the following 
considerations. First, its retrospective and exploratory nature require findings 
validation in a well-powered prospective study. Second, although our case-control 
study was sufficiently powered to detect large, clinically relevant effect of common 
gene variants, we cannot exclude small effect sizes of the polymorphisms 
investigated for conferring an increased risk of MOH. Finally, further 
investigations using a pathway-based approach on a larger number of candidate 
polymorphic genes or using a genome-wide approach are strongly warranted for 
identification of the minimal set of polymorphisms that could be clinically useful 
for the identification of MOH patients at higher risk of unsuccessful detoxification. 
In conclusion, our results support the possibility that response of MOH patients to 
medication withdrawal may be a polygenic trait dependent on the combined effect 
of several polymorphic genes and suggest that an approach based on multiple 
genetic markers could be clinically useful for identification of MOH patients more 
likely to respond poorly to drug withdrawal therapy. Nonetheless, further larger 
prospective studies are needed to validate our findings and to verify the clinical 
utility of a multigene approach for prediction of MOH patients at higher risk of 
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 Given our sample size of 108 MOH patients successfully detoxified and 65 MOH 
patients with unsuccessful detoxification, and assuming a power of 80% and a level 
of significance of 0.05, the minimal detectable risk for the investigated gene 
variants (Minor allele frequency:  0.07 to 0.49) ranged from an odds ratio of 1.9 to 
2.7 under the log-additive model of inheritance, from 2.5 to 3.3 under the dominant 
model and from 2.5 to 5.7 under the recessive model of inheritance (MAF: 0.17 to 
0.49). The association between gene polymorphisms and risk for developing MOH 
was evaluated by using logistic regression analysis adjusted for age and gender. 
Our sample size of 227 MOH patients and 312 control subjects has power of 80 ( 
< 0.05) to detect an odds ratio for MOH risk ranging from 1.5 to 1.85 under the 
log-additive model (MAF: 0.07 to 0.49), from 1.6 to 1.9 under the dominant model 
(MAF: 0.07 to 0.49) and from 1.75 to 3.1 under the recessive model (MAF: 0.17 to 







Table S1. Primers and restriction enzymes used for genotyping. 







5HT2A 516C>T F: CATAGGGTACCGGTGGCCTCT 
R: GTCCAAACAGCAATGATTTTCA 
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G: 244,224 
     
SLC6A4   
5-HTTLPR 
F: GGCGTTGCCGCTCTGAATGC 
R: GAGGGACTGAGCTGGACAACCAC  
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STin2 VNTR 
F: TGGATTTCCTTCTCTCAGTGATTGG  








Allele 9: 345 
     




357 ApoI G: 269, 88 
A: 357 





303 BstNI I: 160, 144  
D: 303 
     
DRD2 TaqI A F: CACGGCTGGCCAAGTTGTCTA 
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R: ATCCTGCAGCCATGG 
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T: 278,175 
DBH -1021C>T F: GGAGGACACGTTCTAGTCC 
R: CACCTCTCCCTCCTGTCCTCTCGC 
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40 
BDNF val66met F: CCCCATGAAAGAAGCAAACA 
R: TTTGTCTGCTGCCGTTACC 
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Table S2. Association analysis of polymorphic gene variants (P>0.1) with the risk 
of MOH patients for unsuccessful detoxification at 2-months of follow-up: 
univariate logistic regression analysis. 
 
SNP Successful_withdrawal therapy 
Yes                        NO 
Genetic model OR (95% CI)        P value 



































































































Table S2. Association analysis of polymorphic gene variants (P>0.1) with the risk 
of MOH patients for unsuccessful detoxification at 2-months of follow-up: 
univariate logistic regression analysis. 
Variant Successful_withdrawal therapy 
Yes                    NO 
Genetic 
model 































































Table S3. Cumulative effect of top six gene variants on the risk of unsuccessful 
withdrawal therapy at 2-months of follow-up: subgroup analysis. 
N° of high risk 
genotypes 
Successful_withdrawal therapy 
Yes                        NO#  
n (%)                     n (%) 
OR* (95% CI)  P value 
Subgroup analysis in patients with chronic headache with drug abuse (n=22) 
 3 54 (50.0)                4 (18.2) 1 (Ref)  
4-6 54 (50.0)                18 (81.8) 4.081 (1.227–13.572) 0.022 
    
Subgroup analysis in patients with chronic headache without drug abuse (n=35) 
 3 
4-6 
54 (50.0)              8 (22.9) 





*Logistic regression analysis adjusted for triptan overuse and primary headache diagnosis. # Eight patients were 
not included in the subgroup analysis due to lacking of relevant data. 
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Table S4. Distribution of gene variants in MOH patients (n = 227) e control 
subjects (n = 312) and association analysis with MOH risk. 
 
SNP Controls           MOH Genetic model OR* (95% CI)        P value 



































































































Table S4. Distribution of gene variants in MOH patients (n = 227) e control 
subjects (n = 312) and association analysis with MOH risk (cont’d). 
 
SNP Control                  MOH Genetic model OR* (95% CI)      P 
value 












































































*Logistic regression analysis adjusted by sex and age. NC, not calculated. #Two genotypes in MOH patients are 













Functional polymorphisms in COMT and SLC6A4 genes 
influence the prognosis of patients with medication overuse 
headache after withdrawal therapy 
 
Sarah Cargnina, Michele Vianab, Natascia Ghiottob, Marika Bianchic, Grazia 
Sancesb, Cristina Tassorellib,d, Giuseppe Nappib, Pier Luigi Canonicoa, Armando A. 
Genazzania, Salvatore Terrazzinoa 
 
aDipartimento di Scienze del Farmaco and Centro di Ricerca Interdipartimentale di Farmacogenetica e 
Farmacogenomica (CRIFF), Università del Piemonte Orientale “A. Avogadro”, Largo Donegani, 2, 28100 
Novara, Italy; bHeadache Science Centre, National Neurological Institute C. Mondino, Pavia, Italy; cLaboratory 
of Experimental Neurobiology, National Neurological Institute C. Mondino, Pavia, Italy; dDept. of Brain and 
Behaviour, University of Pavia, Pavia, Italy. 
Published in Eur J Neurol. 2014. 21(7):989-95. 
Abstract 
Background: It is currently unknown if common genetic variants influence the 
prognosis of patients with medication overuse headache (MOH). We herein 
evaluated the role of two common SNPs in the COMT gene (rs4680 and rs6269), 
as well as the STin2 VNTR polymorphism in the SLC6A4 gene, as predictors for 
long-term outcomes of MOH patients after withdrawal therapy. 
Methods: Genotyping was conducted by PCR, PCR-RFLP analysis or real-time 
PCR allelic discrimination assay on genomic DNA extracted from peripheral 
blood. Gene variants association was evaluated by logistic regression analysis 
adjusted for clinical confounding factors, and the threshold of statistical 
significance for multiple testing was set at P <0.012. 
Results: Sixty-five MOH patients with unsuccessful detoxification and 83 MOH 
patients with effective drug withdrawal therapy were available for the analysis. 
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rs4680G allele carriers or the COMT rs6269G-rs4680G haplotype were found 
associated to a lower risk of relapse within the first year after successful 
detoxification therapy, in comparison to homozygous rs4680A allele carriers (OR: 
0.17, 95%CI: 0.05-0.61, P=0.007) or to the COMT rs6269A-rs4680A haplotype 
(OR: 0.19, 95% CI 0.06-0.54, P= 0.003), respectively. In addition, carriers of the 
STin2 VNTR short allele were found at higher odds for the composite poor 
outcome including unsuccessful withdrawal therapy and relapse within 12 months 
of follow-up after successful detoxification (OR: 2.81, 95%CI: 1.26-6.25, 
P=0.009). 
Conclusions: Our results indicate that genotyping for COMT rs4680 and SLC6A4 
STin2VNTR could be useful for the identification of MOH patients at higher risk 
of poor prognosis after drug withdrawal. 
 





Medication overuse headache (MOH) is a daily or almost-daily type of headache 
which results from chronicization of episodic migraine or tension-type headache as 
a consequence of symptomatic drug overuse [1]. Long-term prospective studies 
indicate that 30-45% of MOH patients relapse into overuse after successful 
withdrawal therapy, the majority of them within the first year of follow-up [2]. 
Despite the growing number of studies focusing on the role of clinical factors as 
predictors of long-term outcome [3,4], to date no study has investigated the 
contribution of common genetic variants as determinants of relapse of MOH 
patients after successful withdrawal therapy. 
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The rs4680 (G>A) polymorphism at the COMT locus at chromosome 22q11 causes 
a four-fold decrease in enzyme activity, which in turn leads to higher dopamine 
levels in the synaptic cleft [5]. Also known as valine158methionine (Val158Met), 
rs4680 contributes to inter-individual differences in pain sensitivity [6], being the 
Met/Met genotype associated with increased pain sensitivity in human pain studies 
[7,8]. Given the occurrence of dysfunctions in the mesocorticolimbic dopamine 
circuit and in other pain-processing-related areas of MOH patients [9], we 
hypothesized that an alteration of COMT activity, as expected in Met/Met patients, 
may have an impact on the prognosis of MOH patients. On the other hand, the 
SLC6A4 gene locus on chromosome 17q11.2 encodes the serotonin transporter, 
which is a key synaptic regulator acting in the fine-tuning of brain serotonergic 
neutrotrasmission [10]. Recently, we reported in MOH patients a relationship 
between the STin2 VNTR polymorphism of the SLC6A4 gene and the number of 
monthly headache days before withdrawal therapy [11]. On the basis of this 
observation, we herein re-analysed STin2 VNTR genotype data in MOH patients to 
evaluate its value as predictor of long-term outcome after successful withdrawal 
therapy. 
Given the potential role of polymorphisms in monoamine neurotransmitter related 
genes in pain modulation, the primary aim of the present study was to evaluate the 
role of COMT (rs4680G>A and rs6269A>G) and SLC6A4 (STin2 VNTR) gene 
polymorphisms as determinants of relapse of MOH patients within the first year 
after successful drug withdrawal. The secondary objective of the study was to 
investigate the role of the aforementioned polymorphisms as predictive factors for 






Materials and methods 
Partecipants 
The medical records of 227 MOH patients who underwent withdrawal therapy 
between March 2005 and September 2008 at the inpatient Headache Unit of 
IRCCS ‘C. Mondino National Neurological Institute’ Foundation (Pavia, Italy) and 
had given their informed consent to genetic analysis were retrospectically 
reviewed. Inclusion and exclusion criteria for MOH patients have been previously 
described [11]. Patients that had completed a detoxification program conducted 
according to previously described procedures [12] or had follow-up visits after 2, 6 
and 12 months after successful detoxification were included in the analysis. The 
following items were assessed during follow-up visits: (i) frequency and clinical 
characteristics of headache; (ii) types of preventive medication currently used, and 
compliance with the prescribed therapy (regularity of intake); and (iii) types of 
symptomatic medication currently used and frequency of their use. Relapsers were 
defined as those patients who were no longer overusers at the 2-month follow-up, 
as a result of detoxification, but reverted back into overuse during the subsequent 
observation period.       
This study was approved by the local Ethics Committee and it met the requirements 
of the Declaration of Helsinki. Written informed consent was obtained from all 
patients before participation in the study. 
 
Genotyping  
Genomic DNA was extracted from peripheral blood by using the QiaAmp DNA 
Mini Kit (Qiagen Valencia, California, USA). Of the several single nucleotide 
polymorphisms (SNPs) of COMT gene, rs4680 and rs6269 were selected based on 
the observation that these two SNPs in combination are sufficient to differentiate 
between the three most common COMT activity haplotypes [13]. COMT rs6269 
genotype was determined by real-time PCR using Applied Biosystems TaqMan 
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Pre-Designed SNP Genotyping assays [Assay ID:  C_2538746_1]. Genotyping of 
COMT rs4680 was performed by PCR-RFLP according to previously described 
procedures [14]. For quality control purposes, each PCR run included negative as 
well as positive controls for the three genotypes. Genotyping was done blinded to 
the outcome status of patients. 
 
Statistical analysis 
Each COMT polymorphism was tested for deviation from the Hardy-Weinberg 
equilibrium (HWE) by use of Pearson’s chi-square test as implemented in the 
Finetti’s program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The association between 
gene variants and relapse risk was evaluated in a binary logistic regression model 
adjusted for clinical variables with P 0.1 upon univariate correlation analysis. The 
SNPStats software [15] was used for the calculation of linkage disequilibrium 
(measured as Lewontin’s D′-values) between COMT SNPs, for the estimation of 
COMT haplotype frequencies and for the evaluation of haplotype association with 
relapse risk. As the haplotype test was a post-hoc analysis, we considered it to be 
an additional test. Therefore, for a Bonferroni correction on the P values we used P 
< 0.012 as a threshold for significance [0.05/4 (total 3 polymorphisms + 1 
haplotype)]. Given the sample size of our cohort (54 relapsers and 29 non-
relapsers) and assuming a power of 80% and a level of significance of 0.012, the 
minimal detectable risk for the investigated gene variants (minor allele frequency: 
0.38-0.49) ranged from an odds ratio of 3.1 to 3.3 under the log-additive model of 







Association of clinical variables with relapse risk  
The flow-chart of MOH patients is shown in Figure 1. A total of 227 MOH patients 
undergoing drug withdrawal therapy were retrospectively evaluated. Sixty-five 
MOH patients with unsuccessful detoxification and 83 MOH patients with 
effective drug withdrawal therapy were available for the analysis. Seventy-nine 
subjects (34.8%; 65 females and 14 males; mean age 46.211.3) were lost to 
follow-up mainly due to patients’ decision of not returning to the centre or failure 
to comply with the protocol. Among these, 54 patients dropped out at the 2-month 
follow-up and 25 patients at 1 year after successful detoxification. No significant 
differences in demographic data, clinical history and genotype distribution were 
found between available patients and those lost to follow-up (data not shown).  
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Clinical and demographic characteristics of 83 MOH patients with successful drug 
withdrawal treatment are displayed in Table S1. Twenty-nine MOH patients 
(34.9%) with successful drug withdrawal relapsed within the first year of follow-
up. In the univariate logistic regression analysis triptan overuse (OR: 0.19, 95% CI 
0.04-0.91, P = 0.038), onset of primary headache before 10 years of age (vs >20 
years, OR: 3.69, 95% CI 0.96-14.21, P= 0.057) and higher number of headache 
days per month before detoxification (OR: 1.07, 95% CI 0.99-1.16, P = 0.091) 
were found related to relapse risk with a cut-off of P  0.1 (Table S1).                                                                                                                 
 
Association of COMT and SLC6A4 gene variants with relapse risk  
The genotype frequency distributions of the three polymorphisms analysed were in 
accordance with Hardy-Weinberg equilibrium (P > 0.05). The distribution of 
COMT SNPs after stratification of MOH patients according to the 1-year relapse 
status is shown in Table 1. The major allele at rs6269 (A) (OR 2.53, 95% CI 1.27-
5.03, P = 0.007) or the variant allele at rs4680 (A) (OR 3.51, 95% CI 1.77-6.95, p = 
0.0002) were more frequently found in patients who relapsed within the first year 
after successful drug withdrawal. For each COMT SNP, the proportion of relapsed 
subjects increased with the number of risk alleles carried by an individual subject, 
as shown by the Armitage’s trend test (rs6269: P = 0.006; rs4680: P = 0.0002, 
Table 1). To control for triptan overuse as potential confounding factor in the effect 
of COMT SNPs on relapse risk, we conducted an analysis limited to triptan 
nonoverusers (n=66). The significance of P-values for both COMT SNPs was 
retained when patients overusing triptans alone were excluded from the analysis 
(Table 1). As none of MOH patients with rs6269GG relapsed within the first 1 year 
after drug withdrawal, adjusted OR for confounding clinical factors was calculated 
for rs4680 only. In the logistic regression analysis adjusted for confounding clinical 
factors, rs4680G allele carriers were found at lower risk of relapse compared to 
patients with rs4680AA genotype (OR: 0.17, 95%CI0.05-0.61, P=0.007, Table 2). 
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In contrast to COMT SNPs, no difference in distribution of SLC6A4 STin2 VNTR 
was observed between relapsing and not relapsing MOH patients (Table 2). As 
expected, haplotype analysis of COMT SNPs revealed a strong pairwise linkage 
disequilibrium between rs6269 and rs4680 (D’ = 0.988). In the logistic regression 
analysis adjusted for confounding clinical factors, the G-G haplotype was found at 
lower risk to relapse within the first year of follow-up, compared to the most 
common A-A haplotype (OR: 0.19, 95% CI 0.06-0.54, P= 0.003, Table 2).  
 
Table 1. Association of COMT alleles with relapse risk of MOH patients during 
the first year of follow-up after successful withdrawal treatment. 
 
SNP ___Outcome at 1 year____ 
No relapse        Relapse 
    n (%)            n (%) 
OR (95% CI) P value  Armitage’s 
trend test P 
value 
All patients (n=83)  
  rs6269 A>G      
    AA 
    AG 







 2.53 (1.27-5.03)* 0.007 
 
0.006 
      
  rs4680 G>A 
    GG 
    GA 
















      
Triptan non-overusersa (n=66)  
  rs6269 A>G      
    AA 
    AG 







 3.19 (1.52-6.72)* 0.002 
 
0.002 
      
  rs4680 G>A 
    GG 
    GA 
















a1, or more, types of triptan. *Allele 1 vs Allele 2 (ref); #Allele 2 vs Allele 1 (ref). For multiple 





Table 2. Association of SLC6A4 STin2VNTR, COMT rs4680 and COMT 
haplotype (rs6269-rs4680) with relapse risk of MOH patients during the first year 
of follow-up after successful withdrawal treatment. 
 
SNP ______Outcome at 1 year____ 
    No relapse             Relapse 
         n (%)                   n (%) 
OR* (95% CI)  P value 




     30 (55.6) 
     19 (35.2) 





D: 1.71 (0.60-4.86) 





COMT rs4680 G>A 
 AA (158Met/Met)      9  (16.7)             13 (44.2) 1 (Ref)  




____Outcome at 1 year____ 
No relapse (%)      Relapse (%) 
OR* (95% CI)  P value 
 A-A         0.41 0.69 1 (Ref)  
 G-G         0.49 0.26 0.19 (0.06-0.54) 0.003 
 A-G         0.10 0.04 0.16 (0.01-2.03) 0.16 
*Logistic regression analysis adjusted for age of primary headache onset, triptan overuse and 
headache days per month before withdrawal therapy. #The STin2.9 allele was accumulated with 
STin2.10 as one unit termed short allele (s), as previously reported [11]. D, dominant model of 
inheritance; R, recessive model of inheritance. The threshold of significance required for Bonferroni 
correction was P <0.012. 
 
Association of COMT and SLC6A4 gene variants with clinical outcome of MOH 
patients after withdrawal therapy 
From a clinical stand-point it could be of interest to include patients that have 
undergone an unsuccessful detoxification, thereby comparing MOH patients with 
good clinical outcome (i.e. patients with successful detoxification and not 
relapsing) to MOH patients with poor prognosis (i.e unsuccessful detoxification 
and relapse within 12 months of follow-up after successful detoxification. Indeed, 
this would include all patients classified as MOH in the new ICHD-III guidelines 
[16]. Clinical and demographic characteristics and comparisons of these two 
groups are shown in Table S2. After adjusting for confounding clinical variables, 
homozygous rs6269G allele carriers were found at lower odds to be MOH patients 
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with poor composite outcome in comparison to rs6269A carriers (OR: 0.37, 95% 
CI: 0.14-0.97, P value = 0.043), while rs4680A allele carriers displayed an 
increased risk to be patients with poor prognosis in comparison to rs4680GG 
homozygotes (OR: 2.59, 95%CI: 1.14-6.34, P = 0.036, Table 3). However, P-
values for both COMT SNPs did not reach the significance required for Bonferroni 
correction (P<0.012) and the association of their haplotype combination did not 
reach nominal statistical significance (G-G vs A-A haplotype, OR=0.60, 0.33-1.11, 
P=0.11, Table 5). Conversely, carriers of the STin2 VNTR short allele were found 
at higher odds to be MOH patients with poor prognosis in comparison to carriers of 
STin2 VNTR 12.12 genotype and the statistical significance did not exceed that 
required for Bonferroni correction (OR: 2.81, 95%CI: 1.26-6.25, P=0.009). When 
the combined effect of COMT rs4680 and SLC6A4 STin2VNTR genotypes was 
examined, carriers of 1 risk genotype (OR: 10.97, 95%CI: 2.036-59.10, P=0.005) 
or 2 risk genotypes (OR: 20.04, 95%CI: 3.48-115.40, P= 0.001) were found at 
higher odds for the development of poor prognosis than were patients without risk 













Table 3. Association of SLC6A4 STin2 VNTR and COMT SNPs with risk for the 
composite poor outcome including unsuccessful detoxification and relapse within 
12 months of follow-up after successful detoxification. 
 
 
Genetic marker  ___Composite outcome __ 
Good (n=54)   Poor (n=94) 
OR* (95% CI) P value  
SLC6A4 STin2 VNTR 
    12/12 
    12/s 













COMT  rs6269 A>G 
    AA 
    AG 













COMT rs4680 G>A 
    GG 
    GA 













Number of high risk genotypes† 
    0 
    1 















__  Composite outcome___ 
Good  (%)        Poor (%) 
OR* (95% CI) P value  
A-A 40.7 51.0 1 (Ref)  
G-G 49.1 40.9 0.60 (0.33-1.11) 0.11 
A-G 10.2 7.5 0.66 (0.20-2.12) 0.49 
*Logistic regression analysis adjusted for age of primary headache onset, primary headache diagnosis, 
familiarity of primary headache, number of headache days per month, triptan overuse and NSAIDS overuse. D, 
dominant model of inheritance; R, recessive model of inheritance. †STin2 VNTR 12/s or s/s and rs4680GA or 




In the present study we found that about 35% of MOH patients with successful 
drug withdrawal were found to relapse within the first year of follow-up, a relapse 
rate which is comparable to previous results [17,18]. In addition, MOH patients 
overusing triptans alone were less likely to relapse compared to patients overusing 
other types of analgesics, a result also consistent with prior studies [4,18]. The 
present study shows for the first time that common genetic variants of COMT and 
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SLC6A4 genes affect clinical long-term outcome of MOH patients receiving 
detoxification therapy. More specifically, the COMT rs4680AA genotype 
(158Met/Met) confers a higher risk of relapse within the first year of follow-up 
after successful drug withdrawal. In addition, carriers of the STin2 VNTR variant 
allele were found at higher odds for the composite poor outcome including 
unsuccessful detoxification and relapse within 12 months of follow-up after 
successful detoxification. 
It has been argued that rs4680 alone cannot fully account for the variation in 
enzyme activity since COMT haplotypes formed by rs4680 and tightly linked SNPs 
may influence COMT function and explain the effects on pain perception to a 
greater extent than rs4680 alone [19]. Indeed, three common COMT haplotypes 
have been identified corresponding to three levels of pain sensitivity, with the 
rs4680G (Val) allele being part of both the high- and low- pain sensitive haplotype, 
whereas the haplotype containing the rs4680A (Met) allele is associated to 
intermediate pain sensitivity [19]. Intriguingly, an inverse correlation has been 
reported between pain sensitivity and COMT activity, meaning that the haplotype 
corresponding to the high pain sensitivity represents the low COMT activity 
haplotype, whereas the haplotype corresponding to the low pain sensitivity 
represents the high COMT activity haplotype [20]. Our data shows that the high 
COMT activity haplotype (rs6269G-rs4680G) confers a lower risk of relapse when 
compared to the intermediate COMT haplotype activity (rs6269A-rs4680A). It 
could therefore be that the fact that MOH patients with high COMT activity 
haplotype have a decreased risk of relapse is correlated with their pain sensitivity. 
On the other hand, given that the intermediate COMT haplotype is the only 
haplotype corresponding to methionine at position 158 of the COMT protein, our 
results support that rs4680 genotyping alone could be sufficient in the clinical 
setting to identify MOH patients at higher risk of relapse. As the effect size is large, 
studies are warrented to prospectively evaluate the clinical utility of rs4680 
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genotyping for the identification of the subgroup of MOH patients who may benefit 
from a stricter follow-up. The importance of our findings is also strengthened by 
the observation that SLC6A4 STin2VNTR alone, or in combined analysis with 
COMT rs4680, allows the identification of MOH patients at higher risk for the 
composite poor outcome that includes unsuccessful detoxification and relapse 
within 12 months of follow-up after successful detoxification. Since SLC6A4 
STin2VNTR correlates with the composite poor outcome but not with relapse risk, 
our findings suggest a complex relationship between SLC6A4 and COMT gene 
variants and modulation of pain-related phenotypes. 
Our findings should be interpreted in the light of the following limitations. First, its 
single-institution and retrospective nature require its findings to be validated in 
larger, preferably multi-institutional prospective studies. Second, the relatively high 
incidence of patients lost at follow-up (34.8%) could limit the generalizability of 
our study. However, no significant differences of COMT and SLC6A4 genotype 
distribution were found between available patients and those lost to follow-up, thus 
excluding a possible bias on our results. In addition, a similar dropout rate has been 
reported in follow-up of MOH patients, ranging from 20% to 48% [21], a result 
highlighting that effective interventions and therapeutic approaches are required to 
address this specific issue. Third, the wide variety of different types of acute drug 
overused and the limited sample size of our MOH patient cohort limited the 
possibility to conduct a stratified analysis of COMT SNPs and haplotypes 
according to the different type of drug being abused. Finally, since COMT activity 
has been reported to be under estrogen control [22], larger studies are required to 
evaluate gender-specific effects of COMT SNPs and haplotypes on the relapse 
rates of MOH patients.  
In conclusion, the current results highlight the importance of COMT rs4680, alone 
or in haplotype combination with rs6269, as determinant for relapse of MOH 
patients with successful drug withdrawal. In addition, the combined analysis of 
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COMT rs4680 with SLC6A4 STin2 VNTR allows the identification of MOH 
patients more likely to experience the composite poor outcome of non-response to 
detoxification and relapse within 12 months of follow-up after successful 
detoxification. Nonetheless, further genetic and functional studies are needed to 
validate our findings and to clarify the complex relationship between COMT and 
SLC6A4 gene interaction, pain sensitivity and prognosis of MOH patients.  
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Table S1. Clinical and demographic characteristics of MOH patients with 
successful withdrawal treatment in the whole cohort and after stratification 
according to the 1-year relapse status. 
 
Clinical features All patients 
(n=83) 
Outcome at 1 year____ 
No relapse      Relapse 
n (%)              n (%) 



















Age at study entry, years  48.9 (11.7) 48.8 (11.7) 49.1 (12.0) 1.00 (0.96-1.04) 0.90 
Age of primary headache 



















































































Drugs of abuse 
  Triptansb 
    No 
    Yes 
  NSAIDSc 
    No 
    Yes 
  Combination drugsd 
    No 
    Yes 
  Association drugse 
    No 


































































Monthly drug numberf  43.0 (28.5) 41.5 (28.0) 42.2 (23.2) 1.00 (0.98-1.02) 0.91 
Headache days  
per monthf 
24.9 (6.2) 24.1 (6.6) 26.5 (5.0) 1.07 (0.99-1.16) 0.091 















during follow-up (n=78) 
  Beta-blockers 
    No 
    Yes 
Antidepressants 
    No 
    Yes 
Antiepileptics 
    No 
    Yes 
Others 
    No 








































































during follow-up (n=78) 
  Triptans 
     No 
     Yes 
  NSAIDS 
     No 
     Yes 
  Others 
     No 

























































aMigraine associated with episodic tension-type headache; b1, or more, types of triptan. c1, or more, 
types of NSAIDs; da single pharmaceutical product that contains more than 1 active principle, e 2 or 
more drugs of the classes above; fbefore withdrawal therapy. Categorical data are number and 
percentages of total subjects, whereas continuous data are expressed as mean (SD). *Univariate 




Table S2. Association between clinical variables of MOH patients and risk for the 
composite poor outcome including unsuccessful detoxification and relapse within 
12 months of follow-up after successful detoxification. 
 
 
Clinical features ___Composite outcome___ 
Good (n=54)   Poor (n=94) 
















Age at study entry, years  48.8 (11.7) 48.0 (12.1) 0.99 (0.97-1.02) 0.69 
Age of primary headache 
















































Primary headache diagnosis  



















Drugs of abuse 
  Triptans 
    No 
    Yes 
  NSAIDS 
    No 
    Yes 
Combination drugs 
    No 
    Yes 
 Association drugs 
    No 





















































Monthly drug number  









Headache days per month 









Months of MOH desease 
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Abstract 
Introduction: In this drug utilization study, we aimed at assessing the pattern of 
triptan use in Italy by means of the drug prescription databases of two Local Health 
Authorities, accounting for approximately 1 million citizens. 
Methods: The study population included all residents aged 18 to 84 years in the 
Vercelli province (about 175,000 inhabitants) and in the Umbria region (about 
885,000 inhabitants), who had at least one dispensation for triptans in 2012. A 
frequent-user, which might be at risk of medication overuse headache (MOH), was 
defined as a patient being dispensed at least 10 defined daily doses (DDD) of 
triptans every month for at least 3 consecutive months. 
Results: Triptans were used by 0.7-1% of the population. While most patients were 
dispensed less than 60 DDDs per year, about 10% of all triptan users were 
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classified as frequent users. In both areas, patients below the age of 29 were less 
likely to be frequent users while the 40-49 year-old population was the most 
affected, with no sex difference. About two thirds of frequent users persisted in this 
behavior for an additional 3-month period in the following 6 months.  
Conclusions: Our data indicate that approximately 10% of all triptan users in the 
Italian population are potentially at risk for MOH. An approach based on drug 
prescription databases could be useful to identify patients at risk of MOH. 
 
Keywords 




According to the International Classification of Headache Disorders (ICHD-III 
edition beta version) medication-overuse headache (MOH) is a chronic headache 
occurring as a consequence of regular overuse of acute or symptomatic headache 
medications on at least 10 days per month (15 days for simple analgesics and 
NSAIDs) for at least 3 consecutive months (1). While the previous definition of the 
International Headache Society (HIS) included the resolution or improvement of 
the headache after withdrawal of symptomatic treatment (2), the latest criteria have 
excluded this parameter although it is mentioned that chronic headache usually 
resolves after the overuse is stopped (1). In brief, therefore, the cause of MOH is 
the headache treatment itself. Even though every new agent that arrived on the 
market raised the hope that it would not lead to MOH, it is now accepted that all 
symptomatic treatments for migraine can trigger chronic headache. Indeed, 
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ergotamine, triptans, non-steroidal anti-inflammatory drugs, opioids and 
combination treatments, are all listed in the ICHD-III beta as causative factors (1). 
The therapy of MOH entails the discontinuation of the abused drugs, which, 
according to the severity of MOH and to different clinical practices, can be 
achieved with a variety of means ranging from simple advice (3) to hospitalization 
(4). Nonetheless, MOH is a costly disease in terms of social burden as well as from 
a pharmacoeconomic perspective (e.g. increased medicine prescriptions, increased 
costs for headache clinics and hospitalization, etc.) (5,6). Furthermore, while the 
condition is well known to neurologists and to experts in headache clinics, it is 
probably less known to general practitioners and pharmacists. Epidemiological data 
indicate that MOH affects approximately 1% of the general population, with a 
similar prevalence in Europe, North America and Asian countries (7). However, 
given that most analgesics are over-the-counter drugs, it is also difficult to have 
accurate figures, because patients overusing medications not reimbursed by the 
NHS may not be caught in the statistics. On the other hand, in a number of 
countries, including Italy, triptans, which are considered by many experts as the 
gold standard therapy for acute treatment of migraine, are prescribed by General 
Practitioners and are reimbursed by the NHS. In principle, therefore, it is possible 
to identify individual patients’ drug intake to estimate the prevalence of triptan use. 
In a study conducted in the Netherlands, prevalence of triptan use in the Dutch 
population was 1.3%, and 10.4% of these patients could be considered overusers 
following the IHS criteria (8). In Italy, data collected in selected areas suggested a 
slightly lower use of triptans (0.6-0.8% of the population) (9-12) but a higher 
proportion of patients at risk of MOH using the IHS criteria (14.3%) (12). These 
data, nonetheless, run back in time and it would be important to have an updated 
snapshot of triptan use in Italy. 
According to sales statistics published by the Italian medicines agency (AIFA), 
almost the entire amount of triptan use in the 2001-2011 decade (around 95%) was 
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covered by the NHS (13). Thus, when individual prescriptions are recorded, it is 
possible to identify almost all triptan users. To quantify the prevalence of MOH 
related to triptan use and to assess the role of potential risk factors, we carried out a 
drug utilization study in two Italian areas: the Province of Vercelli (about 175,000 
inhabitants) and the Umbria Region (about 885,000 inhabitants). The use of two 
separate databases allowed us to investigate which clinical and demographic factors 




Triptans are reimbursed by the Italian National Health Service (NHS) and data 
relevant to each prescription are recorded for administrative purposes (the 
reimbursement of retail pharmacies). The following data were used in this study: 
drug code, number of dispensed packages, encrypted patient identification number 
and date of prescription. From the drug code we were able to identify the 
information on substances, expected duration of the prescription (on the basis of 
the Defined Daily Doses – DDD - contained in each package), and ATC 
(Anatomical, Therapeutic and Chemical classification). 
Prescribing data were derived from the drug dispensation monitoring system of the 
Local Health Authority of Vercelli and of the Umbria Region. A descriptive drug 
utilization study was conducted on subjects living in Vercelli (exploratory cohort) 
and in the Umbria Region (validation cohort). All subjects aged 18 to 84 years who 
received at least one triptan (ATC N02CC) prescription in the period from 1 
January 2012 to 31 December 2012 were included in the study. Patient 
demographic data were obtained by means of automated record-linkage with the 
regional health office database in which all individuals assisted by the NHS are 
listed. The record-linkage procedure is based on the NHS patient identification 
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code, which does not contain any sensitive data related to patient identity, thus 
ensuring confidential treatment of personal data. 
Triptans are reimbursed by the Italian National Health Service (NHS) and related 
prescription details are entirely recorded in regional health authorities databases. 
All triptans available in 2012 on the Italian market (almotriptan, rizatriptan, 
frovatriptan, sumatriptan, zolmitriptan and eletriptan) were included in the analysis. 
A “triptan user” was defined as a patient who was prescribed and dispensed at 
least one triptan during the study period. A “frequent user” was categorized as a 
patient being dispensed at least 10 DDDs of triptans every month for at least 3 
consecutive months. Assuming that the patient takes all the triptans prescribed, but 
not more than one dose per day, this definition would parallel that of the 
International Headache Society for MOH. DDDs used herein are updated to 2011 
and refer to the indications of Durg-Italia, a scientific association affiliated with the 
European Drug Utilization Research Group (Euro-Durg) (Supplementary Table 1). 
We also identified a subgroup of patients, “consistently frequent users”, as subjects 
who were classified as frequent users between January and June 2012, and who 
were exposed to an additional 3-month period of frequent use between July and 
December 2012. 
Triptan users in the study populations were described in terms of age, sex, 
administered triptan and months of treatment. Drug consumption was evaluated in 
terms of: prevalence of use (by dividing the number of drug users by the overall 
resident population) and DDDs per 1,000 users/inhabitants per day (the mean 
number of doses consumed every day by 1,000 patients included in the 
study/resident population). The risk of frequent use was estimated for each triptan 
found in the observation period.  
Concomitant drug prescriptions were also retrieved for frequent users to identify 
comorbidities and consumption of migraine prophylactic medications. 
Supplementary Table 2 illustrates the categories of drugs that were considered as 
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indicators of comorbidities. With regard to migraine prophylactic medications, 
given that no information on the indication is recorded in the administrative 
databases, it was impossible to establish whether these drugs were prescribed for 
migraine or for other indications. However, we assumed that the following drugs 
might be prescribed as prophylactic medicines: metoprolol (ATC C07AB02), 
propranolol (C07AA05), topiramate (N03AX11), valproic acid (N03AG01), 
timolol (C07AA06), atenolol (C07AB03), amitriptyline (N06AA09), venlafaxine 
(N06AX16), and pizotifen (N02CX01). 
 
Statistical analysis 
Clinical characteristics of frequent users and regular users and the difference for 
continuous variables are presented with 95% CIs. The two groups were compared 
using Mann-Whitney U- test for median age and prophylactic medications. To 
evaluate the differences among triptans, we estimated the odds ratio (OR) using 
almotriptan, the most frequently used drug, as reference. Adjusted odds ratios, with 
95% confidence interval, were assessed by a logistic regression model. ORs were 
adjusted for age, gender and prophylactic medications. IBM® SPSS® software 




Triptan use in Italy 
First, we referred to a comprehensive database on drugs bought by the National 
Health system, updated to 2012 (13). The prescription of triptans has steadily 
increased in the last decade in Italy (Supplementary figure 1A). In 2011, 0.76 
DDDs/1,000 inhabitants per day were prescribed/dispensed. The prescription 
pattern differs significantly from Region to Region, ranging from 40% below (e.g. 
Umbria, Campania) to 40% (e.g. Sardegna, Valle d’Aosta) above the national 
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average (Supplementary figure 1B). Unlike many other drug classes (13), there is 
no North-to-South trend in the number of prescriptions and there is little variability 
in the regional expenditure per DDD since prices of various triptans are fairly 
similar. 
 
Triptan use in the two Italian areas in 2012 
Having gathered a general picture of triptan use in Italy, we then proceeded in 
analyzing triptan use in the Vercelli province and in the Umbria region. The 
prevalence of triptan use, stratified by age, sex and different substances, was fairly 
similar in the two areas, even though the level of use observed in Vercelli was 
approximately 30% higher than in Umbria (Table 1). This observation parallels the 
one obtained with the national database. 
 
Table 1. Characteristics of the triptan users in the two areas 
 Province of Vercelli Umbria Region 
Male Female Total Male Female Total 
Prevalence of use, N (%) 
Total 299 (0.4) 1141 (1.5) 1440 (1.0) 
1043 
(0.3) 
3614 (1.0) 4657 (0.7) 














30-39 48 (0.4) 223 (2.0) 271 (1.2) 198 (0.3) 706 (1.2) 904 (0.7) 
40-49 85 (0.6) 359 (2.6) 444 (1.6) 302 (0.5) 1218 (1.8) 1520 (1.1) 
50-59 72 (0.6) 273 (2.2) 345 (1.4) 224 (0.4) 842 (1.4) 1066 (0.9) 
60-69 44 (0.4) 126 (1.1) 170 (0.8) 141 (0.3) 362 (0.7) 503 (0.5) 
≥70 16 (0.1) 57 (0.4) 73 (0.3) 70 (0.1) 149 (0.2) 219 (0.2) 
almotriptan, N(%) 66 (0.1) 303 (0.4) 369 (0.3) 288 (0.1) 1014 (0.3) 1302 (0.2) 
rizatriptan, N (%) 81 (0.1) 309 (0.4) 390 (0.3) 291 (0.1) 1010 (0.3) 1301 (0.2) 
frovatriptan, N (%) 56 (0.1) 285 (0.4) 341 (0.2) 205 (0.1) 837 (0.2) 1042 (0.1) 
sumatriptan, N (%) 71 (0.1) 179 (0.2) 250 (0.2) 192 (0.1) 582 (0.2) 774 (0.1) 
zolmitriptan, N (%) 17 (0) 72 (0.1) 89 (0.1) 89 (0) 331 (0.1) 420 (0.1) 
eletriptan, N (%) 34 (0) 112 (0.2) 146 (0.1) 78 (0) 278 (0.1) 356 (0) 
1 triptan 275 (0.4) 1037 (1.4) 1312 (0.9) 953 (0.3) 3235 (0.9) 4188 (0.6) 
2 or more triptans 24 (0) 104 (0.1) 128 (0.1) 90 (0) 379 (0.1) 469 (0.1) 
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Median age, year 48 47 47 47 46 46 
Expenditure per 
capita (€) 
0.93 3.47 2.24 0.60 1.97 1.31 
Expenditure per 
user (€) 
213.6 224.4 222.1 198.1 201.5 200.7 
DDD/1,000 inhab. 
per die 
0.54 1.95 1.27 0.27 1.04 0.67 




3 (3.1) 4 (3.1) 4 (3.1) 3 (3.1) 4 (3.4) 4 (3.3) 
DDD:defined daily dose 
 
As expected, most users were dispensed less than 60 DDDs per year (Table 2). 
Seven to ten percent (Vercelli and Umbria, respectively) of patients were dispensed 
an average of at least 10 DDDs/month (120 DDDs/year), while a small proportion 
(3% in Vercelli and 2% in Umbria) were dispensed 18 DDDs/month (216 
DDDs/year) or more. 
 
Table 2. Number of defined daily doses (DDDs) per user in 12 months. 
 
 
About 13% of all users in the Vercelli population and 10% in the Umbria Region 
fell in the category of frequent users (Table 3). Younger patients were less likely to 
be frequent users (with patients below the age of 29 being significantly less at risk), 
while the most affected age group in both regions was the 40-49 year old category, 
with no sex difference. Frequent users were older than regular users; the difference 













       
<60 224 (75) 846 (74) 1070 (74) 869 (83) 2811 (78) 3680 (79) 
60-119 46 (15) 183 (16) 229 (16) 115 (11) 553 (15) 668 (14) 
120-180 20 (7) 68 (6) 88 (6) 35 (3) 154 (4) 189 (4) 
181-215 1 (0) 15 (1) 16 (1) 7 (1) 36 (1) 43 (1) 
≥216 8 (3) 29 (3) 37 (3) 17 (2) 60 (2) 77 (2) 
Total 299 (100) 1141(100) 1440 (100) 1043 (100) 3614 (100) 4657 (100) 
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was slight, but statistically significant in both geographical areas. Frequent users 
had a significantly higher prescription of prophylactic medications for migraine in 
Umbria, though this finding was not confirmed in Vercelli. What was confirmed 
and significant was a strong increase in drug expenditure of frequent users in both 
Vercelli and Umbria, although this result was obvious given the increased amount 
of bought drugs. Frequent users, which accounted for 10-13% of the analyzed 




Table 3. Characteristics of frequent triptan users compared with regular users. 
 
Total Regular users Frequent users 
Frequent users vs Regular users 
difference, 
N (95% IC) 
VC U VC U VC U VC U 
Male, N 
(%) 
299 (21) 1043 (22) 259 (21) 956 (23) 40 (22) 87 (19) 1 (-5,5;7,2) -4 (-8,1;-0,6) 
Female, N 
(%) 
1141 (79) 3614 (78) 995 (79) 3231 (77) 146 (78) 383 (81) -1 (-7,2;5,5) 4  (0,6;8,1) 
Total, N 
(%) 
1440 (100) 4657 (100) 1254 (87) 4187 (90) 186 (13) 470 (10)   
Median age 47 46 47 46 48 48 p=0,009* p<0,001* 
Prophylaxis 
(%) 
14 13 14 12 14 21 p=0,876* p<0,001* 
Expenditure 
per user (€) 
222 201 139 131 782 820   
DDD/1000 
Ut die 
128 105 78 68 466 434   
Age, N (%)         
18-29 137 (10) 445 (10) 129 (10) 424 (10) 8 (4) 21 (4) -6 (-9,4;-2,6) -6 (-7,7;-3,6) 
30-39 271 (19) 904 (19) 242 (19) 857 (20) 29 (16) 47 (10) -4 (-9,4;1,9) -10 (-13,4;-7,5) 
40-49 444 (31) 1520 (33) 376 (30) 1315 (31) 68 (37) 205 (44) 7 (-0,8;13,9) 12 (7,5;16,9) 
50-59 345 (24) 1066 (23) 305 (24) 941 (22) 40 (22) 125 (27) -3 (-9,2;3,5) 4 (-0,1;8,3) 
60-69 170 (12) 503 (11) 143 (11) 447 (11) 27 (15) 56 (12) 3 (-2,2;8,5) 1 (-1,8;4,3) 
≥70 73 (5) 219 (5) 59 (5) 203 (5) 14 (8) 16 (3) 3 (-1,1;6,8) -1 (-3,2;0,3) 
aMann-Whitney U test. 
VC: Province of Vercelli; U: Umbria region; CI: confidence interval. 
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When analyzing the relative risk of high frequency use given by the single triptans 
(Table 4), there was a trend for eletriptan and sumatriptan to confer an increased 
risk and of rizatriptan and frovatriptan to confer a lower risk compared to 
almotriptan. However, no drug appeared to carry a distinctly elevated or decreased 
risk of high frequency in both areas, weakening any conclusion that could be 
drawn. 
Last, we verified whether the status of frequent user was transitory or persisted in 
time: it is noteworthy that about two thirds of identified frequent users qualified as 
‘consistently frequent user’ (Table 5). 
 
Table 4. Risk of overuse for each triptan in the two areas. 
 
Non-overusers Overusers OR (95% IC)* 
Triptan VC U VC U VC U 
almotriptan, N 282 1004 36 99  1 (Ref)  1 (Ref) 
rizatriptan, N 308 995 25 47 0.64 (0.37-1.10) 0.45 (0.32-0.65) 
frovatriptan, N 261 775 19 62 0.55 (0.31-0.99) 0.78 (0.56-1.09) 
sumatriptan, N 163 528 35 72 1.53 (0.91-2.57) 1.22 (0.88-1.70) 
zolmitriptan, N 54 301 19 33 2.54 (1.33-4.83) 1.00 (0.65-1.52) 
eletriptan, N 93 226 17 36 1.37 (0.73-2.56) 1.55 (1.02-2.34) 
*
Adjusted by age, gender and prophylaxis; VC, Vercelli; U, Umbria Region. In the analysis were considered 










Table 5. Consistently frequent users in the two areas by age and sex. 
 Frequent users identified Jan-Jun Consistently frequent users 
 VC U VC (%) U (%) 
Gender     
Male, N (%) 28 57 18 (64) 37 (64) 
Female, N (%) 93 240 57 (61) 168 (70) 
Total, N (%) 121 297 75 (62) 205 (69) 
Age, N (%)     
18-29 4 12 3 (75) 8 (67) 
30-39 17 32 14 (82) 17 (53) 
40-49 41 125 24 (59) 86 (69) 
50-59 28 75 12 (43) 51 (68) 
60-69 19 42 14 (74) 30 (71) 
≥70 12 14 8 (67) 13 (93) 




Our analysis suggests that about 10% of triptan users are prescribed and dispensed 
a number of monthly doses that, if taken on separate days, would lead them to meet 
the IHS criteria for medication overuse headache. These frequent users are 
responsible for 40% of the total cost of triptans. Focusing medical attention on this 
relatively small proportion of migraineurs might save and optimize a significant 
part of NHS resources. With respect to our study design, by using two separate 
populations, we were able to use the two databases as both exploratory and 
confirmatory and to find common determinants of this pattern of use. While a 
number of factors (e.g. type of triptan) showed a consistent trend in both 
populations, only age correlated significantly with frequent use. The finding that 
relatively older patients (40-49 age category) appeared at higher risk is consistent 
with the data reported in a meta-analysis of 29 studies comprising a total of 2612 
patients with MOH, where patients had a mean duration of primary headache of 
around 20.4 years (14). 
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With respect to the prescription of prophylactic medications we found conflicting 
results in the two areas, with a higher level of use in the Umbria population. It must 
be acknowledged that migraine prophylaxis is difficult to monitor using NHS 
databases, as most medications are not solely prescribed for migraine and many are 
not dispensed by the NHS. For example, the prescription of flunarizine, which in a 
recent study was found to be the most used preventive medication in two provinces 
(Novara and Pavia) (15) bordering with the Vercelli province could not be 
monitored as flunarizine is not covered by NHS. In a broader study, involving 10 
headache centers from all over Italy, flunarizine was the third used preventive 
medication (16). Nonetheless, our study suggests that only 14-21% of frequent 
users of triptans are prescribed a prophylactic medication than can be monitored 
and these data are in line with a recent Dutch study on migraine preventive 
medications (17), It would therefore be important to design a study to assess the 
use of preventive medication in Italy. 
The main strength of our study is represented by the fact that triptans in Italy are all 
reimbursed via the NHS and therefore our census covers the entirety of triptan use 
in the population of two geographic areas. The very limited amount of triptans that 
are purchased out of pocket (around 5% of total prescriptions) cannot modify our 
estimates. 
The study also faced several limitations: (i) we focused solely on triptan use and 
were unable to monitor over-the-counter drugs or other prescription drugs that are 
not dispensed by the NHS. It is likely that including these drugs would increase 
significantly the number of patients which might meet IHS criteria for medication 
overuse headache; (ii) we defined as frequent user a patient that is dispensed more 
than 10 DDDs per month for three consecutive months. It must be acknowledged 
that the relation “one DDD one attack” might not hold, as guidelines suggest that 
patients might decide to take a second dose for the same attack in the same day. It 
is possible, therefore, that triptan overusers are less than frequent users, as defined 
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in this study; (iii) as in all pharmacoepidemiological studies, this report is unable to 
discriminate between dispensation and use, and some factors (e.g. sharing of the 
same prescription among family members, accumulating the drug for future use) 
might contribute to overestimating the phenomenon. 
A number of other studies have been performed in Europe in the last 20 years, 
using different methods and different thresholds to define a triptan overuser 
(8,9,12,18-24, see Table 6). Our data are in line with prevalence data obtained in 
most of these studies and suggest that MOH is not a culture-bound disorder. Yet, 
probably most important, our data suggest that administrative databases would in 
principle be able to identify those at higher risk of suffering from this disorder, 
giving them earlier access to specialized care. This approach might significantly 
reduce the prevalence and duration of this chronic headache as well as the impact 
in terms of social and economic burden. 
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Table 6. Prevalence of frequent triptan users in population studies. 
Study 
[Ref] 













Gaist [18]# Denmark 
1992/1994 
Prescription data of the Odense 
Pharmacoepidemiological Database 
(OPED) derived from the County of 
Funen, Denmark 
465,000 27  2,878  
(0.62) 




Gaist [19]# Denmark 
1994/1995 
Nationwide prescription data of the 
Register of Drug Statistcs (RDS)  
4,243,942 (1994) 
4,253,960 (1995) 




Sondegaard [20] Denmark 2000 Dispensing data of 22 community 
pharmacies in the County of Funen, 
Denmark  
472,000 3  2,463 
(0.52) 
82.8 88 (3.6)f - 
Lohman [21] Netherlands 
2001/2002 
Dispensing data from 18 community 
pharmacies of Sittard, Netherlands 




Lugardon [22] France 2002 Prescription data of National French 
Health Insurance System in the Midi-
Pyrenees area 
1,550,000 6  13,860 
(0.89) 
80.6 866 (10.0)g 
166 (1.9)h 
80.66 
Perearnau [23] France 2003/2004 Prescription data of five of the French 
National Health’s local health agencies 
in Alsace  
1,793,000 12  20,686 
(1.1) 
78.5 399 (1.9)e - 
Dekker [8] Netherlands 2005 Prescription data of the Dutch Drug 
Information System/Health Care 
Insurance Board (GIP/CVZ) 
6,704,627 12 85,172 
(1.3) 




Pavone [9] Italy 2005 Prescription data of a Regional Health 
Authority (Tuscany) 
224,065 12 1,238 
(0.55) 
77.9 40 (3.2)c 
12 (0.9)d 
77.5 
Biagi [12] Italy 2007 Prescription data of a Regional Health 
Authority (Emilia-Romagna) 
4,249,533 12 34,915 
(0.8) 




Braunstein [24] France 2010/2011 French reimbursement database in two 
French administrative regions (PACA† 
and Corse) 
- 20  95540 - 2243 (2.3)j - 
# Data refer to use and frequent use of sumatriptan only; †Provence-Alpes-Côte d'Azur. Criteria to define frequent triptan users: a 30-59 DDDs/month; b ≥60 DDDs/month; c users of 120 
DDDs or more per year; d users of 216 DDDs or more per year; e 244 DDD/year; f ≥15 doses/month; g15-29 DDD/month among new users of triptans (n=8625); h >29 DDD/month among 




Public Health relevance 
 In the present study, a descriptive drug utilization study was conducted by 
means of the drug prescriptions databases of two Local Health Authorities 
in Italy to evaluate triptan use 
 About 10% of identified triptan users are dispensed at least 10 DDDs of 
triptans every month for at least 3 consecutive months. If these doses were 
actually taken on different days, these patients would meet the IHS criteria 
for medication overuse headache.   
 An approach based on drug prescription databases could be useful for early 
identification of patients at higher risk of MOH. Such approach might also 
reduce the prevalence and duration of MOH as well as decrease its social 
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Supplementary Table 1. Medications covered by the analyses and related Defined 
Daily Dose designated by World Health Organization (WHO). 
Active ATC Dose WHO DDD  
    
almotriptan N02CC05 3, 6 tablets of 12.5 mg 12.5 mg 
eletriptan N02CC06 3, 6 tablets of 40 mg 40 mg 
  3 tablets of 20 mg  
frovatriptan N02CC07 2, 6 tablets of 2.5 mg 2.5 mg 
rizatriptan N02CC04 3, 6 tablets of 10 mg 10 mg 
  3 tablets of 5 mg  
sumatriptan N02CC01 4 tablets of 50 and 100 
mg 
50 mg 
  2 syringes of 6 mg 6 mg 
  2 nasal spray 20 mg 
  2 suppositories of 25 mg 25 mg 
zolmitriptan N02CC03 2, 3, 6 tablets of 2.5 mg 2.5 mg 
 
Supplementary Table 2. Therapeutic categories considered in the analysis. 




Antiplatelet/anticoagulant agents B01A 
Other cardiovascular drugs C01-C03; C07-C09 
Lipid-lowering agents C10 
Drugs used in benign prostatic hypertrophy G04C 




NSAIDs M01A; N02B 
Osteoporosis medications M05; A12A 
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Supplementary Figure 1. Defined Daily doses (DDD) of triptans dispensed in 
Italy during the last decade (A) and regional variability of triptans utilization 

















In 2000, Allen Roses published on Nature a comprehensive review concerning the 
potential application of pharmacogenetic knowledge in clinical practice and drug 
development. In the introduction, he emphasized how the medical thinking has 
radically changed during last century in parallel with new available genetic 
information. 
 
‘ “If it were not for the great variability among individuals, medicine 
might as well be a science and not an art.” The thoughts of Sir William 
Osler in 1892 reflect the view of medicine over the past 100 years. The 
role of physicians in making the necessary judgements about the medicines 
that they prescribe is often referred to as an art, reflecting the lack of 
objective data available to make decisions that are tailored to individual 
patients. Just over a hundred years later we are on the verge of being able 
to identify inherited differences between individuals which can predict 
each patient’s response to a medicine. Sir William Osler, if he were alive 
today, would be re-considering his view of medicine as an art not a 
science.’ [1].  
 
Significant advances in genetic technologies have been actually made in the last 
decades, resulting in a consistent enrichment of the pharmacogenetic and genomic 
knowledge of several diseases. It is often argued that personalizing treatment may 
improve the prognosis of patients underwent a pharmacological treatment and help 
optimizing the use of health care resources. Given the high burden of migraine, in 
terms of high prevalence, disability and healthcare costs, in principle, one would 
expect that many efforts must have been made for identifying genetic predictors of 
migraine pharmacological treatment too. In spite of this, our systematic review 
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showed that only sparse and contrasting pharmacogenetic evidences have been 
reported in migraine. In addition to this, we highlighted many consistent 
methodological limitations in several hitherto performed studies. Among the 
aforementioned, the small sample size of populations included in the studies stands 
out and this is remarkable if we consider that migraine has a high prevalence in the 
general population. Furthermore, in some studies, the size of samples was 
arbitrarily decided, without a priori- or post hoc analysis supporting the adequacy 
of population samples included in the association analysis. Therefore, the 
conduction of pharmacogenetic studies on large population samples of migraineurs 
is strongly warranted, aiming to reduce the risk of reporting false-negative findings 
and that uncontrolled variables influencing migraine severity may not, by chance, 
be equally distributed in each genotype. 
 
In addition to this, none of the studies included in the systematic review had a 
replication cohort. Validation of observed effects is a key issue in pharmacogenetic 
and genomic research. The strength and replicability of results obtained in the 
exploratory cohort have to be tested in independent large cohorts of subjects 
characterized by the same phenotype outcomes and pharmacological treatment (i.e. 
the same drug/s or, if clinically correct, drug/s belongings to the same therapeutic 
class) of subject included in the exploratory cohort. For instance, when we 
identified a significant correlation between COMT rs4680 and frovatriptan 
response in migraineurs (n=75), we replicated our results in a validation cohort of 
migraineurs (n=123) treated with triptans other than frovatriptan [2]. 
As expected, besides being a crucial step in the field, results validation often 
represents a challenge. Enrollment of additional patients for replication cohorts can 
be a lengthy process for several reasons (e.g. low disease prevalence, specific 
exclusion criteria, dropouts), so the conduction of multicenter studies ensuring 
patients’ recruitment at many centers may overcome this obstacle. In the light of 
these limitations, pharmacogenetic and genomic researchers may also focus on 
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validating potential association reported in previous studies. This is the case, for 
example, of our replication study published in 2010 that failed to confirm a 
previously reported correlation between DRD2 rs6275 and triptan response in 
migraineurs [3] [4] [5]. The same validation approach is obviously applicable in the 
field of genetic and genomic research. In this context, we were unable to confirm 
the correlation between migraine susceptibility and polymorphisms in GRIA1 gene 
[6][7]. 
Given the growing amount of human pharmacogenetic evidences, it’s common that 
several studies may have attempted to answer similar pharmacogenetic questions. 
Often, many of the individual studies might report contrasting results in terms of 
correlation between a specific genetic variant and the response to a given drug or, 
alternatively, might all fail to show a significant association because of insufficient 
statistical power. In the light of the need to validate available evidences, the 
combining of all results concerning a specific association may be effective to verify 
the strength and replicability of results obtained in different studies. The statistical 
technique aimed to quantitatively combine results obtained by independent studies 
is called meta-analysis. Nowadays, meta-analyses are a hallmark of evidence-based 
medicine, offering a rational and helpful way of i) collecting all relevant studies 
(published or not) on a specific topic, ii) assessing the methodological quality of 
the design and execution of each included study, and iii) offering an unbiased 
synthesis of the available empirical data. It’s clear that pharmacogenetic studies 
included in a meta-analysis may differ from each other in terms of study design 
(e.g. prospective/retrospective, multicenter/single center, cross 
sectional/longitudinal), patient’s characteristics (e.g. ethnicity, disease severity, 
comorbidities, exclusion and inclusion criteria) and drug administration (e.g. 
dosages, administered molecule/s). However, the heterogeneity induced by these 
systematic differences may be tested by meta-analysis technique, which applies a 
specific statistical analysis method that can take into account the absence/presence 
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of heterogeneity among studies. Due to the lack of evidences concerning migraine 
pharmacogenetics, we were unable to perform a systematic review of the literature 
followed by a meta-analytic quantification of obtained results. However, we 
recently performed several meta-analysis aimed to assess the clinical validity of 
extensively studied genetic variants as genetic predictors of drug-induced adverse 
reactions [8] [9] [10], drug response 4 or prognosis of patients underwent a specific 
intervention [11] [12] in subjects other than migraineurs. 
 
Lastly, no genome-wide association studies (GWAS) were performed with the aim 
of exhaustively assessing the role of the whole individual genetic background on 
the response to symptomatic or preventive anti-migraine drugs. It is known so far 
that pharmacogenomic GWAS are generally markedly fewer than GWA studies 
investigating disease risk [13]. A plausible explanation to this observation may lie 
in the major complexity of pharmacogenomic GWAS study design compared to 
that one of disease susceptibility GWAS. For instance, the recruitment of controls 
samples for pharmacogenomic GWAS requires the enrollment of subjects taking 
the same drug/s of cases but not experiencing the same phenotype; conversely, 
controls included in disease risk GWAS may simplistically be individuals from 
geographically matched population not experiencing the studied disease. Moreover, 
contrary to disease susceptibility GWAS, the collection of medical data concerning 
populations included in pharmacogenetic GWAS is specific for each study. 
However, it is undeniable that an enormous distance exists between the 
pharmacogenetic knowledge of migraine and the study of the genetic basis of 
migraine susceptibility. Given that the cost of genotype for a GWAS is at least one 
order of magnitude higher than the cost required to genotype several candidate 
genes, funding may be one of the limiting factors in migraine pharmacogenomics 
                                                 
4 “BDNF genetic variation and clinical response to antipsychotic drugs: a systematic review and 
meta-analysis”. Authors: Cargnin S, Massarotti A, Terrazzino S. Accepted for publication on 
European Psychiatry journal. 
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research. In this context, it’s paradoxical that limited economical resources are 
destined to study such a common and highly costly disease. 
 
It is acknowledged that, when a GWAS in a given disease or in populations treated 
with specific drugs has not yet been performed, it is still cost-effective to conduct a 
candidate gene/pathway association study. In the light of the aforementioned, we 
performed several candidate gene association studies aimed to enlarge 
pharmacogenetic knowledge in both migraine and medication overuse headache. 
We identified COMT Val158Met (rs4680) as a potential genetic predictor of 
individual response to different classes of drugs used for chronic pain, such are 
opioids and triptans, irrespective of their primary molecular target. More precisely, 
COMT rs4680 Met/Met individuals affected by chronic low back pain showed 
better response to intrathecal morphine compared to Val/Val and Val/Met subjects. 
Intriguingly, the impact of the same genetic variant on triptan response in 
migraineurs was in the opposite direction, being Met/Met carriers at higher risk of 
being poor responders compared to Val/Val and Val/Met subjects. If, on the one 
hand, the overexpression of MORs (μ-opioid receptors) detected in Met/Met 
patients [14] may explain a consistent response to morphine, on the other hand the 
molecular mechanisms underlying COMT rs4680 Met/Met and poor triptan 
response are missing. On the basis of recent evidences suggesting a more 
aggressive phenotype in Met/Met migraine patients [15], we hypothesized that 
poorer response to triptans in these subjects may reflect the failure to control more 
intense migraine attacks compared to Val/Val or Val/Met migraineurs. Even if our 
data in migrainerus represent an interesting and entirely novel finding, our results 
must be viewed in the light of some limitations, such as: i) the need of being further 
replicated in larger and, preferably, prospective studies; ii) due to the fact that 
rs4680 cannot fully account for the variation of COMT enzyme activity, additional 
COMT haplotypes analyses are required to extend the current findings; iii) 
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approaches based on multiple genetic markers may allow to more accurately shed 
light on the plausible joint effect of multiple genes in predicting clinical response to 
morphine or triptans. 
Subsequently, we investigated the influence of genetic variants in GRIA1 gene 
(rs548294 and rs2195450) on triptan response but we were unable to find a 
significant correlation between the two SNPs (either as single markers or in 
haplotype combination) and drug response in 186 migraineurs without aura. 
Furthermore, we failed to confirm a previously reported association of these 
variants with migraine susceptibility. Nevertheless, we cannot definitely exclude a 
plausible enrollment of GRIA1 gene in determining variability in triptan response 
and migraine susceptibility because, in principle, polymorphisms in other linkage 
disequilibrium groups may potentially be, almost in part, responsible for migraine 
development and headache response to triptans. 
In the same way, we did not found a significant correlation between three SNPs of 
CGRP-related genes (CALCA rs3781719, RAMP1 rs3754701, RAMP1 
rs7590387) and triptan response in 219 patients affected by migraine without aura. 
We acknowledge that our study was underpowered to detect small genetic main 
effects; however, it had sufficient power to detect medium-large effect sizes of 
clinical relevance. In this context, our results suggested that even if these SNPs 
were not correlated with drug response in migraineurs, the genetic variant RAMP1 
rs7590387 might have a role in the transformation of episodic migraine into MOH. 
Given that CGRP blood levels are higher in women with chronic migraine 
compared with women affected by episodic migraine, the plausibility of this 
observation is strong, representing the first evidence of CGRP involvement in the 
genetic basis of migraine transformation into MOH. However, being rs7590387 
localized 1.4 kb downstream of the RAMP1 gene, we can hypothesize that 
rs7590387 may not be that true causal variant but that, more probably, an unknown 
functional polymorphism in linkage disequilibrium with rs7590387 may be the 
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actual determinant factor for migraine transformation. Also noteworthy is the 
observation of a lack of association between rs7590387 and triptan response 
despite a correlation with migraine transformation. This deserves further study to 
investigate whether an inadequate response to triptans could entail the 
transformation of episodic migraine into MOH. 
As previously mentioned, no information concerning genetic predictors of MOH 
patients’ prognosis was reported in the literature. We showed for the first time that 
common genetic variants may influence short-term outcome of MOH patients after 
withdrawal. Specifically, DRD2 NcoI was found to be an independent predictor of 
unsuccessful detoxification, with TT genotype carriers of DRD2 NcoI being at 
lower risk of not responding to withdrawal compared to C allele carriers. 
Moreover, results of the analysis comprising the six top-ranking polymorphisms 
highlighted the notion that common gene variants with small effects can be 
clinically relevant when analyzed in combination, being their cumulative effect 
found significant even after Bonferroni’s correction. So, further investigations 
using a pathway-based approach on a larger number of candidate polymorphic 
genes or using a genome-wide approach are strongly warranted for the 
identification of the minimal set of polymorphisms that could be clinically useful 
for the identification of MOH patients at higher risk of unsuccessful detoxification. 
We further identified COMT rs4680 (as single marker or in haplotype combination 
with rs6269) and SLC6A4 STin2 VNTR variants as potential genetic determinants 
of long-term prognosis in MOH patients underwent inpatient withdrawal. More 
precisely, COMT rs4680AA genotype (158Met/Met) emerged to confer a higher 
risk of relapse within the first year of follow-up after successful drug withdrawal. 
Furthermore, we considered interesting, from a clinical perspective, comparing 
COMT rs4680 and SLC6A4 STin2 VNTR genotypes’ distributions between MOH 
patients with good clinical outcome (i.e. patients with successful detoxification and 
not relapsing) and MOH patients with poor prognosis (i.e. unsuccessful 
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detoxification and relapse within 12 months of follow-up after successful 
detoxification). In this context, carriers of the STin2 VNTR variant allele were 
found to be at higher odds for the composite poor outcome after successful 
detoxification. Since SLC6A4 STin2 VNTR correlates with the composite poor 
outcome but not with relapse risk, our findings suggest a complex relationship 
between SLC6A4 - COMT gene variants and modulation of pain-related 
phenotypes. 
Overall, our results demonstrate that genetic background seems to play a relevant 
role in determining variability in both antimigraine drug response and prognosis of 
MOH patients underwent drug withdrawal. The contribution of pharmacogenetic 
testing for tailoring pharmacological therapy of migraine and MOH could be 
therefore still considered of primary relevance in the light of the need to optimize 
patient’s clinical outcomes and healthcare resources. 
 
Given the necessity to curb MOH development among episodic migraineurs, there 
is a growing interest in actually identifying the proportion of subjects at risk of 
developing MOH in a real scenario, outside the context of selected patient samples 
enrolled in clinical trials. Drug utilization studies performed by means of 
administrative databases have represented a good tool for describing the pattern of 
use/overuse of triptans in general population. In this context, administrative 
databases offer the chance of studying patterns of drug use/overuse in unselected, 
heterogeneous and large populations, including vulnerable patients usually 
excluded by randomized clinical trials. Second, contrary to randomized clinical 
trials, data recorded in administrative databases are free from the so-called 
Hawthorne effect, which is the behavioral distortion that occurs when human 
beings know to be under observation. Third, beyond low cost of 
pharmacoepidemiologic investigation, the profile of drug use can be in principle 
determined over prolonged follow-ups and a comprehensive healthcare history of 
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each beneficiary of healthcare system may be available [16]. In the light of the 
need to update available pharmacoepidemiological evidences in migraine, we 
performed a drug utilization study aimed to quantify and describe triptan users and 
overusers in two vast Italian geographical areas by means of the analysis of 
administrative database’s data.  We reported that the 0.7-1% of the general 
population used triptans during the study period and that around the 10% of them 
showed an episode of triptan overuse. What is clinically relevant is that the two-
thirds of overusers persisted in this behavior over the studied year. Then, focusing 
medical attention on this relatively small proportion of migraineurs may obviously 
result in optimization of a significant part of NHS resources. Yet, probably most 
important, an approach based on drug prescription databases could be useful for 
early identification of subjects at higher risk of developing MOH, giving them a 
prompt access to specialized care. Nevertheless, our results might be interpreted in 
the light of some limitations: i) given that we focused solely on triptan use and that 
we were unable to monitor over-the-counter drugs or other prescription drugs that 
are not dispensed by the NHS, the proportion of MOH subject might be 
underestimated; ii) as in all pharmacoepidemiological studies, this report was 
unable to discriminate between dispensation and use, and some factors (e.g. sharing 
of the same prescription among family members, accumulating the drug for future 
use) might contribute to overestimating the phenomenon.  
 
In principle, many of the results obtained in drug utilization research are important 
for supporting or modifying a rational drug policy at both national and local levels 
[17]. In this context, a drug utilization study recently performed by Amadio and 
colleagues reported considerable variations in triptans usage patterns across several 
provincial jurisdictions in Canada characterized by different public drug 
reimbursement criteria [18]. Overall, their results suggest that areas without limits 
in triptan prescriptions (i.e. Alberta and Ontario) showed significantly higher rates 
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of subjects at risk of developing MOH compared with other jurisdictions with 
prescribing restrictions. An exceeding of triptans dispensations was also observed 
in some areas where prescription quantity limits were imposed by health 
authorities. However, given that MOH rates in regions without prescription limits 
were comparable with those ones reported in other countries worldwide without 
imposed limitations in triptan prescription (including Italy), we consider reasonable 
to assume that restrictions in triptan prescription at national level may be useful to 
curb the development of MOH in triptan users and to reduce related costs. 
 
The urgent, presently unmet need for early detection of non-responders to 
antimigraine drugs and of patients at risk of developing MOH is a strong 
motivation for a multidisciplinary approach based on the integration of 
pharmacogenetics and pharmacoepidemiology. On the one hand, 
pharmacoepidemiology may gather heterogeneity in drug-related outcomes among 
large and not-selected populations. On the other hand, pharmacogenetics may 
explain the aforementioned heterogeneity in drug response, both in terms of drug 
efficacy and safety. In 2010, Şardaş introduced the neologism 
pharmacogenovigilance, defined as a discipline integrating pharmacogenetics and 
pharmacovigilance, the latter including pharmacoepidemiology, which is its active 
branch of research [19]. In this context, the merging of this complementary 
disciplines may significantly enhance the collection and the interpretation of 
clinically useful pharmacogenetic and genomic data. Moreover, we strongly 
believe that such a holistic approach may offer the chance to have more discerning 
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